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Abstract 
Apicomplexan parasites of the genus Plasmodium are the causative agent of 
malaria, one of the most prevalent infectious diseases worldwide. Five different 
Plasmodium species can cause malaria in humans, leading to a total of 
approximately 500 million cases each year and of these, P. falciparum causes 
the most deadly form of the disease and is responsible for more than one million 
deaths annually. A major problem in the global fight against malaria is the 
widespread resistance of the parasites against the currently available drugs. It is 
of great importance to identify new drug targets as well as to understand the 
mechanisms that lead to drug resistance in the first instance in order to 
potentially reverse the resistant phenotypes and to avoid the development of 
resistance against currently effective drugs in the future. 
The tripeptide glutathione (GSH) or γ-glutamyl-cysteinyl-glycine is the most 
abundant low molecular weight thiol in most eukaryotic organisms and serves a 
number of important functions as sulfhydryl-buffer, cofactor for enzymes and for 
the detoxification of xenobiotics and drugs. GSH is an important component of 
the antioxidant machinery and because malaria parasites live in an environment 
rich in iron and oxygen and thus increased oxidative stress, they depend on 
functional antioxidant systems. The biosynthesis pathway for GSH, consisting of 
γ-glutamylcysteine synthetase (γGCS) and glutathione synthetase (GS) is present 
in malaria parasites as well as in their host cells. Previous studies have shown 
that depletion of GSH has an antimalarial effect, but it remained unclear 
whether parasites were killed directly or died because their host cell could not 
survive the depletion of GSH. To address this question, the knockout of both 
genes encoding the enzymes of the GSH biosynthesis pathway in P. falciparum 
was attempted. While both gene loci were targeted by control constructs, the 
knockout of either pfγgcs or pfgs was impossible, indicating both genes are 
essential for parasite survival in the erythrocytic stages. To analyse the 
localization of γGCS and GS, GFP-tagged recombinant fusion proteins were 
expressed in the parasites and showed that GSH biosynthesis is cytosolic. 
Apart form its other functions GSH has previously been suggested to be involved 
in resistance to the antimalarial drug chloroquine (CQ). CQ was for a long time 
the first line antimalarial drug due to its high efficiency, low cost and low 
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toxicity, but is now widely inefficient in the treatment of the disease. CQ 
resistance is associated with mutations in the CQ resistance transporter (PfCRT), 
a membrane protein of the digestive vacuole that allows the efflux of the drug 
from its site of action. However, PfCRT mutations alone cannot explain the full 
array of phenotypes found in resistant parasites. Since GSH is able to degrade 
heme, the target of CQ in vitro it has been suggested that elevated GSH levels 
contribute to CQ resistance. However, analyses of isogenic parasite lines bearing 
different forms of PfCRT in this study revealed lower GSH levels and higher 
susceptibility to inhibition of GSH biosynthesis in the CQ resistant lines. These 
changes did not correlate with changes in the expression of enzymes involved in 
the de novo biosynthesis or consumption of GSH. In spite of this, the cellular 
accumulation ratio for CQ indicated a decrease of free heme in the resistant 
parasites. Mutant forms of PfCRT expressed in oocytes of Xenopus laevis were 
able to transport GSH, while the sensitive wild-type form did not transport the 
tripeptide. The findings of this study suggest that in parasites bearing mutant 
PfCRT, GSH is transported into the digestive vacuole where it is able to 
contribute to resistance by degrading heme, before the tripeptide itself is 
degraded by peptidases inside the vacuole, consistent with the overall reduction 
of GSH levels in CQ resistant parasites. 
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1 Introduction 
1.1 Malaria 
Malaria is one of the most important infectious diseases with approximately 40 % 
of the world’s population at risk of infection, particularly in tropical and 
subtropical regions (Figure 1-1A). Worldwide an estimated 500 million clinical 
cases occur each year leading to the death of approximately 1 million people. 
The disease is particularly serious in Africa, where malaria causes about 20 % of 
all childhood deaths under the age of five. Another high risk group are pregnant 
women, where complications of the disease can lead to severe malaria or severe 
anaemia in the mother or to reduced birth weight, premature delivery, 
spontaneous abortion or stillbirth of the child (World Health Organisation, WHO, 
http://www.who.int/topics/malaria/en/). 
The disease is caused by protozoan parasites of the genus Plasmodium. Five 
different Plasmodium species cause malaria in humans, P. falciparum, P. vivax, 
P. malariae, P. knowlesi and P. ovale. The parasites are transmitted by female 
Anopheles mosquitoes and the disease is prevalent in those areas supporting the 
development of the vector. Of the approximately 430 different Anopheles 
species only 30-40 are vectors for the parasites (Center for Disease  
Control and Prevention, CDC, http://www.cdc.gov/Malaria/biology/mosquito). 
Environmental factors such as rainfall levels influence mosquito numbers and 
thus the transmission rate of malaria and epidemics frequently occur when the 
parasites are introduced to areas where the local population has little immunity 
to the disease, e.g. in times of flooding, or when non-immune people move into 
areas where malaria is endemic such as refugees in times of conflict. Vector 
control offers the best preventative measure against malaria in endemic areas so 
far (World Health Organisation, WHO, http://www.who.int/topics/malaria/en/). 
Clinical symptoms of malaria include high fever, myalgia, vomiting and 
headaches in recurring bouts every 48-72 hours and usually appear 10-15 days 
after the bite by an infected mosquito. The most severe forms of the  
disease are caused by P. falciparum infections, which exceed more than 75%  
of all malaria cases in most African countries (Figure 1-1B) (WHO, 
http://www.who.int/topics/malaria/en/).
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Figure 1-1: Distribution of malaria in 2006 
Panel A: Estimated incidence of malaria in 2006 per 1000 population. The vast majority of cases 
occurred in the African region (89 %) followed by Southeast-Asia (9 %). In white regions no malaria 
transmission occurs. Grey areas have limited risk of transmission and in the dark blue areas 
transmission is high. Worldwide most cases of malaria are caused by P. vivax, followed by P. 
falciparum, which causes the most severe form of the disease. Panel B: Estimated percentage of 
malarial cases due to P. falciparum in 2006. The percentage of malaria cases caused by P. 
falciparum exceeds more than 75 % in most African counties but is lower in most other countries 
where malaria occurs. This figure was constructed from figures taken from the World Malaria 
Report 2008, World Health Organisation (http://www.who.int/malaria/wmr2008). 
In cases of severe malaria, patients suffer from severe anaemia, acute renal 
failure, pulmonary oedema and cerebral malaria. Adhesion of parasite infected 
red blood cells (RBC) to non-infected RBCs and capillary walls leads to 
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disruptions of the blood supply in small capillaries and subsequent organ failure 
(Miller et al., 2002). Even after recovery from the acute disease 
children can be impaired in their intellectual and physical development. 
Malaria has an enormous economic impact on endemic countries. Up to 40 % of 
all public health expenditure is consumed by malaria and 30-50 % of all hospital 
admissions are due to the disease in heavy burdened endemic countries. Not 
only medical costs, but also days lost for labour take a huge toll,  
leading to an average loss of 1.3 % of annual economic growth (WHO, 
http://www.who.int/topics/malaria/en/). 
1.2 The lifecycle of Plasmodium 
Plasmodium species undergo a complex life cycle, switching between two hosts 
and between sexual and asexual development (Figure 1-2). Once a female 
mosquito takes a blood meal from an infected patient, female 
macrogametocytes and male microgametocytes are taken up. In the mosquito 
midgut, the male gametocyte develops into 4-8 flagellated microgametes while 
the female develops into a spherical macrogamete (Sinden et al., 1978). 
Fertilisation of a macrogamete by a single microgamete leads to a zygote, which 
develops into a motile ookinete. The ookinete migrates through the midgut 
epithelium and encysts on the basal lamina (Matuschewski, 2006). Inside this 
oocyst, sporozoites form through several rounds of asexual multiplication until 
they are released into the body cavity of the mosquito in an active process 
which in P. berghei involves the proteolytic activity of the egress cysteine 
protease ECP1, a homologue to the P. falciparum SERA8 (Aly and Matuschewski, 
2005). The sporozoites migrate to the salivary gland of the mosquito where they 
invade gland cells (Matuschewski, 2006). Once the mosquito takes another blood 
meal, now highly infective sporozoites are released into the human host. They 
migrate through the bloodstream and the lymphatic system to the liver where 
they invade hepatocytes. Inside hepatocytes, sporozoites develop to schizonts 
and asexually multiply to produce between 10,000-30,000 merozoites (exo-
erythrocytic schizogony) (Prudencio et al., 2006; Sherman, 2005). P. vivax and P. 
ovale can prevail as dormant hypnozoites in the liver and can cause relapses of 
the disease years after the initial infection (Cogswell, 1992). Merozoite filled 
vesicles, so-called merosomes, bud from the host hepatocyte and merozoites are 
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released into the bloodstream where they infect erythrocytes and continue their 
asexual reproduction in the intra-erythrocytic schizogony (Prudencio et al., 
2006; Silvie et al., 2008). The intra-erythrocytic development of P. falciparum 
takes approximately 48 hours before parasites egress from the infected RBC and 
merozoites are released which invade fresh erythrocytes. The rupture of the 
infected blood cells causes the pathogenesis of the disease and the typical bouts 
of fever. 
 
Figure 1-2: The life cycle of Plasmodium. 
During its life cycle Plasmodium changes between human (a) and female Anopheles mosquito 
hosts (b) and between asexual and sexual development. Once an infected mosquito takes a blood 
meal, sporozoites are released into the blood stream and migrate to the liver of the human host. 
Inside hepatocytes the parasites asexually multiply until up to 30,000 merozoites are released 
again into the blood stream. The merozoites invade red blood cells and develop from ring stages to 
trophozoites and schizonts. The schizonts divide asexually into merozoites which are released 
once the host erythrocyte ruptures. This lysis of the blood cells causes the typical symptoms of 
malaria. The released merozoites infect new erythrocytes and the next intra-erythrocytic cycle 
continues. In some cases merozites enter red blood cells and develop into male and female 
gametocytes, the sexual stages of Plasmodium. If these stages are ingested by another mosquito, 
male gametocytes develop into motile male microgametes and the female gametocytes develop 
into macrogametes. Once a macrogamete is fertilized by a microgamete, the resulting zygote 
develops into a motile ookinte, which moves to the outside of the midgut epithelium and forms an 
oocyst. Inside the oocyst, sporozites are asexually produced and finally released into the 
mosquito’s body cavity. The sporozoites migrate into the salivary glands from where they can be 
finally transmitted to the next human host. This Figure was taken from Wirth (2002), with 
permission from Nature Publishing Group. 
1.3 Blood stages of P. falciparum 
During the intra-erythrocytic stages, P. falciparum asexually develops in a 48 
hour cycle. After the release from hepatocytes, merozoites immediately invade 
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erythrocytes in a process involving multiple receptor-ligand interactions. During 
invasion of the P. falciparum merozoite, the RBC membrane invaginates and 
parts of it finally separate to form a parasitophorous vacuole which completely 
encases the parasite and separates it from the erythrocyte cytosol (Cowman and 
Crabb, 2006; Silvie et al., 2008). In Figure 1-3 a 3D-reconstruction of the ultra-
structure of a merozoite is displayed. Merozoites are ellipsoidal with a group of 
secretory vesicles called the apical organelles located at one pole and the large 
hemispherical nucleus at the other pole. The apical organelles consist of the 
rhoptries, micronemes and dense granules, all surrounded by a single 
membrane. They are essential for the invasion of the parasite into the RBC and 
release their contents during this process. A single elongated mitochondrion is 
closely associated with a plastid-like organelle, the apicoplast. 
 
Figure 1-3: 3D-organisation of a P. falciparum merozoite. 
This reconstituted image is based on serial electron microscope slices. This image was taken from 
Bannister et al. (2000) with permission from Elsevier Publishing Group. 
The apicoplast arose through secondary endosymbiosis of a plastid carrying 
eukaryote, likely to be a red algae (Sherman, 2005; Waller and McFadden, 2005). 
It is enclosed by four membranes and has its own 35 kb genome encoding for 30 
proteins, most of which are involved in their own synthesis. Most of the genes 
encoded for in the originally engulfed organism were transferred to the nuclear 
genome of P. falciparum and the encoded proteins have to be imported into the 
apicoplast after their biosynthesis. The major functions of the apicoplast appear 
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to be type II fatty acid biosynthesis, assembly of [Fe:S] clusters, synthesis of 
isopentenyl diphosphate, the precursor for isoprenoid biosynthesis and in 
conjunction with the mitochondrion, heme biosynthesis (Sherman, 2005; Waller 
and McFadden, 2005). 
The mitochondrion arose through the endosymbiosis of an α-proteobacterium. It 
is surrounded by a double membrane and contains a very small mitochondrial 
genome of only 6 kb which only encodes for three protein genes and 20 
mitochondrial rRNAs (Feagin et al., 1997; Feagin et al., 1992; Sherman, 2005; 
van Dooren et al., 2006). Most of the mitochondrial genes were transferred to 
the nuclear genome. In other organisms the mitochondrion is the major 
organelle responsible for the generation of ATP. However, for erythrocytic 
stages of Plasmodium, the major energy source is glycolysis in the cytosol and 
the pyruvate generated is converted to lactate rather than acetyl-CoA to feed 
into the tricarbolic acid (TCA) cycle (Sherman, 2005). Despite the presence of all 
TCA cycle enzymes in the P. falciparum genome, a mitochondrial pyruvate 
dehydrogenase (PDH) to produce acetyl-CoA is lacking and the single PDH 
present in the parasites is localized in the apicoplast. It has therefore been 
suggested that the TCA cycle instead serves to provide substrates for 
biosynthesis pathways such as succinyl-CoA for heme biosynthesis (Bozdech et 
al., 2003; Foth et al., 2005; Gardner et al., 2002). Potentially the TCA cycle 
serves a more important function during insect stage development. The other 
important function of the mitochondrion in mammals is the electron transport 
chain and ATP synthesis by the F0F1ATP synthase. No homologues to the 
mammalian complex I dehydrogenase of the electron transport chain are 
present, but several other dehydrogenases present can provide electrons instead 
and compensate for its absence (Gardner et al., 2002; Painter et al., 2007). 
Homologues to complex II, III and IV are present in the P. falciparum genome 
and can generate a membrane potential across the inner mitochondrion 
membrane (Gardner et al., 2002). However, two subunits of the F0F1ATP 
synthase are missing, suggesting that this enzyme cannot synthesize ATP 
(Gardner et al., 2002). Recently it was thus suggested that a major function of 
the electron transport chain is to act as electron acceptor for dihydroorotate, an 
essential step in the synthesis of pyrimidine (Baldwin et al., 2002; Krungkrai et 
al., 1990; Krungkrai et al., 1991; Painter et al., 2007; Sherman, 2005). The 
pyrimidine biosynthesis pathway is essential for P. falciparum parasites, which 
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cannot scavenge pyrimidines. Other functions of the mitochondrion are the 
synthesis of [Fe:S] clusters and heme biosynthesis together with the apicoplast. 
Both apicoplast and mitochondrion remain associated on at least one or two 
contact points throughout the intra-erythrocytic cycle, suggesting that 
potentially metabolites are exchanged between the two organelles (Bannister et 
al., 2000; Hopkins et al., 1999; Kobayashi et al., 2007; van Dooren et al., 2005). 
After invasion, the parasite enters the ring stage of the intra-erythrocytic cycle, 
lasting from 1-18 hours after invasion. Parasites are small at this stage and often 
resemble a miniature of the RBC in shape. Several food vacuoles are present 
which contain material of the host cell’s cytosol endocytosed through the 
cytostome. These vacuoles initially possess two membranes, the outer being 
derived from the parasite plasma membrane and the inner derived from the 
parasitophorous membrane (Francis et al., 1997; Sherman, 2005). The inner 
membrane is broken down during the processing of the vacuoles’ contents and 
malaria pigment, or hemozoin begins to form. Globin, the protein component of 
hemoglobin, is degraded by peptidases, thus providing amino acids for the 
parasite (Francis et al., 1997). Degradation of globin is a process involving 
several proteases and peptidases such as plasmepsin aspartic proteases I, II, III 
and IV, the falcipain cysteine proteases falcipain-2, falcipain-2’ and falcipain-3, 
the metalloprotease falcilysin and aminopeptidases (Banerjee et al., 2002; Dahl 
and Rosenthal, 2005; Francis et al., 1997; Murata and Goldberg, 2003a; Murata 
and Goldberg, 2003b; Sherman, 2005). Digestion of large amounts of hemoglobin 
leaves the parasite with large quantities of free heme containing Fe2+, which 
once released are oxidized to ferriprotoporphyrin IX (FPIX), containing Fe3+. FPIX 
causes damage to membranes and proteins and the parasites therefore depend 
on its efficient detoxification (Orjih et al., 1981). FPIX is initially dimerized to β-
hematin which is then converted to hemozoin. It has been argued that lipids are 
the primary mediator of non-enzymatic hemozoin formation (Egan et al., 2006; 
Egan et al., 2002; Pisciotta et al., 2007), but a recent study identified a heme 
detoxification protein which when recombinantly expressed and purified was 
able to bind to heme and to convert it into hemozoin (Jani et al., 2008). The 
parasitophorous membrane begins to undergo changes in this stage as the 
parasite starts remodelling its host cell. 
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In the trophozoite stage 18-28 hours post invasion the parasites have rounded up 
and a single large hemozoin containing vacuole, the digestive vacuole (DV), is 
present. Smaller vacuoles are formed at the two or three cytostomes containing 
erythrocyte cytosol which move towards and merge with the DV. Large 
quantities of host cell hemoglobin are being broken down in the DV. The 
mitochondrion and apicoplast increase further in size (Sherman, 2005). 
The surface of the parasite begins to form deep invaginations and the 
parasitophorous vacuolar membrane equally begins to form several extensions, 
forming an interconnected network of tubular and vesicular membranes. These 
structures mediate both export and import pathways across the intraerythrocytic 
space and can be divided into several different structures, such as Maurer’s 
clefts, circular cisternae and small vesicles. Some authors use the term 
tubulovesicular network (TVN) for all these structures, while others refer to only 
circular cisternae as TVN. The overall functions of these membrane enclosed 
structures are the uptake of nutrients by providing access to the RBC surface and 
transport of parasite proteins to the RBC surface (Sherman, 2005). 
Proteins exported from the parasite include variant surface antigens such as 
members of the subtelomeric variable open reading frames family (STEVOR) 
(Niang et al., 2009) and A-Type RIFINS of the repetitive interspersed family (rif) 
(Khattab and Klinkert, 2006; Petter et al., 2007). Of particular importance for 
the development of severe malaria is the P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) encoded by the variant antigene (var) gene family (Pasternak 
and Dzikowski, 2008). On the erythrocyte membrane PfEMP1 is associated with 
other parasite secreted proteins which together form “knobs” on the host cell 
surface. The major structural component of the macromolecular complexes 
forming these knobs is the knob-associated histidine-rich protein (KAHRP), which 
itself interacts with PfEMP1 and the erythrocyte cytoskeleton (Crabb et al., 
1997; Rug et al., 2006). PfEMP1 interacts with several proteins found on the 
membrane of endothelial cells or with proteins found on the surface of 
uninfected RBC. This interaction leads to the sequestration of infected RBC in 
several tissues and to the rosetting of uninfected and infected RBC. Both can 
cause occlusions in the vascular system and lead to organ and tissue damage. 
Sequestration helps the parasite to evade the host’s immune system by avoiding 
clearance of infected RBC by the spleen (Miller et al., 2002). 
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RNA and protein synthesis are at high levels in the trophozoite stage and the 
replication of DNA begins. These processes continue in the schizont stage 28-48 
hours after erythrocyte invasion. In this stage nuclear divisions take place, 
leading to 16-32 nuclei while the digestion of host cell hemoglobin and the 
export of proteins to the RBC surface continue. In preparation for the division 
into daughter cells, several centres of merozoite formation are created and the 
assembly of the apical organelles begins with formation of the rhoptries 
(Bannister et al., 2000). Micronemes and dense granules are formed later in 
parasite development. The apicoplast begins to elongate and branches before 
dividing. The mitochondrion begins branching during the trophozoite stage and 
exists as a branched structure until late in the schizont stage, when it finally 
divides. Both apicoplast and mitochondrion segregate as a pair into the daughter 
merozoites (van Dooren et al., 2005). 
At the end of schizogony, the DV remains in the residual body, while the 
daughter merozoites separate. The merozoites remain in the parasitophorous 
vacuole, until the vacuolar membrane and the erythrocyte plasma membrane 
break open to release them (Bannister et al., 2000). There is some controversy 
about the detailed mode of egress and the order in which vacuolar membrane 
and plasma membrane are broken down. However, despite some controversial 
data of different studies it is generally suggested that an important role in the 
egress process is held by parasite proteolytic enzymes (Blackman, 2008). 
1.4 Chemotherapies 
1.4.1 Antifolates  
Antifolates such as pyrimethamine and proguanil target the parasites 
dihydrofolate reductase (DHFR) (Hyde, 2005; Le Bras and Durand, 2003). 
Proguanil is a prodrug, which is converted to the active form cycloguanil by the 
parasite. Antifolates are often used in combination with sulpha drugs such as 
sulphonamides and sulphones, which inhibit dihydropteroate synthase (DHPS). 
Both enzymes are involved in the biosynthesis pathway of folate, a cofactor 
essential for DNA synthesis and other metabolic pathways. Combinations of DHFR 
and DHPS inhibitors such as sulfadoxine and pyrimethamine (Fansidar) or 
chloroproguanil-dapson (LapDap) are used as antimalarials. Proguanil is not only 
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effective on the erythrocytic stages but also on the liver stages of the parasite. 
However, resistance to antifolates and their combinations with sulpha drugs soon 
emerged after their introduction due to point mutations in both DHFR and DHPS 
(Hyde, 2005; Le Bras and Durand, 2003). 
1.4.2 Artemisinin 
Artemisinin is the active component extracted from the Chinese herb Artemisis 
annua, which has been used in traditional Chinese medicine for centuries to 
treat fevers and malaria. Analogues such as the water soluble artesunate and the 
oil soluble artemether are now commonly used in combination therapies with 
other anti-malarials like mefloquine. The artemisinin based combination 
therapies (ACT) are recommended by the WHO as the best current treatment of 
falciparum malaria. Several modes of action have been suggested for 
artemisinins, such as inhibition of heme detoxification (Meshnick, 1998; Pandey 
et al., 1999). Studies in a yeast model suggested that artemisinin affects the 
membrane potential in the mitochondria of P. falciparum in a mechanism 
different to atovaquone and leads to the generation of reactive oxygen species 
(Li et al., 2005). Another target of artimisinin is the SERCA-type ATPase PfATP6 
in the parasites endoplasmatic reticulum (Eckstein-Ludwig et al., 2003; 
Uhlemann et al., 2005). 
The artetmisinins were considered to be the only family of drug components 
fully effective against all strains of P. falciparum, but recently a decrease in the 
efficacy of ACT on the Thai-Cambodian border has been reported (Lim et al., 
2005; Vijaykadga et al., 2006).  
1.4.3 Atovaquone 
Atovaquone is a hydroxynaphthoquinone and an analogue of ubiquinone which 
targets the electron transfer chain in the parasite mitochondrion by inhibition of 
the cytochrome bc1 complex. (Srivastava et al., 1997). However, resistance to 
this drug emerged fast when the drug was tested as a single therapy due to 
mutations of cytochrome b (Srivastava et al., 1999). Atovaquone is therefore 
only used in combination therapy with the synergistic partner proguanil 
trademarked as Malarone (Sherman, 2005). The conversion of the prodrug 
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proguanil to the active DHFS inhibitor cycloguanil is not required for this synergy 
(Srivastava and Vaidya, 1999). It has been shown in vitro that despite inhibition 
of the cytochrome bc1 complex, atovaquone does not eliminate the 
mitochondrial membrane potential, whereas in combination with proguanil the 
membrane potential collapses (Painter et al., 2007). It was therefore suggested 
that proguanil is an efficient inhibitor of an alternative pathway for the 
generation of this potential and the authors hypothesized that this pathway most 
likely involves the F1 subunit of the mitochondrial ATP synthase and the 
ATP/ADP transporter in the mitochondrial membrane (Painter et al., 2007). 
The high cost makes Malarone essentially unaffordable for the population in 
endemic countries and the drug is usually used by travellers as Malaria 
prophylaxis. 
1.4.4 Quinolines 
Quinoline antimalarials are derived from quinine, the active component 
extracted from the bark of cinchona trees (Quinona officinalis). The ground tree 
bark has been used since the beginning of the 17th century to treat malaria. 
Derived from quinine, several other quinolines were developed such as 
chloroquine (CQ), amodiaquine, mefloquine and primaquine. The quinolines can 
be divided into subclasses, CQ and amodiaquine are 4-aminoquinolines, 
primaquine is an 8-aminoquinoline and quinine and mefloquine belong to the 
quinoline-4-methanol drugs. 
Of the quinolines, CQ was for a long time the preferred drug for the treatment 
of malaria due to its low cost, effectiveness and low toxicity. CQ targets the 
heme detoxification mechanisms in the parasite. It accumulates in the digestive 
vacuole of the parasite where it binds to FPIX and prevents its detoxification, 
thus leading to the accumulation of this toxic compound. However, resistance to 
the drug is now widespread and chloroquine is largely ineffective. Reasons for 
this drug resistance will be discussed in section 1.6. Amodiaquine like CQ binds 
to heme and prevents its detoxification.  
The modes of action for quinine, mefloquine and primaquine are less well 
understood. Quinine and mefloquine both interact with heme, but bind with 
lower affinity to FPIX than CQ (Chou and Fitch, 1993; Slater and Cerami, 1992). 
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Both partially prevent and reverse some of the abnormalities observed when 
parasites are treated with CQ. Mefloquine binds with high affinity to 
phospholipids and even though quinine accumulation in infected RBC has been 
less well studied, there is evidence that it also binds to phospholipids, suggesting 
inhibition of the endolysosomal system as their mode of action (Fitch, 2004). 
Resistance to both mefloquine and quinine has been reported, but while 
mefloquine resistance arose rapidly, quinine remains widely effective and is 
often used in combination with antibiotics like tetracycline and clindamycin for 
the treatment of CQ resistant malaria (Sherman, 2005). 
The exact mechanism of primaquine action is equally unknown, but it has been 
suggested that the drug acts on the parasite’s mitochondrion (Foley and Tilley, 
1998). Primaquine is effective against liver stages of Plasmodium and is 
therefore used for the treatment of the hypnozoite forming species P. vivax and 
P. ovale in combination with quinine or chloroquine. 
1.5 Redox and antioxidant systems of P. falciparum 
1.5.1 Generation of reactive oxygen species 
The generation of reactive oxygen species (ROS) such as hydrogen peroxide 
(H2O2), hydroxyl radicals (OH·) and superoxide anions (O2
-·) are a challenge 
faced by all organisms living in an oxygenated environment, as ROS directly or 
indirectly damage macromolecules such as DNA, proteins and lipids inside cells 
in various ways (Imlay, 2003; Imlay et al., 1988; Storz and Imlay, 1999). P. 
falciparum erythrocytic stages live in an environment of increased oxidative 
stress, rich in iron and oxygen, the key components for the generation of ROS via 
the Fenton reaction (Reaction 1). In the parasite’s DV, where large quantities of 
hemoglobin are digested at acidic pH, the conversion of oxidized oxy-hemoglobin 
containing ferroprotoporphyrin IX (Fe2+) to met-hemoglobin containing 
ferriprotoporphyrin IX (Fe3+) and O2
-· is increased compared to uninfected RBC, 
where only 3% of total hemoglobin is converted in this way (Atamna and 
Ginsburg, 1993; Becker et al., 2004; Hunt and Stocker, 1990; Misra and 
Fridovich, 1972). 
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Reaction 1: The Fenton reaction. 
ROS are generated in the Fenton reaction in the presence of iron and oxygen. 
In infected RBC, not only the parasite but also the host cell itself is subject to 
increased oxidative stress and oxidative damage. Several blood cell disorders 
such as α- and β-thalassaemia and sickle cell anaemia as well as glucose 6-
phosphate dehydrogenase deficiency cause a naturally higher level of oxidative 
stress in the RBC and confer a certain protection against infection with 
Plasmodium (Aslan and Freeman, 2007; Fibach and Rachmilewitz, 2008; Ho et 
al., 2007; Kwiatkowski, 2005; Rachmilewitz et al., 2005; Williams, 2006). This 
may either be caused by impaired infection and growth of the parasites in these 
host cells due to increased oxidative stress or by earlier damage induced 
alterations to the red blood cell membranes during the development of the 
parasite and earlier recognition of the infected cells by the immune system 
(Cappadoro et al., 1998; Eaton et al., 1976; Friedman, 1978; Giribaldi et al., 
2001; Pasvol et al., 1978; Williams et al., 2002). 
1.5.2 Superoxide dismutases 
Superoxide dismutases (SOD) are metalloproteins responsible for the 
detoxification of superoxide anions. They can be copper/zinc, iron or manganese 
dependent. P. falciparum possesses two distinct Fe-dependent SODs, one 
localized in the cytosol and one in the mitochondrion (Gratepanche et al., 2002; 
Sienkiewicz et al., 2004). Both enzymes are responsible for the conversion of 
superoxide anions generated by the electron transport chain and other 
metabolic processes to molecular oxygen and hydrogen peroxide. It has 
previously been suggested that large amounts of the host cell Cu/Zn-SOD taken 
up into the DV can contribute to the detoxification of superoxide anions 
generated in this organelle before the enzyme is digested (Fairfield et al., 
1983). However, the dismutation of superoxide anions can occur spontaneously 
in this organelle and might be efficiently accelerated by the low pH and not in 
need of enzymatic catalysis (Ginsburg and Atamna, 1994). No gene for a catalase 
has been identified in P. falciparum. 
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1.5.3 Glutathione 
In most aerobic organisms low molecular mass thiols function as the principal 
redox buffer of the cells. The most abundant low molecular weight thiol is the 
tripeptide glutathione (GSH) or γ-glutamyl-cysteinyl-glycine, which is found in 
eukaryotes and gram-negative bacteria, whereas gram-positive bacteria 
synthesize mycothiol (Fahey et al., 1978; Newton and Fahey, 2002; Sies, 1999). 
An interesting exception are trypanosomatids like the causative agents of African 
sleeping sickness (Trypanosoma brucei gambiense, Trypanosoma brucei 
rhodesiense) and leishmaniasis (for instance Leishamnia major, Leishmania 
donovani), where two GSH molecules are conjugated to spermidine to form 
trypanothione (Fairlamb and Cerami, 1992; Steenkamp, 2002). 
 
Figure 1-4: Structure of GSH. 
The tripeptide GSH consists of the amino acids glutamate, cysteine and glycine. Glutamate and 
cysteine are ligated through a γ-glutamyl amide linkage. 
GSH serves various different functions in cells apart from being a redox buffer. It 
is a cofactor for detoxifying enzymes and proteins such as glutathione-S-
transferases (GSTs), glutatredoxins and glyoxalases and is involved in non-
enzymatic reactions such as the termination of radical chain reactions. 
1.5.3.1 Glutathione metabolism of P. falciparum 
Figure 1-5 displays an overview of the GSH metabolism in P. falciparum parasites. 
GSH is synthesized in two consecutive steps by the enzymes γ-glutamylcysteine 
synthetase (γGCS) and glutathione synthetase (GS) (Figure 1-5). Both enzymes 
have been identified in the malaria parasite P. falciparum (Lüersen et al., 1999; 
Meierjohann et al., 2002a) and because their roles and importance for the 
survival of the intra-erythrocytic stages of P. falciparum is analysed in this 
study, both are described in more detail in section 1.5.3.2. 
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Figure 1-5: GSH metabolism of P. falciparum. 
GSH is synthesized in two consecutive steps by the enzymes γ-glutamylcysteine synthetase 
(γGCS) and glutathione synthetase (GS). GSH is used by the single glutathione-S-transferase 
found in P. falciparum to label xenobiotics (X) for export (GS-X). GS-X adducts are excreted from 
cells via pumps such as multidrug resistance proteins. GST can also use GSH to detoxify 
peroxides which leads to the formation of oxidized glutathione disulphate (GSSG). GSSG is also 
produced by the reduction of glutaredoxins (Grx-S2 to Grx(SH)2) and the degradation of 
ferriprotoporphyrin IX (FPXI). GSSG is either excreted from the parasite or reduced to GSH by 
glutathione reductase (GR). This figure was taken from Müller (2004) with permission from 
Blackwell publishing group. 
Oxidation of GSH leads to the formation of glutathione disulphide (GSSG), which 
is reduced back to GSH by the flavoenzyme glutathione reductase (GR) in a 
NADPH dependent mechanism in order to maintain a high GSH:GSSG ratio (Figure 
1-5) (Meister and Anderson, 1983). The NADPH needed for the reduction of GSH 
is mainly provided by the hexose monophosphate shunt, which shows an 
approximately 78 times higher activity in infected RBC than in uninfected RBC 
(Atamna et al., 1994; Meister and Anderson, 1983). PfGR has been biochemically 
characterized and received a lot of interest as a potential drug target (Farber et 
al., 1996; Gilberger et al., 2000; Krauth-Siegel et al., 1996). The antimalarial 
dye methylene blue is a selective inhibitor of PfGR and chemosensitizes 
parasites by the depletion of reduced GSH (Becker et al., 2003b; Farber et al., 
1998). 
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In order to maintain a high GSH:GSSG ratio, parasites not only reduce GSSG, but 
also excrete large amounts of the disulphide (Figure 1-5). Ginsburg and 
colleagues previously suggested that this might be a way in which the parasites 
supply their host cell with GSH, as erythrocytes contain high levels of HsGR 
(Atamna and Ginsburg, 1997). However, later studies found that the disulphide is 
lost entirely from the infected RBC and is released into the culture medium 
(Lüersen et al., 2000; Meierjohann et al., 2002b). This efflux of GSSG is possibly 
the reason why infected RBC contain lower GSH concentrations than non-
infected RBC (Ayi et al., 1998; Lüersen et al., 2000; Meierjohann et al., 2002b). 
Earlier studies detected glutathione peroxidase activity in P. falciparum (Fritsch 
et al., 1987), but no glutathione peroxidase protein was identified and a 
potential candidate turned out to be thioredoxin-dependent rather than GSH-
dependent (Sztajer et al., 2001). Potentially the detected activity was due to 
peroxidase activity of the single glutathione-S-transferase (GST) found in P. 
falciparum, which serves as an alkyl hydroperoxide peroxidase in vitro (Figure 
1-5) (Harwaldt et al., 2002; Liebau et al., 2002). This GSH-dependent enzyme is 
present in high concentrations in the parasites. GSTs conjugate GSH to a variety 
of substrates such as mutagens and drugs and thus label them for export. 
Another interesting function that has been suggested for PfGST is the 
sequestration of FPIX, which binds uncompetitively to this protein (Harwaldt et 
al., 2002; Liebau et al., 2002). 
P. falciparum possesses one classical glutaredoxin (Grx1) in addition to three 
glutaredoxin-like proteins (GLPs) (Becker et al., 2003b; Rahlfs et al., 2001). 
Glutatredoxins are small heat-stable dithiol-dilsufide oxidoreductases, which 
protect cells from oxidative damage and can interact with sulphydryl groups of 
other proteins in order to either reduce or oxidize them (Becker et al., 2003b; 
Müller, 2004). One function suggested for Grx1 in P. falciparum is to reduce 
ribonucleotide reductase, which is involved in the first step of DNA synthesis. 
Glutaredoxins are reduced by GSH, which leads to the formation of GSSG (Figure 
1-5). In rice Grx was also found to have glutathione peroxidase activity (Lee et 
al., 2002). 
GSH is also used as a cofactor for the detoxification of toxic 2-oxoaldehydes such 
as glyoxal and methylglyoxal by the glyoxalases GlxI and GlxII in P. falciparum. 
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In the first reaction step, GlxI forms a thiol ester bond between GSH and the 
aldehyde, thus producing an S-2-hydroxyacylglutathione conjugate. This ester is 
hydrolysed by GlxII, thus releasing GSH and a non-toxic 2-hydroxycarbolic acid 
(Akoachere et al., 2005). 
1.5.3.2 Glutathione biosynthesis 
The PfγGCS is encoded by a single exon gene on chromosome 9 (PFI0925w, 
http://plasmodb.org) and is related to the γGCS of other non-plant eukaryotes. 
The predicted PfγGCS amino acid sequence of the 3D7 strain has a molecular 
mass of 124 kDa and is thus almost twice the size of the human catalytic 
subunit. The P. falciparum enzyme has not been biochemically characterized. 
Alignment of the deduced amino acid sequence with the human and T. brucei 
homologues reveals an overall sequence identity of only 19.7 and 18.6 %, 
respectively, but in four more conserved regions the homologies are much higher 
and share 31.3 -43.9 % identities (Figure 1-6) (Lüersen et al., 1999). Within these 
regions of homology, several amino acid residues involved in substrate binding in 
other species are conserved (Chang, 1996; Lueder and Phillips, 1996; Lüersen et 
al., 1999). The PfγGCS further possesses a conserved cysteine residue in or near 
the proposed active site. Three large insertions divide the regions of homology 
and the function of these insertions is unclear. Several other plasmodial proteins 
contain such insertions and their function in those is also unknown. The first  
insertion (from residue 151-389) contains a repetitive sequence motif 
(Y/C)QS(N/D)LQQ(Q/R). This octamer is only present once in 3D7 PfγGCS, but 
other strains investigated by Lüersen et al. contained eight (FCBR, FCH5, K1, 
7G8), nine (HB3) or ten (Dd2) repeats, leading to an increase in the predicted 
size for PfγGCS in those strains (Lüersen et al., 1999). The function of such 
repetitive elements is unknown, but they have also been found in other 
Plasmodium proteins (Cowman et al., 1984; Eisen et al., 1998). No correlation 
between the repeats and the geographic origin of the parasite strains 
investigated was found for PfγGCS (Lüersen et al., 1999). Northern analysis 
showed a stage specific transcription pattern of PfγGCS, with a baseline level of 
transcription throughout the intra-erythrocytic life cycle and a peak in the 
mature trophozoite stage (Lüersen et al., 1999). Microarray data published on 
PlasmoDB (http://plasmodb.org) shows a continuous expression with a peak in 
the schizont stage. 
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Figure 1-6: Alignment of PfγGCS with human γGCS catalytic subunit and T. brucei γGCS. 
Insertions in PfγGCS are in italics while invariant amino acid residues are bold. Lys and Arg 
residues potentially involved in substrate binding and the putative active site Cys are boxed. 
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Shaded areas and arrows indicate primers used in the previous study by Lüersen et al. This figure 
was taken from Lüersen et al. with permission from Elsevier Publishing Group (Lüersen et al., 
1999). 
An inhibitor for γGCS, L-buthionine sulfoximine (L-BSO) (Griffith, 1982) has 
previously been shown to inhibit P. falciparum growth in vitro (Lüersen et al., 
2000). Inhibition of γGCS activity takes place in both the host cell and the 
parasite compartment and leads to a decrease in cellular GSH in both. Within 2 
hours, half of the cellular GSH is lost from infected RBC after inhibition of the 
biosynthesis of the tripeptide. Therefore the effect of L-BSO was related to an 
increased physiological need for GSH in infected RBC instead of specific 
inhibition of PfγGCS (Lüersen et al., 2000).  Administration of extracellular GSH 
relieves the effect. It remained unclear whether the animalarial effect of L-BSO 
observed was due to a direct killing of the parasite through inhibition of PfγGCS, 
or if the effect was a consequence of the death of the host cell due to inhibition 
of the human enzyme, or indeed a combination of both. 
In various species, γGCS catalyses the rate limiting step of GSH biosynthesis. 
Studies of recombinant T. brucei γGCS showed that TbγGCS is active as a 
monomer and feedback inhibited by GSH (Lueder and Phillips, 1996). Further 
studies of γGCS in this organism showed that a gene knock-down using RNAi is 
lethal for T. brucei. This phenotype was rescued by extracellular GSH, 
suggesting that T. brucei has the ability to take up the tripeptide (Huynh et al., 
2003). Human γGCS is active as a heterodimer consisting of a catalytic and a 
regulatory subunit (Tu and Anders, 1998). Activities of both the catalytic subunit 
and the holoenzyme are regulated by intracellular GSH levels by feedback 
inhibition. Other mechanisms regulating the activity and abundance of human 
γGCS were suggested to be subunit interactions and control of gene expression 
(Tu and Anders, 1998). Disruption of the catalytic γGCS subunit in mice is lethal 
during embryonic development (Shi et al., 2000). Interestingly, cell lines 
isolated from blastocysts in the same study were viable in the presence of N-
acetylcysteine or GSH, but failed to grow in their absence. Similar results were 
found for the fungi Saccharomyces cervisiae and Candida albicans. A mutation in 
γGCS abolishing enzyme activity leads to GSH auxotrophy in S. cervisiae (Grant 
et al., 1996) as does the knockout of γGCS in C. albicans (Baek et al., 2004). In 
contrast to the S. cervisiae mutants which can survive the loss of γGCS activity 
in the presence of other thiols such as dithiothreitol, cysteine and β-
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mercaptoethanol, C. albicans γGCS knockout cells required exogenous GSH, 
GSSG or γGC for survival. 
Recently a knockout of the γgcs gene was reported in P. berghei (Vega-Rodriguez 
et al., 2009). The knockout line displayed only a mild growth defect in the intra-
erythrocytic stages, while the development in the mosquito was severely 
affected and the genetically modified parasites were unable to produce 
sporozoites. Interestingly, the knockout parasites still contained low levels of 
GSH in the erythrocytic stages, albeit 7 to 26 times less than the wildtype. The 
authors suggested that the remaining GSH may be attributable to uptake from 
the host cell and is sufficient for intra-erythrocytic development (Vega-
Rodriguez et al., 2009). 
γ-GCS sequences can be divided into three different groups: those of γ-
protobacteria, those of non-plant eukaryotes and those of α-protobacteria and 
plants (Copley and Dhillon, 2002). Their origin is not clear, one hypothesis is that 
the gene arose amongst the bacteria and was transferred by lateral gene 
transfer from a mitochondrial progenitor. Another hypothesis is that the gene 
arose in the last common ancestor and was subsequently lost from archea, many 
bacteria and those eukaryotes lacking mitochondria (e.g. Giardia, Trichomonas). 
Even though the massive disappearance of the gene from anaerobe living 
organisms is plausible, it would mean that the γgcs gene originated before the 
emergence of an aerobic atmosphere (Copley and Dhillon, 2002). 
A single exon gene on chromosome 5 encodes for the second enzyme for GSH 
biosynthesis, PfGS (PFE0605c, http://plasmodb.org) and the enzyme has 
previously been characterized (Meierjohann et al., 2002a). The recombinant 
enzyme is active as a homodimer with a subunit mass of 77 kDa. PfGS only 
displays a moderate degree of amino acid identity compared with its homologues 
in humans, Arabidopsis thaliana and S. cervisiae (18.2, 19.8  and 18.5 %, 
respectively), but several residues involved in binding of substrates and 
cofactors are conserved (Figure 1-7) (Meierjohann et al., 2002a). A highly 
conserved region is a glycine rich loop between Lys-517 and Lys-525, which in 
the E. coli homologue is involved in binding of ATP and stabilisation of the γ-
glutamyl-cysteinyl-phosphate intermediate. Due to several insertions, the P. 
falciparum enzyme is 150 to 200 amino acids longer than its homologues 
Introduction  21 
(Meierjohann et al., 2002a). These insertions are spread over the entire 
sequence, the largest being between residues 351-392 (Figure 1-7). 
Knockout studies revealed that GS is not essential for the survival of S. cervisiae 
(Grant et al., 1997), where mutants are viable, albeit showing reduced growth 
and presumably depend on the precursor of GSH, γ-GC. In mammals a decreased 
activity of GS can cause mild to debilitating diseases including 5-oxoprolinuria, 
haemolytic anaemia and neurological dysfunction (Dahl et al., 1997; Shi et al., 
1996). No complete loss of GS activity in humans has been reported, indicating 
an essential role for the enzyme in humans. 
GS sequences fall into two distinct groups, bacterial GS and eukaryotic GS. GS 
most likely was recruited from the ATP-grasp superfamily of proteins after a 
γGCS gene was acquired and evolved independently in bacteria and eukaryotes 
(Copley and Dhillon, 2002). 
 
Figure 1-7: Alignment of the PfGS amino acid sequence with the Homo sapiens, A. thaliana 
and S. cervisiae sequences. 
Asterisks, arrows and crosses indicate conserved residues for ATP, γGC and GSH binding, 
respectively. A highly conserved glycine rich loop is marked by the shaded box. This figure was 
taken from Meierjohann et al. (2002a), with permission from the Biochemical society.  
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1.5.4 Thioredoxin  
Another important thiol antioxidant system is the thioredoxin (Trx) system. 
Similar to GSH, the small 12 kDa Trx proteins detoxify ROS and nitrogen 
metabolites, are involved in protein folding and provide reducing equivalents for 
enzymes such as ribonucleotide reductase. Trx and the glutaredoxins belong to 
the thioredoxin superfamily characterized by the active site CXXC motif (Rahlfs 
et al., 2003). Often more than one Trx can be found in a single organism. P. 
falciparum possess a classical Trx, PfTrx1 which localizes to the cytosol (Kanzok 
et al., 2000; Krnajski et al., 2001a; Rahlfs et al., 2002) as well as a second 
mitochondrial Trx, PfTrx2 (Boucher et al., 2006). In addition, two thioredoxin-
like proteins have been identified as well as the Trx related protein 
plasmoredoxin (Becker et al., 2003a; Sherman, 2005). Plasmoredoxin appears to 
be a unique antioxidant of Plasmodium species, but it is not essential for the 
survival of the rodent species P. berghei (Buchholz et al., 2008). 
To maintain Trx in a reduced state, P. falciparum possesses a high molecular 
weight Trx reductase (TrxR), similar to the TrxR found in mammals and insects 
(Müller et al., 1996). Similar to GR, TrxR is a flavoenzyme and uses NADPH as 
reducing cofactor. The function of TrxR is essential for parasite survival (Krnajski 
et al., 2002). 
1.5.5 Peroxiredoxins 
P. falciparum possesses five peroxiredoxins, antioxidant enzymes which act as 
peroxidases and thus contribute to the detoxification of hydrogen peroxide and 
other peroxides. Two of the peroxiredoxins are Trx-dependent, belong to the 
family of typical 2-Cys peroxiredoxins and are localized in the cytosol (PfTrx-
Px1) (Krnajski et al., 2001b; Rahlfs and Becker, 2001) and mitochondrion (PfTrx-
Px2) (Boucher et al., 2006). A third is a typical 1-Cys peroxiredoxin which has 
only slight activity with Trx and the electron donor is still controversial (Kawazu 
et al., 2000; Kawazu et al., 2007; Krnajski et al., 2001b). The two groups of 
peroxiredoxins differ in the number of conserved cysteine residues within the 
active site. The P. falciparum antioxidant protein (PfAOP) is another 1-Cys 
peroxiredoxin which displays some homologies to atypical 2-Cys peroxiredoxins 
(Sarma et al., 2005). The fifth peroxiredoxin is the glutathione-peroxidase like 
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protein, which despite its homology to glutathione peroxidases prefers Trx as a 
reducing agent (Sztajer et al., 2001). Even though disruption of the single Trx 
reductase is lethal for the parasites and thus suggests an important role of the 
Trx system for the parasites survival (Krnajski et al., 2002), there is some 
redundancy between the peroxiredoxins. PfTrx-Px1 appears to be the major 
cytosolic peroxidase, but a knockout of this gene is not lethal in erythrocytic 
stages (Komaki-Yasuda et al., 2003; Sherman, 2005). 
1.6 Chloroquine resistance 
CQ is a lipophilic, weak base which crosses membranes by passive diffusion and 
accumulates in the DV of Plasmodium species due to protonation in this acidic 
environment and binding to free heme (Bray et al., 1999; Saliba et al., 1998). 
Several mechanisms have been suggested to be involved in the establishment of 
CQ resistance: (1) Reduced access of CQ to hematin (2) increased efflux of CQ 
(3) decreased influx of CQ, potentially caused by changes of vacuolar pH (4) 
increased detoxification of CQ, heme and CQ-heme complexes. 
CQ resistant strains of P. falciparum have been shown to accumulate 
significantly less CQ in their DV than CQ sensitive strains, thus keeping the 
concentration of the drug below the toxic level. The phenotype of reduced CQ 
accumulation in these studies is reversible with verapamil, a Ca2+ channel 
blocker and inhibitor of ABC transporters (Bray et al., 1998; Fidock et al., 2000; 
Fitch, 2004; Sanchez et al., 2003). Recent studies showed that reduced CQ 
accumulation did not correlate with changes in the vacuolar pH as sensitive and 
resistant parasites have comparable steady-state pH values (Hayward et al., 
2006; Kuhn et al., 2007). Without changes in the vacuolar pH and hemoglobin 
digestion, CQ accumulation should be comparable between sensitive and 
resistant strains; this suggests the presence of a permeation pathway in resistant 
parasites. 
1.6.1 P. falciparum Chloroquine Resistance Transporter 
Analyses of a genetic cross between the CQ sensitive HB3 and the CQ resistant 
Dd2 strain of P. falciparum led to the identification of a gene locus and finally to 
the identification of one particular gene within this locus whose inheritance 
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matched with the inheritance of CQ resistance (Fidock et al., 2000; Su et al., 
1997; Wellems et al., 1991). The hypothetical protein encoded by this gene was 
named chloroquine-resistance transporter (PfCRT) because of the predicted 10 
transmembrane domains (Figure 1-8). PfCRT has since been shown to be 
expressed in erythrocytic stages and to localize to the membrane of the 
parasite’s DV (Cooper et al., 2002; Fidock et al., 2000). Bioinformatic studies 
placed PfCRT within the drug/metabolite transporter (DMT) superfamily. The 
bioinformatic analyses suggested that PfCRT might be active as a dimer with its 
N- and C-terminus and the even numbered loops facing the cytosol (Martin and 
Kirk, 2004; Tran and Saier, 2004). 
Several mutations in PfCRT have been found in various CQ resistant and sensitive 
parasite lines, but the single mutation found in almost all resistant lines and 
absent in the sensitive lines is the mutation of a lysine residue to a threonine in 
amino acid position 76 (Figure 1-8). This mutation is in P. falciparum always 
accompanied by several other mutations, suggesting that the K76T substitution 
interferes with the natural function of PfCRT and compensatory mutations need 
to be established concomitantly to allow this exchange. The additional 
mutations vary in relation to the geographic origin of the isolates. However, 
most CQ resistant field isolates carry an A220S mutation in addition to K76T 
while the other mutations vary, indicating a special importance of this mutation 
for the maintenance of PfCRT function (Cooper et al., 2005). The exceptions are 
strains isolated from the Philippines, where instead of the A220S mutation two 
mutations, A144T and L160Y, are found in combination with K76T (Chen et al., 
2003). Allelic exchange studies showed that replacement of the wild-type pfcrt 
allele in a CQ sensitive strain with the pfcrt alleles of resistant strains is 
sufficient to establish CQ resistance (Sidhu et al., 2002). Further studies showed 
that the reversal of the single K76T mutation to T76K abolishes CQ resistance 
(Lakshmanan et al., 2005). In laboratory strains it was also possible to generate 
CQ resistance by replacing the lysine residue at position 76 with a neutral 
residue other than threonine such as asparagine or isoleucine (Fidock et al., 
2000; Lakshmanan et al., 2005). 
Introduction  25 
 
Figure 1-8: Predicted structure of PfCRT. 
The PfCRT protein is predicted to possess 10 transmembrane domains with the N- and C-terminus 
extending into the parasite cytosol. The red circle indicates the critical K76T mutation found in CQ 
resistant parasites. Black circles indicate additional mutations found in CQ resistant field isolates. 
Green and blue circles indicate mutations selected for in amantadine resistant parasites, where the 
S163R mutation (green) re-establishes CQ sensitivity. This Figure was taken from Bray et al. 
(2005) with permission from Wiley-Blackwell publishing group. 
Two models currently exist for the functions of PfCRT in CQ resistance, that of a 
channel allowing protonated CQ to exit the DV along the electrochemical and 
concentration gradient and that of an active transporter (Sanchez et al., 2007b). 
Data arguing for PfCRT being an active transporter were presented by Sanchez et 
al., who observed the phenomenon of trans-stimulation in CQ resistant 
parasites. Trans-stimulation describes the apparent stimulation of the transport 
of one substrate from the cis to the trans-site of a membrane (e.g. from cytosol 
to the DV) by the presence of the substrate on the trans site. Indeed the amount 
of radioactive CQ taken up by resistant parasites was higher, when parasites 
were preloaded with low concentrations of unlabelled CQ before the uptake of 
radio-labelled CQ was measured. This was not observed in sensitive strains or if 
the parasites were energy starved (Sanchez et al., 2005; Sanchez et al., 2003). 
Investigation of efflux under reverse trans-stimulation conditions however 
revealed a trans-stimulation effect in sensitive as well as resistant parasites 
(Sanchez et al., 2007a). The interpretation by Sanchez et al. is that wild-type 
PfCRT may be a predominantly exchange-only carrier which is converted to a 
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net-transporting carrier by the K76T mutation and co-transports CQ with protons 
(Sanchez et al., 2007b). 
Data in favour of the channel model show that efflux of CQ is energy 
independent and also independent of the vacuolar pH gradient. (Bray et al., 
2006). Moreover, CQ efflux occurs in starved sensitive parasites and resistant 
lines (Bray et al., 2006). The authors of this study argued that their data were 
more in favour of PfCRT acting as a gated aqueous pore, a model originally 
proposed by Warhurst et al., who noted that PfCRT shows some sequence 
resemblance to the E. coli ClC channel (Warhurst et al., 2002). In analogy to the 
bacterial channel, PfCRT is suggested to be in an open conformation while the 
interior of the food vacuole is positively charged (Bray et al., 2006). The K76T 
mutation leads to the loss of a positive charge in the interior of the pore, thus 
allowing charged protonated CQ to move through. The importance for this loss of 
a positive charge is supported by the fact that introducing a positive charge in a 
different position on transmembrane domain 4 (S163R mutation) after selection 
for amantadine resistant parasites restores the sensitivity to CQ despite the 
presence of the K76T mutation (Figure 1-8) (Johnson et al., 2004). Verapamil 
and amantadine presumably block the pore and thus reverse CQ resistance 
(Johnson et al., 2004). The trans-stimulation of CQ accumulation observed if 
parasites are preloaded with CQ is alternatively explained in the gated channel 
model with the depolarization of the DV by the escape of protonated CQ and 
closure of the gated channel (Bray et al., 2006). 
1.6.2 Other transporters involved in chloroquine resistance 
Several other transporters have been associated with CQ resistance, such as 
members of the ABC transporter superfamily like the multidrug resistance 
transporter 1 (pfmdr-1) (Cowman et al., 1991; Reed et al., 2000) and the 
multidrug resistance associated protein 1 (pfmrp-1) (Klokouzas et al., 2004; Raj 
et al., 2008). 
Although pfcrt is the main determinant for CQ resistance, polymorphisms in the 
pfmdr1 gene frequently correlate with CQ resistance and though this does not 
confer resistance by itself, it does modulate the level of resistance. The pfmdr1 
gene encodes the P-glycoprotein homologue-1 (Cowman et al., 1991), a 
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homologue of the human multidrug resistance transporters, which are frequently 
associated with drug resistance in cancer cells. Pgh-1 is a 162 kDa protein with 
12 predicted transmembrane domains and sequence similarities to primary 
active ATP-binding cassette (ABC) transporters. 
Some point mutations in pfmdr1 have been found to alter CQ sensitivity and 
changing a certain mutated pfmdr1 allele back to the wild-type form can half 
the level of CQ resistance, while other mutations in the transporter do not 
affect the susceptibility of parasites to CQ (Reed et al., 2000; Sidhu et al., 
2005). Amplification of pfmdr1 has also been implicated in drug resistance. 
Interestingly, parasites with multiple copies of pfmdr1 appear to be rather more 
sensitive to CQ, while the amplification leads to a decrease in susceptibility to 
mefloquine, quinine, halofantrine, artesunate and dihydroartemisinin (Cowman 
et al., 1994; Price et al., 2004). 
Similar to Pgh-1, the PfMRP1 transporter can modify CQ resistance. An 
association between mutations in pfmrp1 and quinoline resistance has been 
reported from field isolates (Ursing et al., 2006) and a recent study showed that 
the knockout of the pfmrp1 gene in a CQ resistant parasite line increased the 
susceptibility of these parasites to the drug, albeit without complete reversal of 
the resistance (Raj et al., 2008). 
1.6.3 Glutathione mediated heme detoxification 
Previous studies have suggested a role for GSH in the establishment of CQ 
resistance. Several studies on cancer cells found a correlation between drug 
resistance and elevated GSH levels, often due to increased γGCS activity. The 
elevated GSH levels are often associated with over-expression of GSTs and efflux 
pumps for GSH-labelled xenobiotics such as homologues of MRP and MDR 
transporters (Balendiran et al., 2004; Fojo and Bates, 2003; Yang et al., 2006). 
Studies on the rodent malaria parasite P. berghei found increased GSH levels in 
CQ resistant strains in correlation with a three times higher GST activity 
compared to sensitive parasites (Dubois et al., 1995). Treatment with L-BSO led 
to a much more spectacular depletion of GSH in the resistant strains, indicating 
a higher turnover of the tripeptide in these parasites and partly reversed CQ 
resistance. Atamna and Ginsburg demonstrated in vitro that GSH is able to non-
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enzymatically degrade the cellular target of CQ, FPIX, in a radical mediated 
mechanism, which is however independent of the presence of GST (Atamna and 
Ginsburg, 1995). Further studies on CQ resistant P. berghei by Platel et al. found 
that the resistant parasites displayed a lower hemozoin content, which could be 
increased when infected mice were treated with L-BSO to deplete GSH (Platel et 
al., 1999). In an in vitro assay in the same study GSH was shown to partly inhibit 
hemin polymerization, which was not influenced by the absence or presence of 
GST. The role for GST in CQ resistant P. berghei remains unclear, if GSH alone is 
able to mediate decreased drug susceptibility by removing the target FPIX. No 
correlation was found between CQ resistance and GST in P. falciparum and no 
CQ conjugates or metabolites have been found in the resistant parasites (Berger 
et al., 1995). 
Because GSH is usually synthesized in the cytosol, Platel et al. suggested that 
the increased GSH levels they detected in CQ resistant P. berghei parasites are 
of erythrocyte origin, as they observed a preference of the resistant parasites 
for reticulocytes which contain higher GSH levels than mature erythrocytes 
(Sailaja et al., 2003). They hypothesized that the parasites take up erythrocytic 
GSH during the digestion of the host cell cytosol (Platel et al., 1999). Support for 
the uptake of GSH from the host cell comes from the observation that blood 
stages of genetically modified P. berghei parasites lacking the pbγgcs gene still 
contain appreciable levels of GSH, despite no longer having a functional 
biosynthesis pathway (Vega-Rodriguez et al., 2009). Studies in P. falciparum led 
to the suggestion that FPIX exits the DV in large amounts and is degraded by GSH 
of parasite origin in the cytosol (Ginsburg et al., 1998; Ginsburg and Golenser, 
2003). These studies found that GSH degrades FPIX at a much higher rate at 
neutral pH than at the acidic pH of the DV. 
Consistent with the hypothesis that GSH affects CQ resistance, increased levels 
of mRNA for PbγGCS were found in CQ resistant P. berghei (Perez-Rosado et al., 
2002) and several drugs able to decrease or increase cellular GSH levels were 
found to decrease or increase CQ susceptibility of murine malaria species, 
respectively (Deharo et al., 2003). Increased PfγGCS activity and higher GSH 
levels were also found in the multi-drug resistant P. falciparum isolate Dd2 in 
comparison to the sensitive strain 3D7 (Meierjohann et al., 2002b). 
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However, analysis of the distribution of FPIX by Mössbauer spectroscopy showed 
that more than 90 % of FPIX are retained in the DV, which argues against the 
degradation of FPIX by GSH in the cytosol (Egan et al., 2002). Analysis of the 
hemozoin content of several resistant and sensitive strains found no correlation 
between CQ susceptibility and the level of hemozoin accumulation, suggesting 
that higher GSH levels in resistant parasites are not resulting in increased FPIX 
degradation (Zhang et al., 1999). In another rodent parasite, P. chabaudi, no 
alteration of the GSH metabolism was found in correlation to CQ resistance and 
CQ resistance is most likely independent of GSH (Ferreira et al., 2004). 
1.7 Aims of this study 
• Establish that the GSH biosynthesis pathway is present in the P. 
falciparum cytosol. 
• Determination of the role and importance of GSH biosynthesis for P. 
falciparum survival and possible validation of γGCS and GS as drug targets 
in erythrocytic stages by reverse genetics. 
• Investigation into the role of GSH in the degradation of FPIX in CQ 
sensitive and resistant parasites and the influence of mutations in PfCRT 
on GSH metabolism. 
The results of this study are presented in three chapters. In Chapters 3 and 4 
the GSH biosynthesis enzymes PfγGCS and PfGS are investigated, 
respectively. The influence of GSH on CQ resistance and the influence of 
PfCRT mediated CQ resistance on GSH metabolism are described in Chapter 
5. The results and their implications are discussed in Chapter 7. 
  30 
2 Material and Methods  
2.1 Consumables, biological and chemical reagents 
Abcam  Mouse monoclonal anti-FKBP12 antibody 
ABgene  2x PCR Reddy Mix 
BD biosciences  Mouse monoclonal anti-His-antibody 
BDH  Saponin 
Bio-Rad Bradford protein assay reagent, Gene pulser 
electroporation cuvette (0.2 cm), Precision plus 
dual color protein standard 
Blood transfusion service  Human full blood 
BOC  Malaria culture gas (5% CO2, 1% O2, 94% N2) 
Clontech  Shld1 
Eurogentec  Oligonucleotides 
Fisher Scientific  10 x Phosphate buffered saline (PBS) 
Fluka  1-Choro-2,4-dinitrobenzene 
GE Healthcare Gene images AlkPhos direct labeling and 
detection system, Gene images CDP-Star 
detection module, Hypercassettes (18 x 24 cm), 
Hyperfilm ECL 
Invitrogen Accuprime Pfx SuperMix, Albumax II, 
chemically competent E. coli TOP10 and ccdB 
Survival T1 cells, gentamycin, PCR SuperMix, 
TOPO TA cloning kit, Trizol, RPMI 1640 (with 
25mM HEPES, L- glutamine, without NaHCO3), 
SYBR Safe 
Jacobus pharmaceuticals  WR99210 
Machery & Nagel  NucleoBond Xtra Maxi Plus Kit 
Melford Ampicillin, Carbenicillin, Isopropyl-β-D-
thiogalacopyranoside (IPTG), dithiothreitol 
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(DTT), β-nicotinamide adenine dinucleotide 
reduced (NADH), β-nicotinamide adenine 
dinucleotide phosphate reduced (NADPH), 
proteinase K 
Millipore  Immobilon Western Blot detection kit 
Nalgene  1.0 ml cryotubes 
New Engand Biolabs 1 kb DNA ladder, PCR marker, all restriction 
endonucleases and associated buffers,  
Novagen BugBuster protein extraction solution, 
benzonase, Chemically competent E. coli BLR 
(DE3) 
Promega Anti-mouse IgG (HRP conjugated), anti-rabbit 
IgG (HRP conjugated) 
Qiagen Qiaprep spin DNA miniprep Kit, Qiaquick gel 
extraction kit, Qiaamp DNA mini kit, Qiaquick 
PCR purification kit 
Roche Bovine Serum Albumin (BSA), Expand High 
Fidelity PCR system, Mouse monoclonal anti- 
GFP antibody, Rapid DNA ligation kit 
Schleicher & Schuell  Protran Nitrocellulose 
Sigma  All chemicals unless otherwise stated 
Stratagene Chemically competent E. coli XL10-Gold, 
Chemically competent Strataclone Solo Pack 
cells, Strataclone Blunt PCR cloning kit 
VWR  Giemsa stain 
Zeiss     Imersol 
2.2 Equipment 
Beckman Avanti J-26 XP centrifuge with JA20 rotor and 
JSP F10 rotor 
Billups Rothenberg  Modular incubation chamber 
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Biorad Gel tanks, Gene pulser Xcell electroporator, 
Power Pac 300, Power Pac Basic, Transblot 
semi-dry transfer cell 
Constant Systems  One shot cell disrupter 
Eppendorf  Microcentrifuge 5415D with F45-24-11 rotor 
Fisher Gel tanks, Microcentrifuge Accuspin MicroR 
with 24 place rotor, Waterbath 
GE Healthcare  Vacu Gene Pump, Vacu Gene XL 
G Storm  PCR machine 
Grant  Heat block QBT2 
Haereaus  Incubator 
Heidolph  Shaker Titramax 100 
IKA  Minishaker MS2 
Kuehner  Shaking incubator ISF-1-W 
Sciquip Sigma 6K 15 centrifuge with 11150 rotor and 
12500 rotor 
Shimadzu  UV-2401 and UV-2501 spectrophotometer  
Thermo electron  Jouan CR3i centrifuge with T40 rotor 
UVP  Hybridization oven HB-1000, UV cross linker 
Zeiss     Axioplan 2 microscope 
2.3 Buffers, Solutions and Media 
2.3.1 General Buffers 
1 x PBS 140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4, pH 7.4  
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2.3.2 DNA analysis 
6x DNA loading buffer 0.25 % (w/v) bromophenol blue, 0.25 % (w/v) 
xylene cyanol FF, 0.25 % (w/v) orange-G, 40 % 
(w/v) sucrose 
20 x SSC  300 mM Trisodium citrate, 3 M NaCl, pH 7-8 
Southern depurination  0.25 N HCl  
Southern denaturing   1.5 M NaCl, 0.5 M NaOH  
Southern hybridization Gene images AlkPhos hybridization buffer, 0.5 
M NaCl, 4 % (w/v) blocking reagent 
Southern first wash buffer 2 M Urea, 0.1 % (w/v) SDS, 50 mM sodium 
phosphate pH 7.0, 150 mM NaCl, 1 mM MgCl2, 
0.2 % (w/v) blocking reagent 
Southern second wash buffer 50 mM Tris base, 100 mM NaCl, 2 mM MgCl2 
TE 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
1 x TAE    40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
2.3.3 Protein analysis 
Coomassie stain 40 % (v/v) Methanol, 10 % (v/v) acetic acid, 0.1 
% (w/v) Coomassie brilliant blue R-250 
Destaining solution  20 % (v/v) Methanol, 10 % (v/v) acetic acid 
GS activity assay buffer 100 mM Bicine / Bis-Tris propane / Mes pH 7.5, 
10 mM MgCl2, 75 mM KCl 
6 x SDS loading buffer 62.5 mM Tris / HCl pH 6.8, 2 % (w/v) SDS, 10 % 
(v/v) glycerol, 0.001 % (w/v) bromophenol 
blue, 5 % (v/v) 2- mercaptoethanol 
2D Lysis buffer 100 mM HEPES pH 7.4, 5 mM MgCl2, 10 mM 
EDTA, 0.5 % Triton X-100, 5 µg/ml RNase A, 1 
mM PMSF, 1 mM benzamidine, 2 µg/ml 
leupeptin, 10 µM E-64, 2 mM 1,10- 
phenanthroline, 4 µM pepstatin A (protease 
inhibitors added fresh prior to use) 
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Running gel mix 375 mM Tris-base pH 8.9, 0.1 % SDS (w/v), 5-15 
% (v/v) acrylamide 
1x SDS PAGE running buffer 25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS 
Stacking gel mix 122 mM Tris-HCl pH 6.7, 0.1  SDS (w/v), 5 % 
acrylamide 
Towbin buffer 25 mM Tris, 192 mM glycine, 20 % (v/v) 
methanol 
Protein purification buffer A 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 1mM DTT 
Protein purification buffer B 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 20 mM 
imidazole, 1mM DTT 
Protein elution buffer C 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 300 mM 
imidazole, 1mM DTT 
2.3.4 Bacteria culture 
Ampicillin  100 mg/ml in ddH2O 
Carbenicillin  100 mg/ml in ddH2O  
Chloramphenicol  34 mg/ml in ethanol 
Kanamycin  50 mg/ml in ddH2O 
Luria Bertani (LB) medium  10 g/l Tryptone, 5 g/l yeast extract, 5 g/l NaCl 
LB agar  1.5 % (w/v) agar in LB medium 
Terrific Broth medium  12 g/l Tryptone, 24 g/l yeast extract, 0.4 % 
(v/v) glycerol, 9.4 g/l K2HPO4, 2.2 g/l KH2PO4 
pH 7.2 
Tetracycline    5 mg/ml in ethanol 
TfB I 100 mM RbCl, 50 mM MnCl2 x 4 H2O, 30 mM 
potassium acetate, 10 mM CaCl2 x 2 H20, 15 % 
(v/v) glycerol 
TfB II 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2 x 2 H20, 
15 % (v/v) glycerol 
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2.3.5 P. falciparum culture 
Ancotil  1 mM in blood wash medium 
Blasticidin-S-HCl  10 mg/ml in blood-wash medium 
Blood-wash medium 15.9 g/l RPMI 1640 (with 25 mM HEPES and L- 
glutamine), 0.1 % (w/v) sodium bicarbonate, 10 
mM glucose, 200 µM hypoxanthine, 20 µg/ml 
gentamycin, pH 7.4 
Complete RPMI 1640 medium Blood wash medium supplemented with 0.5 % 
(w/v) Albumax II 
Earle’s balanced salt solution (EBSS) 6.8 g/l NaCl, 0.4 g/l KCl, 0.2 g/l MgSO4 x 
7H2O, 0.158 g/l NaH2PO4 x 2 H2O, 0.264 g/l 
CaCl2 x 2H2O, 2.2 g/l NaHCO3, 1 g/l D-glucose 
IC50 Medium Complete RPMI 1640 medium without 
hypoxanthine 
Cytomix 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM 
MgCl2, 10 mM K2HPO4 / KH2PO4 pH 7.6, 25 mM 
HEPES pH 7.6 
Freezing solution  30 % (v/v) glycerol in PBS 
WR99210  Stock solution: 20 mM in dimethylsulphoxide 
     Working solution: 20 µM in blood- wash medium 
2.3.6 Bacteria strains 
BLR (DE3) (Novagen): 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) ∆(srl-recA)306::Tn10 (Tet
R) 
One Shot® ccdB Survival T1 (Invitrogen): 
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 ara∆139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG tonA::Ptrc-ccdA 
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One Shot® Top10 (Invitrogen): 
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 ara∆139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG 
XL10-Gold (Stratagene): 
Tetr ∆(mcrA)183 ∆(marc-hsdSMR-mrr)173 end A1 supE44 thi-1 recA1 gyrA96 relA1 
lac The [F’ proAB lacIq Z∆M15 Tn10 (Tetr) Amy Camr]a 
2.3.7 P. falciparum strains 
3D7 The Netherlands 
D10  Papua New Guinea 
GC03 Progeny of Dd2 X HB3 cross (Wellems et al., 1990) 
C2GC03 kind gift of D. Fidock (Sidhu et al., 2002) 
C3Dd2 kind gift of D. Fidock (Sidhu et al., 2002) 
C67G8    kind gift of D. Fidock (Sidhu et al., 2002) 
2.3.8 Oligonucleotide Primers 
Oligonucleotide primers were designed to amplify genes or gene fragments for 
knockout and localization studies, to introduce mutations or for quantitative real 
time PCR. To allow cloning into destination vectors, primers for knockout studies 
contained a 5’-extension containing the appropriate restriction sites. The 
primers used in this study are listed below according to application. Restriction 
sites are highlighted in bold print. Sites changed to introduce mutations are 
underlined. 
2.3.8.1 Mutagenesis 
GS muta fwd GAT ATA AAA CAA ATA AAG TAC GCT ACA ATA TCT 
GTT GCC 
GS muta rev GGC AAC AGA TAT TGT AGC GTA CTT TAT TTG TTT 
TAT ATC 
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2.3.8.2 Knockout studies in P. falciparum– cloning and analysis 
γGCS pHH1 KO fwd GCGC AGATCT CGT TAT GAT GAA AAT ATA ATG TTT 
GG (BglII) 
γGCS pHH1 KO rev GCGC CTCGAG ATC TTG TGT ATT TGA ACT ATC ATT 
AAC (XhoI) 
γGCS pHH1 KOcon fwd GCGC AGATCT GAT GTA ATA CTT GAC AAA AAT G 
(BglII) 
γGCS pHH1 KOcon rev GCGC CTCGAG TTA TGC ACT CAG TTC GTA C (XhoI) 
GS pHH1 KO fwd GCGC AGATCT GAT ATG ATT GCT TTT TTG AAT AC 
(BglII) 
GS pHH1 KO rev  GCGC CTCGAG GTC GTT CAA ATC GAT AAG AAG (XhoI) 
GS pHH1 KOcon fwd GCGC AGATCT CAT GAA GAT GAT TTT AAT AGT TTT G 
(BglII) 
GS pHH1 KOcon rev GCGC CTCGAG CTC AAT GTT CAG TTA AAA AAA AAG 
(XhoI) 
γGCS pCC 5’ fwd GCGC CCGCGG CGG AAC GCC ATT AAG CTG GGA TG 
(SacII) 
γGCS pCC 5’ rev GCGC CTTAAG CAT GGC CAG TAA TTC TTC TAG CC 
(AflII) 
γGCS pCC 3’ fwd GCGC CCATGG GAG CAT CCA AAA GAG AAG CTT TAA C 
(NcoI) 
γGCS pCC 3’ rev GCGC GGCGCC GCA AGT ATT GCG TAT AAT CCT CTC C 
(NarI) 
GS pCC 5’ fwd GCGC CCGCGG GTC CCA ATG GAA AGA ATG AAT ATC 
(SacII) 
GS pCC 5’ rev  GCGC CTTAAG CGA TTA GTC ATA TAA TCA GAT CTT 
CC (AflII) 
GS pCC 3’ fwd GCGC CCATGG GCC TTA CAA GTA GAC CCA TCT C 
(NcoI) 
GS pCC 3’ rev GCGC GGCGCC CCA AGC TTG ATA TAC CAC AAA TGG 
(NarI) 
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pCC 5’ sequencing fwd CTT TAA ATT CAT GCA AAA ATT TAC 
pCC 5’ sequencing rev CCA ATA GAT AAA ATT TGT AGA G 
pCC 3’ sequencing fwd CAT ATG TTA AAT ATT TAT TTC TC 
pCC 3’ sequencing rev CGG CAT CAG AGC AGA TTG TAC 
2.3.8.3 Expression constructs for P. falciparum– cloning and analysis 
γGCS gateway fwd CACC ATG GGT TTT CTA AAA ATC GGA ACG 
γGCS gateway rev TGC ACT CAG TTC GTA CAT TTT TTT TGC 
GS gateway fwd CACC ATG GAA AGA AAG GTA GAT GAG TT 
GS gateway rev ATG TTC AGT TAA AAA AAA AGA ATC C 
γGCS sequencing 1 CGA ATT TAC AAC AAC AAA ATG 
γGCS sequencing 2 GCT ATG ACA AAT AAA GAA G 
GS sequencing  CTG TTG CCT TTG GTA ATC TTT C 
2.3.8.4 Quantitative real time PCR 
γGCS-RT-fwd TCC TTG CTC TTA CTG CAT GTA CT 
γGCS-RT-rev TTC CGT TCT ACA ATC AAC ACT GT 
GS-RT-fwd CTT TAG AGC ATT ATA TAC ACC TAA CCA 
GS-RT-rev CGA ACC AAC AAG TTG ATA AGG TA 
CRT-RT-fwd GGA AAT ATC CAA TCA TTT GTT CTT 
CRT-RT-rev CAA CAA TAA TAA CTG CTC CGA GAT 
stRNAS-fwd AAG TAG CAG GTC ATC GTG GTT 
stRNAS-rev   TTC GGC ACA TTC TTC CAT AA 
2.3.9 Constructs 
Constructs generated and used for this study are listed in Table 2-1. The 
constructs were either used for recombinant expression of proteins or knockout 
studies in P. falciparum or for recombinant expression of proteins in E. coli. 
  
Name Insert Oligonucleotides Selectable Marker 
for P.falciparum 
Purpose 
pCC4-∆γGCS nucleotides 18-502 (5’flank) and 
2549-3070 (3’ flank) of γgcs ORF 
γGCS pCC 5’ fwd and rev 
γGCS pCC 3’ fwd and rev 
bsd, cd knockout of pfγgcs by gene 
replacement 
pCC4-∆GS nucleotides 65-542 (5’flank) and 
1468-1942 (3’ flank) of gs ORF 
GS pCC 5’ fwd and rev 
GS pCC 3’ fwd and rev  
bsd, cd knockout of pfgs by gene 
replacement 
pCHD-Hsp86-γGCS-GFP full length γgcs ORF γGCS gateway fwd 
γGCS gateway rev 
hdhfr recombinant expression of PfγGCS-
GFP in P. falciparum 
pCHD-Hsp86-γGCS-HA full length γgcs ORF γGCS gateway fwd 
γGCS gateway rev 
hdhfr recombinant expression of PfγGCS-
HA in P. falciparum 
pCHD-Hsp86-GS-GFP full length gs ORF GS gateway fwd 
GS gateway rev 
hdhfr recombinant expression of PfGS-
GFP in P. falciparum 
pCHD-Hsp86-GS-HA full length gs ORF GS gateway fwd 
GS gateway rev 
hdhfr recombinant expression of PfGS-HA 
in P. falciparum 
pCHD-HSP86-
GSE206K/N208A-FKBP12 
full length gs ORF GS gateway fwd 
GS gateway rev 
hdhfr recombinant expression of 
PfGSE206K/N208A-FKBP12 in P. 
falciparum 
pHH1-∆γGCS nucleotides 181-981 of γgcs ORF γGCS pHH1 KO fwd 
γGCS pHH1 KO rev 
hdhfr knockout of pfγgcs by gene 
disruption 
pHH1-γGCScon nucleotides 1870-3150 of γgcs 
ORF 
γGCS pHH1 KOcon fwd 
γGCS pHH1 KOcon rev 
hdhfr knock-in control for targeting of 
pfγgcs locus in P. falciparum  
pHH1-∆GS nucleotides 121-1125 of gs ORF GS pHH1 KO fwd 
GS pHH1 KO rev 
hdhfr knockout of pfgs by gene 
disruption 
pHH1-GScon nucleotides 886-1965 of gs ORF GS pHH1 KOcon fwd 
GS pHH1 KOcon rev 
hdhfr knock-in control for targeting of 
pfgs locus in P. falciparum 
pJC40-PfGS full length wild type gs ORF n.a. - recombinant expression of PfGS in 
E. coli 
pJC40-PfGSE206K/N208A full length gs ORF with 
E206K/N208A mutation 
GS muta fwd 
GS muta rev 
- recombinant expression of 
PfGSE206K/N208A in E. coli 
Table 2-1: Constructs generated and used in this study. 
Listed above are the constructs I generated in this study with the exception of pJC40-PfGS which was generated by S. Meierjohann (Meierjohann et al., 2002a). The 
oligonucleotides used for their generation are given. All of the constructs contain an ampicillin resistance cassette for selection in E. coli. 
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2.3.10 Antibodies 
Antibodies were used in this study for western blot analyses of recombinant 
proteins or parasite extracts. 
 Raised in Dilution for 
western blot 
Source 
anti-(His)10 mouse 1:10000 BD Biosciences 
anti-FKBP12 mouse 1:2000 Abcam 
anti-GFP mouse 1:1000 Roche 
anti-HA mouse 1:1000 Eurogentec 
anti-PfCK2α rabbit 1:200 kind gift of Prof. 
C. Doerig 
anti-PfCRT rabbit 1:2000 kind gift of Dr. P. 
Bray 
anti-PfGST rabbit 1:5000 kind gift of Prof. E. 
Liebau 
anti-PfGR rabbit 1:15000 Eurogentec 
Table 2-2: Primary antibodies and their dilutions. 
 Dilution in western blot Source 
anti-mouse IgG (H+L) HRP 
conjugate 
1:10000 Promega 
anti-rabbit IgG (H+L) HRP 
conjugate 
1:10000 Promega 
Table 2-3: Secondary antibodies and their dilutions. 
2.4 Molecular Biology 
2.4.1 Agarose gel electrophoresis 
For electophoresis, agarose was dissolved at the required concentration 
(between 0.8 and 2 % w/v) in 1 x TAE buffer (see 2.3.2) containing 0.5 µg / ml 
Sybr safe. For subsequent gel extraction low melting point agarose was used. 
DNA samples were mixed with 6 x DNA loading dye and electrophoresis was 
performed in 1x TAE at 5-10 V/cm gel. To determine the size of DNA bands 1 kb 
ladder (New England Biolabs) was run alongside samples. The DNA was visualized 
on a transilluminator. 
2.4.2 Determination of nucleic acid concentrations 
Concentrations of DNA and RNA solutions were determined by measuring the 
absorbance at 260 nm. Typically 1:50 or 1:100 dilutions in ddH2O were used for 
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standard preparations of DNA or RNA to keep the detected absorbance in the 
linear range between 0.1 and 1. Concentrations were calculated using the 
following equation: 
Concentration [µg /ml] = absorbance260 x DF x MF 
DF= dilution factor, e.g. 100 for a 1:100 dilution 
MF= multiplication factor: 50 for dsDNA, 40 for RNA 
DNA concentrations were alternatively determined by running small aliquots of 
samples alongside a standardized 1 kb DNA ladder of known concentration (NEB) 
on agarose gels. The concentration was determined by comparing the intensity 
of marker bands of the same size to the intensity of the sample on a 
transilluminator. The intensity of a DNA band is directly proportional to the 
amount of DNA. 
2.4.3 Ethanol precipitation of DNA 
Precipitation of DNA was performed to concentrate plasmid DNA or to exchange 
buffers before transfection of plasmids into P. falciparum. For each transfection 
100 µg plasmid DNA was precipitated. DNA solutions were mixed with 1/10 
volume of 3 M sodium acetate pH 5.2 and 3 volumes of 100 % ethanol. To 
facilitate precipitation 1 µl glycogen (Invitrogen; 20 µg/µl) was added. The DNA 
was kept at -20°C for at least one hour before being centrifuged for 20 min at 
15,000 g at 4°C. The supernatant was removed and the DNA pellet was washed 
with 70 % ethanol and centrifuged for 10 min at 15,000 g at 4°C. The following 
steps were carried out under a sterile category 2 tissue culture hood. The 
supernatant was removed and the pellet air dried. DNA for transfections was 
resuspended in 30 µl sterile TE buffer. 
2.4.4 Restriction endonuclease digests 
All restriction endonucleases used were purchased from New England Biolabs and 
used with the appropriate NEB buffer and BSA according to manufacturer’s 
instructions. All digests in this study were preformed in a heat block at 37°C. To 
analyse plasmids typically 2-3 µl of standard small scale purifications were 
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digested for 1.5 hours. For Southern blots 1 µg of genomic DNA was digested for 
approximately 24 hours. 
2.4.5 Polymerase Chain Reaction 
2.4.5.1 From P. falciparum genomic DNA or plasmid DNA templates 
For amplification of P. falciparum 3D7 genomic DNA for cloning, 100 ng of 
template DNA was mixed with each forward and reverse primers and either 
AccuPrime Pfx supermix (Invitrogen) or the components of the Expand High 
Fidelity PCR supermix (Roche) according to manufacturer’s instructions. Both 
kits contain a 3’-5’ exonuclease with proofreading activity. For the generation of 
probes for Southern blots appropriate plasmids containing the desired sequence 
were used as template (typically 1:20 dilution of a standard miniprep) with PCR 
Supermix (Invitrogen) and forward and reverse primers. Primer concentrations 
were 0.4 µM for Pfx supermix and PCR supermix and 0.2 µM for the Expand High 
Fidelity PCR supermix. The programmes used were: 
Pfx supermix / PCR supermix: 
Step 1:  95°C, 5 min 
Step 2: 95°C, 30 sec 
Step 3: annealing temperature between 40 – 60°C, 30 sec 
Step 4: 68°C, 1.5 min per 1000 base pairs to be amplified 
Repeat steps 2-4 for 30 cycles 
Step 5: 68°C, 10 min 
Step 6: Store at 10°C 
Expand High Fidelity Supermix 
Step 1:  95°C, 5 min 
Step 2: 95°C, 30 sec 
Step 3: annealing temperature between 40 – 60°C, 30 sec 
Step 4:  68°C, 1 min per 1000 base pairs to be amplified 
Repeat step 2-4 for 10 cycles 
Step 5: 95°C, 30 sec 
Step 6: annealing temperature between 40 – 60°C, 30 sec 
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Step 7: 68°C, 1 min per 1000 base pairs to amplified, elongate for 10 sec 
with every additional cycle 
Repeat steps 5-7 for 20 cycles 
Step 8: 68°C for 10 min 
Step 9: Store at 10°C 
The resulting PCR products were analysed by agarose gel electrophoreses before 
being used for cloning or the generation of probes for Southern blot analyses. 
2.4.5.2 Colony PCR 
Colony PCR was performed on bacteria clones to facilitate identification of 
correct clones following transformation of ligation reactions between destination 
vectors and inserts. Bacteria colonies were used as templates for the PCR and 
the primers used were specific for the insert. Before the PCR reaction was set 
up, an LB-plate containing the appropriate antibiotic was labelled with a 
numbered grid. PCR reactions were set up as 10 µl reactions per colony using 
Reddymix (ABgene) with each primer at 4 µM concentration according to 
manufacturer’s instructions. Single colonies were picked from transformation 
plates and used to inoculate the prepared gridded plate at a defined position, 
thus giving each colony screened a number before the remainder of the colony 
was transferred into a PCR tube containing the reaction mix. The gridded plate 
was incubated at 37°C overnight. The PCR conditions were: 
Step 1: 94°C, 10 min 
Step 2: 94°C, 60 sec 
Step 3: annealing temperature between 40 – 60°C, 60 sec 
Step 4:  68°C, 2 min per 1000 base pairs to be amplified 
Repeat steps 2-4 for 30 cycles 
Step 5: 68°C, 10 min 
Step 6: Store at 10°C 
PCR products were analysed by agarose gel electrophoreses. Potentially correct 
clones were identified by the presence of a PCR product of the correct size. 
These clones were subsequently analysed by plasmid isolation, restriction 
analyses and sequencing. 
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2.4.5.3 Site directed mutagenesis 
Site directed mutagenesis was carried out as previously described (Braman et 
al., 1996). Using this method, complete plasmids containing the required 
mutation were generated. The template used for mutagenesis was the pJC40-
PfGS wild-type construct previously described (Meierjohann et al., 2002a). Both 
forward and reverse primers contained the desired mutation. The PCR was set 
up using Accuprime Pfx supermix (Invitrogen) as a set of 25 µl reactions, each 
reaction containing 10 ng of plasmid DNA template and forward and reverse 
primers at 0.2 µM. The PCR was performed as a gradient PCR with separate 
reactions incubating at different annealing temperatures between 40 and 65°C. 
The PCR programme was as follows: 
Step 1: 95°C, 5 min 
Step 2: 95°C, 30 sec 
Step 3: 40- 65°C gradient, 15 sec 
Step 4: 68°C, 5 min 
Repeat steps 2- 4 for 15 cycles 
Step 5: 68°C, 10 min 
Step 6: store at 10°C 
To remove template DNA, PCR products were subsequently treated with 20 units 
DpnI at 37°C for 5 to 16 hours. This method removes the methylated plasmid 
template DNA while leaving the non-methylated PCR products containing the 
desired mutation, because DpnI is a restriction endonuclease specific for the 
sequence GATC in methylated and hemi-methylated DNA. The DpnI treated PCR 
products were subsequently transformed into E. coli Top10 cells (Invitrogen) (see 
2.4.7.2). 
2.4.5.4 Quantitative real time PCR 
The transcription levels of pfγgcs, pfgs and pfcrt were analysed using the 7500 
Real Time PCR system by Applied Biosystems. Real time PCR reactions were 
performed in 25 µl reactions using QuantiTect SYBR green master mix (Qiagen) 
and primers at a final concentration of 0.3 µM according to Salanti et al. (Salanti 
et al., 2003). As template 5 µl of a 1:10 dilution of cDNA generated with the 
Ambion RETROscript® kit (see 2.4.9) was used. Seryl-tRNA-synthetase (strs) was 
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used as the mRNA control of a housekeeping gene as it has been described by 
Salanti et al. to have a uniform transcription pattern throughout the parasite life 
cycle and initial tests showed that the abundance of strs mRNA was similar to 
the mRNA of the genes analysed. PCR cycling conditions were 50°C for 2 min, 
95°C for 15 min, followed by 40 cycles of 95°C for 15 sec, 54°C for 30 sec and 
68°C for 35 sec. The length of the fragments amplified was 100 bp for pfγgcs, 
117 bp for pfgs, 117 bp for pfcrt and 157 bp for pfstrs. Relative expression levels 
were calculated using the ∆∆CT method (User Bulletin 2, Applied Biosystems). 
2.4.6 Cloning techniques 
2.4.6.1 TOPO Cloning of PCR products 
PCR products were initially cloned into TOPO vectors (Invitrogen) before cloning 
into the destination vectors pHH1 or pCC4 (Maier et al., 2006; Reed et al., 
2000). This step was introduced because it can facilitate cloning of AT-rich 
fragments if the yield of the PCR reaction is poor and it allows sequencing of the 
fragments prior to introducing them into the destination vectors. Depending on 
the polymerase used for amplification two different types of vectors were used 
for subcloning. PCR products generated using Taq based polymerases, such as in 
the Expand High fidelity PCR supermix (Roche) contained adenine overhangs at 
the 3’-ends. These were cloned into the pCR2.1-TOPO vector (Figure 2-1) using 
the TOPO TA® PCR cloning kit (Invitrogen). PCR products generated using 
Pfx/Pfu based polymerases such as the Accuprime Pfx supermix had blunt ends 
and were cloned into the pCR-Blunt II-TOPO vector (Figure 2-2) using the Zero 
Blunt TOPO® PCR cloning kit (Invitrogen). 
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pCR2.1-TOPO
3931 bp
KanR
M13 forward primer
M13 reverse primer
TOPO binding site
TOPO binding site
3'-T overhang
3'-T overhang
 
Figure 2-1: Vector map of pCR2.1-TOPO. 
This figure displays the important features of the pCR2.1-TOPO plasmid. This plasmid was used to 
clone PCR fragments amplified with Taq based polymerase. The plasmid contains a kanamycin 
resistance cassette (KanR, 795 bp) for selection in E.coli. Topoisomerase I is covalently bound at 
the TOPO binding sites. The binding sites also contain a 3’ T-overhang to allow cloning of PCR 
products with 3’ A-overhangs. After cloning PCR products could be sequenced using the M13 
forward and M13 reverse primers. 
pCR- Blunt II- TOPO
3519 bp
KanR
M13 forward primerM13 reverse primer
TOPO binding site TOPO binding site
 
Figure 2-2: Vector map of pCR-Blunt II- TOPO. 
This figure displays the important features of the pCR-Blunt II- TOPO plasmid. This plasmid was 
used to clone PCR fragments amplified with Pfx/Pfu based polymerase and contains a kanamycin 
resistance cassette (KanR, 795 bp) for selection of constructs in E. coli. Topoisomerase I is 
covalently bound at the TOPO binding sites to allow cloning of blunt PCR products and PCR 
fragments could be sequenced following cloning using M13 forward and M13 reverse primers. 
A special type of TOPO- cloning was performed to generate entry clones for 
MultiSite Gateway® cloning. In this case the forward primer used for the 
amplification of the gene of interest contained four additional bases at the 5’ 
end, creating a CACC overhang homologous to a GTGG overhang in the cloning 
vector. This allowed directional cloning of the gene into the vector pENTR/D-
TOPO (Figure 2-3). 
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pENTR/D- TOPO
2580 bp KanR
M13 forward primer M13 reverse primer
TOPO binding siteTOPO binding site
attL1 attL2
5'-GGTG overhang
 
Figure 2-3: Vector map of pENTR/D-TOPO. 
This figure displays the important features of the pENTR/D-TOPO plasmid. This plasmid was used 
to generate entry clones for the MultiSite Gateway® system (Invitrogen). The plasmid possesses a 
kanamycin resistance cassette (KanR, 795 bp) for selection in E. coli. Topoisomerase I is 
covalently bound at the TOPO binding sites and to allow directional cloning of PCR fragments the 
plasmid contains a 5’ GGTG- overhang which stabilizes PCR products with a 3’ CACC extension 
on the forward primer in the right orientation. Cloned PCR products can be sequenced using M13 
forward and M13 reverse primers. The vector contains attL1 and attL2 sites compatible with the 
MultiSite Gateway® system. 
All kits were used following manufacturer’s instructions. Ligations were 
transformed into E.coli TOP10 chemically competent cells (Invitrogen) and 
selected with kanamycin (see 2.4.7.2). From the transformation plates a number 
of colonies were picked for analyses. Plasmid DNA was isolated and analysed by 
restriction digests (see 2.4.8.1 and 2.4.4, respectively). Plasmids containing 
inserts of the right size were sent for sequencing (The Sequencing Service, 
University of Dundee) using M13 forward, M13 reverse or internal primers. 
2.4.6.2 Subcloning into destination vectors 
TOPO-clones containing the desired inserts were used for subcloning into the 
destination vectors. 3 µg of the respective TOPO vector containing the desired 
inserts and 3 µg of destination plasmid were digested overnight with the 
relevant restriction enzymes (see 2.4.4). The digested DNA was separated on 
agarose gels (see 2.4.1) followed by gel extraction using the Qiaquick gel 
purification kit (Qiagen) according to manufacturer’s instructions. Samples were 
eluted in 30 µl of water and 3 µl per sample were subsequently analysed by 
agarose gel electrophoresis to asses the purity of the samples and to quantify 
DNA concentrations. 
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Ligation reactions of inserts and vectors were performed using 20 units T4 DNA 
ligase (NEB) with the provided buffer in a final reaction volume of 20 µl. Vector 
and insert DNA were mixed at ratios ranging from 1:3 to 1:10. Ligation reactions 
were incubated at 14°C overnight and were subsequently transformed into 
chemically competent TOP10 cells (Invitrogen). Transformed bacteria were 
analysed by colony PCR (see 2.4.5.2) and clones containing the desired inserts 
were analysed by plasmid extraction followed by diagnostic restriction digests. 
Clones with the correct restriction patterns for insert and vector were verified 
by DNA sequencing. 
2.4.6.3 Gateway cloning 
MultiSite Gateway® technology (Invitrogen) is based on the site specific 
recombination system of the bacteriophage lambda (Landy, 1989) and allows the 
simultaneous cloning of multiple DNA fragments in a defined order and 
orientation. The Gateway® technology allows cloning of PCR products into 
MultiSite Gateway® Donor vectors with the BP reaction, which resembles 
integration of the lambda phage into the E. coli chromosome in the lysogenic 
cycle. Thus generated, entry clones can then be combined and cloned into 
destination vectors in an LR reaction, resembling the excision of lambda at the 
start of the lytic cycle.  
In this study, only LR reactions were performed using LR Clonase II Plus enzyme 
mix (Invitrogen) according to manufacturer’s instructions. Gateway cloning was 
preformed to generate expression constructs for C-terminally tagged PfγGCS and 
PfGS. The tags introduced were either green fluorescent protein (GFP), 
hemagglutinin (HA) or a mutant form of the human 12 kDa FK506 binding protein 
(FKBP12) (Armstrong and Goldberg, 2007; van Dooren et al., 2005). The FKBP12-
tag contained two mutations: F36V which allows the binding of the ligand Shld1 
and L106P which destabilizes the tagged protein in absence of Shld1 
(Banaszynski et al., 2006). The destination plasmid used was pCHDR-3/4 (Figure 
2-4) previously described by van Dooren (van Dooren et al., 2005). 
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pCHD-3/4
8058 bp
ccdB
Cm(R)
hDHFR
AmpR
PfHRPII 3'
PbDHFR/TS 3'
PfCAM 5'
attR4
attR3
 
Figure 2-4: Vector map of pCHD-3/4. 
This figure displays the important features of the pCHD-3/4 MultiSite Gateway® destination vector. 
The plasmid contains an ampicillin resistance cassette (AmpR, 861 bp) for selection in bacteria. 
Further, the plasmid contains a negative selection cassette containing the ccdB death gene (306 
bp) flanked by two recombination sites attR4 and attR3 which allow recombination with entry 
clones in a multisite gateway® LR reaction. After recombination the death gene is replaced by the 
expression cassette flanked by the P. berghei dihydrofolate reductase / thymidilate synthase 3’ 
UTR (PbDHFR/TS 3’, 853 bp). The plasmid contains the human dihydrofolate reductase gene 
(hDHFR, 564 bp) for selection in P. falciparum. The hDHFR is under control of the P. falciparum 
calmodulin promoter (PfCAM 5’, 631 bp) and flanked by the P. falciparum histidine- rich protein2 3’ 
UTR (PfHRPII 3’). 
The genes of interest were amplified by PCR and directionally cloned into the 
pENTR/D-TOPO (Invitrogen) vector (see 2.4.6.1). To introduce a promoter to the 
expression cassette, the PfHsp86 5’-pDONR4/1 entry clone was used (van Dooren 
et al., 2005). This construct contains the P. falciparum Hsp86 5’ UTR (Figure 
2-5). 
Hsp86 5`- pENTR4/1
3500 bpattL4
KanR
Hsp86 5'
attR1
 
Figure 2-5: Vector map of Hsp86 5’- pENTR4/1. 
This figure displays the important features of the promoter entry clone Hsp86 5’-pENTR4/1. The 
plasmid contains a kanamycin resistance cassette (KanR, 810bp) for selection in E. coli. The 
Hsp86 5’ element is flanked by the recombination sites attL4 and attL1 which allow recombination 
in a multisite gateway® LR reaction. 
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To introduce the tags, the construct GFPmut2-pENTR2/3 was used for the GFP-
tag, the construct 3x HAc-pENTR2/3 for the HA-tag (van Dooren et al., 2005) and 
the construct FKBP12-pENTR2/3 for the FKBP12-tag (Armstrong and Goldberg, 
2007) (Figure 2-6). 
FKBP12- pENTR2/3
3002 bp
KanR
FKBP12
attR3
attL3
3x HAc- pENTR2/3
2740 bp KanR
3x HA
attR2
attL3
GFPmut2- pENTR2/3
3374 bp
KanR
GFPmut2
attR3
attL3
A B
C
 
Figure 2-6: Vector maps of 3x HAc- pENTR2/3, FKBP12- pENTR2/3 and GFPmut2- pENTR2/3. 
This figure displays the important features of the tag-entry vectors 3x HAc-pENTR2/3 (Panel A), 
FKBP12-pENTR2/3 (Panel B) and GFPmut2-pENTR2/3 (Panel C). All three contain a kanamycin 
resistance cassette (KanR, 810 bp) for selection of the plasmids in bacteria. The tags 3x HAc, 
FKBP12 and GFPmut2 to be introduced into the destination vector are flanked by the 
recombination sites attR3 and attL3 which will fuse the tags to the C-terminus of the gene of 
interest in the MultiSite Gateway® LR reaction. 
2.4.7 Transformation of E. coli 
2.4.7.1 Preparation of chemically competent cells 
A 5 ml pre-culture was grown overnight in LB-medium (see 2.3.4) and used to 
inoculate 500 ml fresh medium the next morning. Cells were grown at 37°C in a 
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shaking incubator until the OD600 of the culture reached 0.5. The bacteria 
culture was subsequently cooled on ice for 15 min before being transferred into 
sterile centrifuge tubes. Cells were spun down at 6,000 g for 10 min at 4°C. The 
supernatant was discarded and the cells were resuspended in 30 ml Tfb I (see 
2.3.4). The cells were incubated on ice for 15 min before centrifugation at  
6,000 g for 5 min. The supernatant was again discarded and the cells were 
resuspended in 6 ml TfB II (see 2.3.4). The cells were aliquoted into 1.5 ml 
Eppendorf tubes and shock frozen on dry ice. Chemically competent cells were 
stored at -80°C. 
2.4.7.2 Transformation of chemically competent cells 
Chemically competent cells were thawed on ice and gently mixed with plasmid 
DNA, either of existing plasmids or ligation reactions. The cells were incubated 
on ice for 30 min before being heat shocked in a heat block at 42°C for 30 to 45 
sec. The cells were immediately transferred back on ice. After 2 min, 5-10 
volumes of SOC- or LB-medium (see 2.3.4) were added. Cells were incubated at 
37°C with constant shaking at 200 rpm for 45 to 60 min before being plated on 
LB-agar plates containing the appropriate antibiotic for selection of the 
plasmids. 
For general cloning either chemically competent OneShot® Top10 cells 
(Invitrogen) or chemically competent Strataclone SoloPack® cells (Stratagene) 
were used. For gateway cloning reactions OneShot® Top10 cells were used 
whereas for amplification of existing plasmids self made chemically competent 
Top10 cells were used. For protein expression self made chemically competent 
BLR (DE3) cells were used. 
2.4.8 Isolation of plasmid DNA from E.coli 
Plasmid DNA was isolated from E.coli by two methods depending on the desired 
amount of plasmid. Both methods involved alkaline lysis of bacteria followed by 
precipitation of most bacterial proteins and genomic DNA with SDS and final 
purification using silica columns. 
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2.4.8.1 Small scale plasmid purification (Miniprep) 
Small scale purifications were performed using the Qiaprep Spin Miniprep Kit 
(Qiagen). Single bacteria colonies were picked from agar plates to inoculate 3 ml 
of LB-medium containing the appropriate antibiotic for selection of the 
respective plasmids (see 2.3.4). Cultures were grown at 37°C overnight with 
constant shaking at 200 rpm. Plasmid DNA was isolated following manufacturer’s 
instructions and eluted with 50 µl sterile water. The typical yield was between 
10 -30 µg of plasmid DNA. 
2.4.8.2 Large scale plasmid purification (Maxiprep) 
Large scale purifications were performed using the Nucleo Bond Xtra Maxi Plus 
Kit from Machery and Nagel. Single bacterial colonies were picked from fresh 
agar plates to inoculate 5 ml pre-cultures of terrific broth medium (see 2.3.4) 
containing antibiotics for selection of the respective plasmids. Pre-cultures were 
incubated for 8 hours at 37°C before being diluted 1:100 into 500 ml of fresh 
terrific broth medium with the appropriate antibiotic. These main cultures were 
incubated at 37°C overnight with constant shaking at 200 rpm. The plasmid DNA 
was extracted following manufacturer’s instructions. The typical yield was 
between 0.5 and 2 mg of plasmid DNA. 
2.4.9 Reverse transcription 
Reverse transcription of RNA was performed using the RETROscript® reverse 
transcription for real time PCR kit from Ambion according to manufacturer’s 
instructions. Prior to reverse transcription, parasite RNA was treated with Turbo 
DNA-free (Ambion) according to manufacturer’s instructions to remove any 
traces of contaminating DNA (see 2.7.8 for RNA preparation). 10 µg of extracted 
RNA were used in a 50 µl reaction for this treatment. Of the DNase treated RNA, 
10 µl corresponding to 1-2 µg of RNA was used for the generation of cDNA. 
Reverse transcription was preformed following the two step RT-PCR protocol 
with heat denaturation step according to manufacturer’s instructions. The cDNA 
was stored at -20°C. 
Materials and Methods  53 
 
2.4.10 Southern blot analyses 
To analyse genotypes of transfected P. falciparum lines, 1 µg samples of isolated 
genomic DNA were analysed by Southern blotting (see 2.7.7 for gDNA 
preparation). The DNA was digested with appropriate restriction endonucleases 
for 24 hours (see 2.4.4). The digested DNA was separated on a 0.8 % agarose gel 
at 20 V overnight. For the transfer, a VacuGene XL apparatus (Amersham) was 
used. The porous filter membrane of the blotter was wetted with ddH20 and a 
Hybond N+ nitrocellulose membrane was placed on top. The plastic mask was 
placed around the membrane and the membrane covered with 0.25 N HCl before 
the gel was placed on top, taking care to achieve a tight seal between 
membrane, mask and gel. The gel was covered with 0.25 N HCl and the vacuum 
pump turned on, keeping the pressure between 50 and 60 mbar. The DNA was 
depurinated with 0.25 N HCl until the colour of bromophenolblue used in the 
DNA loading dye changed from blue to yellow. After the change in colour, the 
HCl was removed and the gel covered with denaturing solution until the colour 
changed back to blue (see 2.3.2 for all buffers and solutions). The denaturing 
solution was removed and the gel covered with 20 x SSC. The transfer continued 
for further 60 min. Afterwards all remaining 20 x SSC was removed and the 
sample wells marked on the membrane with a blunt pencil. The blotting 
apparatus was dismantled and the DNA cross linked with the membrane in a UV 
cross linker at 700 x 100 µJ/cm2. Membranes were pre-hybridized in 
hybridization buffer without probe for at least 15 min at 55°C. 
For the labelling of probes the Gene images AlkPhos direct labelling and 
detection system (GE Healthcare) was used according to manufacturer’s 
instructions. Probes were either gene-specific or specific for the selectable 
marker of the transfection plasmids. DNA for probes was amplified by PCR (see 
2.4.5.1) and the resulting PCR product was purified using the Qiaquik PCR 
purification kit (Qiagen) according to manufacturer’s instructions. The probes 
were added to the hybridization solution and incubated with the membrane 
overnight at 55°C. Membranes were washed twice for 10 min with primary wash 
buffer at 55°C followed by two 5 min wash steps at room temperature with 
secondary wash buffer. CDP Star detection solution (GE Healthcare) was added 
to the membrane for 5 min. After excess detection reagent was removed, 
membranes were heat sealed in plastic bags and the light produced by the 
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decomposition of the detection reagent was detected by exposure to 
autoradiography films (Amersham). 
2.5 Biochemistry 
2.5.1 Sodium dodecyl sulphate polyacrylamide gel 
electrophoreses (SDS PAGE) 
Separation of proteins was performed by SDS-PAGE according to Laemmli 
(Laemmli, 1970). Gels consisted of a running gel and a stacking gel and were run 
using the NuPAGE electrophoresis system by Invitrogen. The percentage of 
running gels ranged from 7.5-15 %, depending on the size of the protein of 
interest. For all buffers and solutions see 2.3.3. The gels were poured into 
empty 1 mm plastic cassettes (Invitrogen) and per gel, 6 ml running gel mix was 
polymerized by addition of 25 µl ammonium persulfate (20 %, w/v) and 5 µl 
N,N,N’,N’- tetramethylethylenediamine (TEMED). Once the running gel was set, 
2 ml stacking gel mix was poured on top after addition of 10 µl ammonium 
persulfate and 2 µl TEMED and an appropriate comb was inserted. 5-20 µg of 
parasite protein extract was mixed with 6 x protein loading dye and denatured 
at 100°C for 5 min. Samples were loaded and the gels ran in 1 x SDS PAGE 
running buffer at 40 mA and a maximum of 200 V. Following electrophoreses, 
gels were either stained with Coomassie or were used for western blots. 
2.5.2 Coomassie blue staining of polyacrylamide gels 
Following electrophoresis, polyacrylamide gels were removed from cassettes and 
stained with Coomassie staining solution for one hour at room temperature with 
gentle agitation. Afterwards, gels were destained with destaining solution for 
several hours at room temperature with gentle agitation. 
2.5.3 Bradford Assay 
Concentrations of parasite protein extracts were determined according to 
Bradford (Bradford, 1976) using 5x Bio-Rad assay reagent. 4 parts protein 
solution were mixed with 1 part Bradford reagent and the absorbance at 595 nm 
determined. BSA solutions of known concentration were used to generate a 
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standard curve as a reference to calculate the concentration of unknown 
samples. 
2.5.4 Western blot analyses 
Proteins were transferred onto Protran nitrocellulose membranes (Schleicher & 
Schuell) following separation by SDS-PAGE. A Transblot semi-dry transfer system 
from Biorad was used according to manufacturer’s instructions. Blots were set 
up as a sandwich of six pieces of Whatman paper cut to size and soaked in 
Towbin buffer (see 2.3.3 for all buffers and solutions), nitrocellulose, gel and 
another six pieces of soaked Whatman paper from bottom to top. Transfer was 
in a downward direction at a fixed voltage of 20 V for 40 min. Following transfer 
membranes were stained with Ponceau S solution (Sigma) and lanes were marked 
on the membrane with a blunt pencil. The Ponceau stain was removed by 
washing the membrane with PBS containing 0.1 % Tween 20 (v/v). Blots were 
blocked in 5 % (w/v) skimmed milk in PBS (see 2.3.1) on a shaker, either for 60 
min at room temperature or overnight at 4°C in the cold room. Following 
blocking membranes were washed 3 x 10 min with PBS/ 0.1 % Tween20 (v/v) and 
subsequently incubated with primary antibodies for at least 60 min at room 
temperature with constant shaking. The antibodies were diluted to the required 
concentration (see Table 2-2) in 2 % (w/v) skimmed milk in PBS/ 0.1 % Tween 
(v/v). Blots were washed three times in PBS/ 0.1 % Tween20 (v/v) for 10 minutes 
with shaking. Secondary antibodies were diluted to the required concentration 
(see Table 2-3) in 2 % (w/v) skimmed milk in PBS / 0.1 % (w/v) Tween20 and 
incubated with membranes for 60 min. The membranes were washed again three 
times in PBS / Tween20 as before. Horseradish peroxidase (HRP) conjugated 
secondary antibodies were detected with the immobilon western blot detection 
kit (Milipore) and visualized by exposing blots to X-ray films. 
2.5.5 BugBuster protein extraction 
The Novagen BugBuster protein extraction solution was used to confirm the 
optimal expression conditions for recombinantly expressed PfGS. A 5 ml 
overnight culture of E. coli BLR (DE3) transformed with the expression construct 
was used to inoculate four 50 ml flasks of fresh LB-medium (1:50 dilution, see 
2.3.4) containing the appropriate antibiotic. Bacteria cultures were incubated at 
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37°C until they reached an OD600 of 0.6 and subsequently induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). Each flask was incubated at a 
different temperature (37°C, 30°C, 25°C, and 18°C) and 1 ml samples were 
taken from each culture at the time of induction and at every following hour. 
The final samples were taken after overnight expression. The samples were 
centrifuged at 15,000 g for 1 min and the supernatant discarded. Bacterial 
pellets were resuspended in 100 µl BugBuster reagent and 0.5 µl benzonase were 
added to digest bacterial DNA. Samples were incubated at room temperature for 
15 min with constant shaking followed by 15 min centrifugation at 15,000 g at 
4°C. The supernatants were transferred into clean 1.5 ml tubes and the pellets 
resuspended in 100 µl PBS. 5 µl of the pellet fractions and 15 µl of the 
supernatant fractions were separated by SDS-PAGE (see 2.5.1) and analysed by 
western blotting (see 2.5.4). 
2.5.6 Expression of P. falciparum glutathione synthetase 
Expression of PfGS and PfGSE206K/N208A was performed as previously described 
(Meierjohann et al., 2002a). The expression constructs for pJC40-GS and pJC40-
GSE206K/N208A were transformed into chemically competent E. coli BLR (DE3) cells. 
The properties of the expression vector pJC40 are displayed in Figure 2-7. 
pJC40
2402 bp
AmpR
Factor Xa
T7- promoter
His10-tag
NdeI
XhoI
 
Figure 2-7: Vector map of pJC40 
This figure displays the important features of the pJC40 recombinant protein expression plasmid. 
The plasmid contains an ampicillin resistance cassette (AmpR, 861 bp) for selection in E.coli. 
Restriction sites NdeI and XhoI were used for cloning the PfGS ORF. Expression is under the 
control of the T7 promoter and a His(10)- tag is attached to the N- terminus of the protein and can be 
cleaved off with factor Xa. 
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Single colonies were picked to inoculate 5 ml LB-ampicillin-medium and 
incubated at 37°C for 8 hours. This starter culture was diluted into 50 ml fresh 
LB-ampicillin medium and incubated overnight. Again the culture was diluted 
1:50 with fresh LB-ampicillin medium and the bacteria were incubated at 37°C 
until the OD600 reached 0.5. The temperature was reduced to 25°C and the PfGS 
expression was induced by addition of IPTG (1 mM final concentration). 
Expression took place overnight and the following day cells were centrifuged for 
15 min at 4°C at 6,000 g in 500 ml aliquots. Each bacteria pellet corresponding 
to 500 ml culture was resuspended in 10 ml buffer A (see 2.3.3) and stored at -
20°C. To purify PfGS, bacteria pellets were thawed and 50 µg/ml lysozyme 
added. The pellets were incubated for 30 min on ice and protease inhibitors 
phenylmethylsulfonylfluoride (PMSF, 1 mM), leupeptin (2 µg/ml) and pepstatin- 
A (1.5 µM) were added. Bacteria were disrupted using a one shot cell disrupter 
(Constant Systems) at 15 kpsi. Subsequently the disrupted bacteria were 
centrifuged at 48,000 g for 60 min at 4°C. 
2.5.7 Purification of PfGS and PfGSE206K/N208A 
Following centrifugation, bacterial lysate (see 2.5.6) was filtered through a 0.8 
µm syringe filter. Nickel-nitrilotriacetic acid (Ni2+-NTA) agarose was washed with 
ddH2O and equilibrated with buffer A (for all buffers see 2.3.3). The filtered 
lysate was added to the Ni2+-NTA agarose and incubated for 60 min on a rotating 
wheel to allow binding of the His-tagged recombinant protein. All steps were 
carried out at 4°C. Approximately 5-10 mg of protein was bound to 1 ml of 
agarose. The agarose was pelleted by centrifugation at 150 g for 5 min. The 
supernatant was carefully removed and the agarose washed with buffer A for 30 
min with rotation. Agarose beads were pelleted as before and washed twice for 
20 min with buffer B. After the last wash the resin was poured into an Econo-Pac 
column (Bio-Rad) and allowed to set. The protein was eluted with elution buffer 
C. For a 500 ml bacterial pellet 1 ml of elution buffer was used. 
2.5.8 Determination of PfGS and PfGSE206K/N208A activity 
The enzyme activity of PfGS and PfGSE206K/N208A was determined as previously 
described (Meierjohann et al., 2002a). The assay was performed in a 1 ml 
volume of reaction buffer (see 2.3.3) at 30°C. NADH was added to a final 
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concentration of 0.2 mM and ATP, sodium phosphoenolpyruvate and glycine were 
added to final concentrations of 5 mM, 5 mM and 40 mM, respectively. 2 mM γ-L-
glutamyl-L-α-aminobutyrate was used as substrate instead of γ-L-glutamyl-L-
cysteine to avoid thiol oxidation. 5 units / ml of pyruvate kinase (type III rabbit 
muscle) and 10 units / ml lactate dehydrogenase (type II rabbit muscle) were 
added and the reaction was started by addition of the purified PfGS or 
PfGSE206K/N208A. The enzyme activity was measured by following the change in 
absorbance at 340 nm. Active GS consumes ATP during the formation of GSH and 
thus leads to the accumulation of ADP. Pyruvte kinase uses phosphoenolpyruvate 
to convert ADP back to ATP, thereby generating pyruvate. The pyruvate is in 
turn converted to lactate by the lactate dehydrogenase in a reaction that leads 
to the oxidation of NADH to NAD+. This oxidation process leads to a decrease in 
absorption at 340 nm detected in a Shimadzu UVPC 2501 spectrophotometer. 
2.6 Bioinformatics 
2.6.1 Statistical analysis 
Statistical analyses were performed using Prism 3.0 software. In order to analyse 
if two groups of samples were significantly different an unpaired Student t–test 
was performed. More than two groups of samples were analysed by one-way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc analyses if 
differences were significant. 
2.6.2 Sequence alignment 
Alignments of multiple protein sequences were performed using either  
ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html) or TCoffee 
(http://www.ebi.ac.uk/Tools/t-coffee/index.html) software. 
2.7 P. falciparum cell culture 
2.7.1 Culturing of P. falciparum 
Erythrocytic stages of P. falciparum were cultured according to Trager and 
Jensen (Trager and Jensen, 1976). All culture work was performed in a category 
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2 tissue culture hood and all solutions used were filter sterilized prior to use. 
Parasites were kept in sterile cell culture flasks at 37°C in an atmosphere of 5 % 
CO2, 1 % O2 and 94 % N2. Erythrocytes were washed in blood wash medium (see 
2.3.5) by centrifuging at 700 g at 4°C for 10 min and subsequently replacing the 
supernatant with fresh blood wash medium. This was repeated 3 to 4 times until 
the supernatant appeared clear. Washed erythrocytes were stored at 4°C and 
used for up to four weeks. Erythrocytes were added to cultures at 5 % 
hematocrit. Every 24 hours the medium was carefully aspirated without 
disturbing the cell layer at the bottom of the flasks and fresh RPMI 1640 
complete medium (see 2.3.5) was added. Cultures were regularly diluted with 
fresh erythrocytes and medium so that the parasitemia was kept below 10 %. A 
parasitemia of 2-4 % was considered optimal. 
2.7.2 Giemsa staining of blood smears 
To determine the parasitemia, Giemsa stained thin smears of infected red blood 
cells were examined using a light microscope with 100 x objective. For the 
smears small amounts of sedimented erythrocytes were taken from the cultures 
and spread on a glass slide. After drying, cells were fixed in 100 % methanol and 
stained for 10 min in Giemsa solution (1:25 dilution). Excess staining solution 
was washed off with water and the slides were air dried. Afterwards slides were 
examined with a 100 x oil immersion objective under the light microscope. To 
determine the parasitemia the ratio of erythrocytes to parasites was 
determined. Erythrocytes infected with multiple parasites were counted as 
single infections. 
2.7.3 Parasite stabilates 
For stabilates, a 10 ml culture with 5-7 % parasitemia containing mostly ring 
stages was used. The infected red blood cells were sedimented by centrifugation 
at 400 g at 4°C for 5 min. The medium was removed and the cell pellet 
resuspended in one pellet volume of cold RPMI 1640 complete medium. Two 
pellet volumes of cold freezing solution (30 % (v/v) glycerol in PBS) were added 
and carefully mixed. 600 µl aliquots of the cell suspension were transferred into 
cryotubes and incubated on ice for 15 min before storage in liquid nitrogen. 
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2.7.4 Thawing of P. falciparum stabilates 
Cells were thawed in a 37°C water bath and immediately placed on ice. The 
stabilates were transferred into a 15 ml tube and 2 volumes of ice cold 27 % 
sorbitol (w/v in 10 mM potassium phosphate pH 7.2) were drop-wise added with 
constant shaking. The cells were incubated on ice for 13 min before twice the 
original pellet volume of ice cold 5 % sorbitol was added. After incubation on ice 
for 10 min the cells were centrifuged at 400 g at 4°C for 5 min. The supernatant 
was removed and the cell pellet carefully resuspended in 5 % sorbitol (w/v in 10 
mM potassium phosphate pH 7.2). After incubation for 8 min the cells were 
pelleted again as before. The supernatant was removed and the cells were 
washed twice with cold RPMI 1640 complete medium. After the final wash, cells 
were resuspended in RPMI 1640 complete medium and erythrocytes were added 
to a hematocrit of 2.5 %. Once parasites had grown to a density of approximately 
2 % the hematocrit was raised to 5 %. If required, the adequate drug was added 
as soon as parasites reached a sufficiently high parasitemia (1-2 %). 
2.7.5 Synchronising of P. falciparum cultures with sorbitol 
Parasites were synchronized in ring stages as previously described (Lambros and 
Vanderberg, 1979). Cultures were centrifuged at 400 g at room temperature for 
5 min and the supernatant was discarded. The cell pellet was resuspended in 5 
pellet volumes of 5 % sorbitol (w/v in 10 mM potassium phosphate pH 7.2) and 
incubated at 37°C for 5 min. After incubation, the cells were centrifuged as 
before and the supernatant removed. The cells were resuspended in complete 
RPMI 1640 medium and cultured as described above (see 2.7.1). 
2.7.6 Saponin lysis of P. falciparum infected red blood cells 
For the subsequent isolation of genomic DNA, RNA or protein, the cells were 
resuspended in the culture medium and 1/10 of the culture volume of 2 % 
saponin in PBS was added. The cells were incubated for 10 minutes on ice to 
allow complete lysis of the red blood cells and the freed parasites were 
precipitated by spinning at 2,700 g for 10 min at 4°C. The supernatant was 
discarded and the parasites were resuspended in 1 ml PBS and transferred into a 
1 ml tube. The parasites were precipitated by spinning in a micro-centrifuge at 
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2,500 g for 3 min at 4°C before the supernatant was removed and the parasites 
were washed again in 1 ml PBS. The parasites were again pelleted by spinning as 
before. The wash step was repeated until the supernatant was clear of traces of 
hemoglobin. The supernatant was removed and the parasite cells were used for 
the preparation of DNA, RNA or protein. 
2.7.7 Extraction of genomic DNA from P. falciparum 
Genomic DNA (gDNA) was extracted using the Qiagen QiaAmp DNA mini kit 
following the blood or body fluid spin protocol according to manufacturer’s 
instructions. For standard preparations, trophozoite stage parasites of a 25 ml 
culture at a parasitemia of 4-5 % were isolated from erythrocytes by saponin 
lysis (see 2.7.6) prior to gDNA extraction. The gDNA was eluted with ddH2O and 
stored at 4°C. 
2.7.8 Extraction of RNA from P. falciparum 
RNA was extracted as previously described (Smith et al., 1998). Following 
saponin extraction of parasites (see 2.7.6) parasite pellets were resuspended in 
10 x their volume of TRIZOL® reagent (Invitrogen) and stored at –80°C until 
further use. After defrosting, RNA was extracted by addition of 0.2 volumes of 
chloroform. Samples were mixed by shaking for 15 sec followed by 2 min 
incubation at room temperature and subsequent centrifugation at 13,000 g at 
4°C for 15 min. The aqueous phase was transferred to a clean 1.5 ml tube and 
0.7 volumes of isopropanol added. The RNA was precipitated at 4°C overnight. 
On the following day samples were centrifuged at 13,000 g at 4°C for 30 min. 
The supernatant was removed and the RNA pellet washed with 70 % ethanol. The 
samples were again centrifuged at 13,000 g at 4°C for 15 min and the 
supernatant removed. The RNA pellet was air dried before being resuspended in 
an appropriate volume of DEPC- treated RNase free water (20-40 µl) by heating 
to 60°C for 10 min. RNA was stored at -80°C. 
2.7.9 Extraction of protein from P. falciparum 
Following saponin lysis (see 2.7.6) parasite pellets were resuspended in 2D-lysis 
buffer and stored at -80°C until further processing. To extract protein, pellets 
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were thawed at 37°C followed by immediate freezing on dry ice. This was 
repeated three times. The samples were sonicated in a sonicating waterbath for 
5 min and centrifuged at 15,000 g at 4°C for 5 min. The supernatant was 
transferred into a clean 1.5 ml tube and the protein concentration determined 
by Bradford assay (see 2.5.3). 
2.7.10 Transfection of P. falciparum 
For transfections synchronized cultures (see 2.7.5) of ring stage infected 
erythrocytes at a parasitemia of 4-7 % were used (Crabb and Cowman, 1996; 
Crabb et al., 2004). The medium of the culture was aspirated and the cells 
resuspended in cytomix (see 2.3.5). Cells were centrifuged at 400 g for 5 min at 
4°C and the supernatant removed. 100 µg of precipitated plasmid DNA (see 
2.4.3) was resuspended in 30 µl of sterile TE buffer and mixed with 370 µl of 
cytomix. 200 µl of infected erythrocytes were added and carefully mixed. The 
cell suspension was transferred into a 0.2 mm electroporation cuvette (Bio-Rad) 
and the cells electroporated at 310 V and 950 µF using a Gene Pulser Xcell 
electroporator (Bio-Rad). The time constant values were between 10- 15 ms. The 
transfected cells were immediately transferred into a culture flask containing 
300 µl of uninfected erythrocytes and 9 ml of pre-warmed complete medium. 
After 6 hours the medium was changed and the appropriate drugs were added to 
the cultures. 
2.7.11 Gene knockout in P. falciparum 
Two strategies were used for gene knockout studies in P. falciparum. The first 
method was based on gene disruption following a single crossover event between 
the gene of interest and a construct based on the pHH1 vector ((Reed et al., 
2000) (Figure 2-8). The plasmid contains the human dehydrofolate reductase 
gene (hDHFR) for positive selection of transfected parasites with the drug 
WR99210. Further, the plasmid contains an ampicillin resistance cassette for 
selection of the constructs in E. coli. Using the restriction sites BglII and XhoI, 
fragments homologous to the target gene were cloned into the plasmid. For 
knockout constructs these fragments were truncated at the N-terminus and thus 
missing the start codon ATG as well as being truncated at the C-terminus and 
containing an artificial stop codon. A single crossover recombination event 
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between such constructs and their target gene leads to disruption of the target 
gene and the formation of two truncated, non-functional copies. Similarly, pHH1 
based constructs were used as knock-in controls. In this case the fragment 
cloned into the vector was only truncated at the N-terminus but contained the 
full C-terminus. Single crossover events between knock-in control constructs and 
the target gene lead to the formation of one full length copy and one truncated 
copy of the gene. 
pHH1
5766 bp
hDHFR
AmpR
PbDHFR/TS 3'
PfHRPII 3'
PfCAM 5'
BglII
XhoI
 
Figure 2-8: Vector map of pHH1. 
This figure displays the features of the pHH1 vector used for single crossover knockout studies in 
P. falciparum. The plasmid contains an ampicillin resistance cassette (AmpR, 861 bp) for selection 
and propagation of the plasmid in E. coli. For selection in P. falciparum the vector contains the 
human dehydrofolate reductase gene (hDHFR, 569 bp) under control of the P. falciparum 
calmodulin promotor (PfCAM 5’, 631 bp) and flanked by the P. falciparum histidine rich protein II 3’ 
UTR (PfHRPII 3’, 574 bp). Fragments homologous to target genes were cloned using the BglII / 
XhoI restriction sites. The cloning site was flanked by the P. berghei dihydrofolate reductase / 
thymilidate synthase 3’ UTR (PbDHFR/TS 3’, 855 bp). 
The second strategy was based on gene replacement following a double cross-
over event and used the pCC-4 plasmid (Maier et al., 2006) (Figure 2-9). Two 
fragments homologous to the start and end of the target genes were cloned into 
this plasmid. A fragment homologous to the 5’-end of the gene was cloned into 
the plasmid using the SacII / AflII restriction sites and a fragment homologous to 
the 3’-end was cloned using the NcoI / NarI sites. The plasmid contained the 
blasticidin-S-deaminase gene which confers resistance to the drug blasticidin-S-
HCl and allows for positive selection of transfected parasites. Furthermore the 
plasmid contains the E. coli cytosine deaminase (cd) gene which converts  
5-fluorocytosine, the active component in Ancotil®, into 5-fluorouracil, an 
inhibitor for RNA synthesis and thymidylate synthase. The cd gene is lost in the 
case of double crossover recombination between the plasmid and the target 
gene, thus allowing for negative selection against parasites maintaining episomal 
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copies of the constructs and enrichment of those parasites that have integrated 
the plasmid. 
pCC-4
7395 bp
CD
AmpR
BSD
PbDT 3'
PfHRPII 3'
PfCAM 5'
Hsp86 5'
NcoI
AflII
NarI
Sac II
 
Figure 2-9: Vector map of pCC-4 
This figure displays the important features of the pCC-4 vector for double crossover knockout 
studies in P. falciparum. The plasmid contains an ampicillin resistance cassette (AmpR, 861 bp) for 
selection of the plasmid in E. coli. For positive selection in P. falciparum the plasmid contains the 
balsticidin-S deaminase gene (BSD, 399 bp) under control of the P. falciparum calmodulin 
promoter (PfCAM 5’, 631 bp) and flanked by the P. falciparum histidine rich protein II 3’ UTR 
(PfHRPII 3’, 574 bp). For negative selection the plasmid contains the E. coli cytosine deaminase 
(CD, 1122 bp) flanked by the P. falciparum heat shock protein 86 promoter (Hsp86 5’, 841 bp) and 
the P. berghei dhfr terminator (PbDT, 845 bp). Restriction sites SacII and AflII were used for 
cloning of the 5’ fragment and restriction sites NcoI and NarI were used for cloning of the 3’ 
fragment homologous to the target gene. 
2.7.12 Determination of IC50 values 
IC50 values were determined by measuring [
3H]-hypoxanthine incorporation in 
the presence of increasing drug concentrations according to Desjardins et al. 
(Desjardins et al., 1979). Cultures were diluted to 0.5 % parasitemia and 2 % 
hematocrit in IC50 medium (see 2.3.5). A serial dilution of twice the drug 
concentration to be tested was prepared on a 96 well plate in IC50 medium. To 
100 µl of drug in each well 100 µl of cells were added, creating a 1 x final 
concentration of the drug. Incorporation of [3H]-hypoxanthine in empty red 
blood cells and parasites incubated without drug was measured as control. 
Plates were placed in an incubation chamber, gassed with malaria gas and 
incubated for 48 hours at 37°C. After 48 hours 100 µl of medium was removed 
from each well and 100 µl of fresh medium containing 5 µCi [3H]-hypoxanthine / 
ml were added. Plates were incubated for further 24 hours before being frozen 
at -20°C. Plates were thoroughly defrosted before being harvested using a 
Tomtec Mach III harvester and Wallac Printed Filter Mat A filter mats. The filter 
mats were dried at room temperature before being sealed in a sample bag with 
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4 ml scintillation liquid. Decay was measured in a Wallac Trilux MicroBeta 
counter for 1 min per well. IC50 values were calculated using GraFit 5 software. 
2.7.13 Magnet activated cell sorting columns 
Trophozoite infected red blood cells were purified using magnet activated cell 
sorting (MACS) columns to obtain highly synchronized cultures with ~90 % 
parasitemia. CS-MACS columns were used with the VarioMACS separator (Miltenyi 
Biotech) and 21 G x 11’’ blunt needles. Columns were assembled according to 
manufacturer’s instructions and equilibrated with 60 ml buffer (0.5 % (w/v) BSA, 
2 mM EDTA pH 8.0 in PBS for subsequent determination of GSH levels, Earle’s 
balanced salt solution (EBSS, see 2.3.5) for subsequent uptake studies). The first 
10 ml of buffer were applied to the column from the bottom using the provided 
syringe, thereby removing all air bubbles from the resin. The remaining buffer 
was added to the top of the column and entered the resin by gravity flow. The 
medium of 100 ml culture was removed and the cells were resuspended in ice 
cold buffer. Cells were centrifuged at 700 g and the supernatant removed. The 
cells were resuspended in 20 ml buffer and loaded onto the equilibrated column. 
The cells were allowed to slowly drip through the column (~1.5 ml/min). In the 
magnetic field of the MACS separator late stage parasites are retained due to 
the paramagnetic properties of hemozoin in the food vacuoles of these stages. 
Once the cells had completely entered the column it was washed with 50 ml 
buffer to remove any unbound cells. To elute the bound cells, the column was 
removed from the magnetic field and turned upside down. Cells were then 
carefully eluted by gently pressing 30 ml of buffer through the column with a 
syringe. The purified infected cells were centrifuged at 400 g and used for 
further experiments. 
2.7.14 Determination of total glutathione levels in P. 
falciparum 
The intracellular levels of total glutathione in P. falciparum were determined 
according to Meierjohann (Meierjohann et al., 2002b) with modifications. Initial 
experiments were performed using MACS purified trophozoite infected red blood 
cells. However, in a second set of experiments 100 ml of tightly synchronized 
culture containing young trophozoites were used instead of MACS or Percoll 
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enriched cultures as it was noted that enriching of parasites had a negative 
effect on GSH levels. All steps were performed at 4°C. The medium was 
removed and the cells washed in cold EBSS. Cells were centrifuged at 400 g for 5 
min and the supernatant removed. The infected red blood cells were carefully 
resuspended in 5 volumes of 0.15 % saponin in EBSS. The cells were incubated on 
ice for 5 min and subsequently pelleted by centrifugation at 2,000 g for 5 min. A 
small sample was taken to control the quality of the parasite preparation under 
a light microscope. The remaining parasite cells were washed twice with 13 ml 
EBSS and centrifuged again for 5 min at 2,000 g. After the second wash parasites 
were resuspended in 5 ml EBSS and a 10µl sample was taken to determine the 
number of cells using a hemacytometer. The remaining cells were centrifuged at 
2,000g for 5 min. After the supernatant was completely removed, parasites were 
resuspended in 250 µl 0.1 M HCl and transferred into a 1.5 ml microfuge tube 
and vortexed for 30 sec to break the cells. Protein was precipitated by 
centrifugation at 15,000 g for 5 min at 4°C. The supernatant was used to 
determine GSH levels according to Tietze (Tietze, 1969). 25 µl and 50 µl aliquots 
of parasite extract were mixed with 700 µl of 143 mM sodium phosphate (pH 7.5) 
containing 6.3 mM EDTA. 10 µl of 34 mM NADPH and 100 µl of 6 mM 5,5-
Dithiobis-(2-nitrobenzoate) (DTNB, Ellman reagent) were added and the volume 
was adjusted to 950 µl with water. The mixture was incubated at room 
temperature for 20 min to allow full reaction of thiols with the DTNB and the 
reaction was started by addition of 50 µl of S. cervisiae GR (Sigma, 15 units ml-
1). GSH reacts with DTNB non-enzymatically to GSSG and 2 molecules of 
chromophoric TNB-. In the presence of GR, GSSG is reduced to GSH which can 
react again with DTNB. The TNB- generated is directly proportional to the GSH 
concentration of the sample or standard. The extinction coefficient of TNB- at 
412 nm is 13,600 M-1 cm-1. The change in absorbance at 412 nm was determined 
using a Shimadzu UV-2501 PC spectrophotometer. GSH levels were calculated 
relative to known standard concentrations of GSH. Standard curves ranged from 
0.5 µM to 3 µM.  
2.7.15 Determination of glutathione uptake 
GSH uptake was measured using MACS column purified trophozoite infected RBC 
and uninfected RBC. Cells were diluted to 2 x 108 cells/ ml in EBSS and kept on 
ice. At time point t= 0 an equal volume of uptake solution containing 100 nCi 
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[3H]-GSH (= 24 pmol) / 100 µl was added and the cells were placed in a 37°C 
water bath. At the time points of interest, 200 µl aliquots were removed and 
layered onto 300 µl of dibutylphthalate and immediately centrifuged at 10,000 g 
to terminate the uptake. The cells were sedimented below the oil while the 
uptake solution remained on top. The uptake solution was removed and the tube 
walls above the oil were carefully rinsed with ddH2O. The water was removed 
and the tube walls wiped with a cotton bud to remove any traces of label. The 
oil was removed and the cells lysed by addition of 100 µl ddH2O. The lysate was 
transferred into a scintillation vial and 50µl H2O2 and 50 µl acetic acid were 
added in order to bleach the hemoglobin in the samples and to ensure complete 
lysis. 3 ml of scintillation liquid were added and samples were counted on the 
following day in a Wallac Trilux MicroBeta counter. 
  68 
3 γ-Glutamylcysteine Synthetase 
3.1 Introduction 
The first step of the biosynthesis of GSH, the ligation of L-glutamate (L-Glu) and 
L-cysteine (L-Cys) to form γ-glutamylcysteine (γGC) is catalysed by the enzyme 
γ-glutamylcysteine synthetase (γGCS) (Reaction 2). 
 
Reaction 2: First step of GSH biosynthesis. 
The ATP dependent ligation of L-Glu and L-Cys to form γGC is catalysed by γGCS. 
In this chapter the localization of PfγGCS was determined by episomal 
expression of PfγGCS-GFP in parasites. In order to determine if the gene is 
essential a knockout of the pfγgcs gene was attempted using two different 
strategies. The first strategy is based on a single crossover recombination and 
leads to gene disruption if the gene is non-essential. The second strategy is 
based on a double crossover recombination that leads to a replacement of non-
essential genes. Further, it was determined if targeting of the pfγgcs gene locus 
with a knock-in control construct is possible and whether the knockout in the 
presence of an additional episomal copy of the gene can be achieved. In 
addition, the effects of over-expressing PfγGCS-HA were also investigated. 
3.2 Sequence considerations 
The predicted PfγGCS protein sequence is almost twice the size of its 
homologues in yeast, humans or T. brucei (Lüersen et al., 1999). The overall 
amino acid sequence identity between PfγGCS and the human and T. brucei 
γGCS is low at 19.7 and 18.6 %, respectively. However, several residues involved 
in binding of substrates and cofactors are conserved in homologous regions 
(Lüersen et al., 1999). An interesting feature of PfγGCS is the presence of a 
repetitive motif whose abundance varies in different strains characterized 
(Lüersen et al., 1999). Due to this variation in repeats of 
(Y/C)QS(N/D)LQQ(Q/R), the predicted molecular mass for PfγGCS also varies 
between different P. falciparum strains and ranges from 124.4 kDa in the 3D7 
strain to 133.2 kDa in the K1 strain. In order to determine the number of repeats 
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for the repetitive element in P. falciparum D10, a part of the pfγgcs coding 
sequence containing the repetitive sequence was amplified by PCR (Figure 3-1), 
cloned into the plasmid pCR-BluntII-TOPO and sequenced. The primers used for 
PCR were those designed for cloning of the pHH1-∆γgcs plasmid (see Table 2-1) 
as the sequence of the insert of this plasmid includes the repetitive element. 
 
Figure 3-1: PCR analysis of the pfγgcs variable repetitive motif in P. falciparum strains D10 
and 3D7. 
A fragment of the pfγgcs gene containing a variable repetitive motif was amplified by PCR from 
D10 (lane 1) and 3D7 gDNA (lane 2). The fragment sizes differ between the strains due to different 
numbers of a variable repetitive motif. 
Sequencing results showed that the D10 PfγGCS contains a total of nine repeats 
of the repetitive motif, while the sequencing strain P. falciparum 3D7 only 
contains this motif once (Figure 3-2). The predicted molecular mass of the D10 
PfγGCS protein is 130.8 kDa. 
3D7    263 ENEQQQQQQQ YQSNLQQQ -------- -------- --------  
D10    263 ENEQQQQQQQ YQSNLQQQ YQSNLQQQ YQSNLQQQ YQSDLQQQ  
  
3D7    -------- -------- -------- -------- -------- NVQPK 285 
D10    YQSDLQQQ YQSDLQQQ YQSDLQQQ YQSDLQQQ CQSDLQQQ NVQPK 349 
Figure 3-2: Alignment of the repetitive sequence motif of P. falciparum 3D7 and D10. 
The D10 PfγGCS enzyme contains a total of nine repeats of a variable repetitive motif as opposed 
to only one repeat found in 3D7, thus increasing the predicted molecular size of the enzyme from 
124.4 kDa to 130.8 kDa. 
3.3 Localization 
To determine the subcellular localization of PfγGCS, recombinant C-terminally 
GFP-tagged PfγGCS was episomally expressed in P. falciparum. Using MultiSite 
Gateway® technology (van Dooren et al., 2005), the full length γgcs ORF of P. 
falciparum 3D7 containing the repetitive motif only once was cloned in frame 
with the sequence for a C-terminal GFP-tag. Expression was under the control of 
the Hsp86 promotor. The construct pCHD-Hsp86-γGCS-GFP was transfected twice 
independently into D10 wild-type parasites and transfected parasites were 
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observed in thin smears five to six weeks post transfection. The transfected 
parasite lines D10γGCS-GFP-1 and D10γGCS-GFP-2 were analysed by fluorescence 
microscopy. 
Both parasite lines showed fluorescence in the cytosol, albeit the fluorescent 
signal was stronger in the D10γGCS-GFP-2 parasites, indicating higher expression 
levels of the PfγGCS-GFP recombinant protein in these parasites. Therefore only 
images taken of D10γGCS-GFP-2 are displayed here (Figure 3-3A). To confirm that 
the fluorescence observed was due to the full-length recombinant protein 
tagged with GFP and not due to degradation products or cleaved off GFP alone, 
protein was extracted from the parasites and analysed by western blotting using 
an anti-GFP antibody (Figure 3-3B). A band of the expected size for PfγGCS-GFP 
was detected at 153.0 kDa. Some bands indicating degradation were also 
observed at smaller molecular sizes and a band at approximately 27 kDa likely to 
be GFP alone is also visible. Despite the presence of some degradation products 
these results indicate that full-length PfγGCS-GFP is cytoplasmic. 
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Figure 3-3: Subcellular localization of PfγGCS-GFP. 
Panel A: To determine the subcellular localization of PfγGCS, a recombinant C-terminally tagged 
PfγGCS-GFP fusion protein was expressed in P. falciparum D10. Expression was under control of 
the Hsp86 promotor. Images were taken from parasite line D10γGCS-GFP-2. The fusion protein 
localized to the parasite cytosol. Panel B: Western analysis of protein extract of D10γGCS-GFP-2 with 
anti-GFP antibody showed the full length PfγGCS-GFP fusion protein at 153 kDa and some smaller 
degradation products. 
3.4 Knockout by gene disruption 
In order to assess whether the pfγgcs gene is essential for the survival of intra-
erythrocytic stages of P. falciparum in vitro, a knockout by gene disruption was 
attempted. For this an 864 bp fragment of P. falciparum 3D7 pfγgcs truncated at 
the 5’- and 3’-end was cloned into the plasmid pHH1 (Reed et al., 2000), thus 
generating the construct pHH1-∆γgcs (see Table 2-1). The insert lacks the start 
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ATG and contains an artificial stop codon. Because the insert includes the area 
that encompasses the repetitive motif, pHH1-∆γgcs is homologous to the 3D7 
strain of P. falciparum. A single crossover recombination event between the 
homologous insert of this construct and the pfγgcs target gene leads to 
disruption of the gene into two truncated copies to form a pseudo-diploid gene 
locus. It is expected that integration of this plasmid results in one copy of pfγgcs 
truncated at the 3’-end by the artificial stop codon and one copy truncated at 
the 5’-end and lacking a start codon, should the gene be non-essential (Figure 
3-4A). pHH1 contains a human dihydrofolate reductase (hdhfr) cassette which 
allows for positive selection of transfected parasites with the drug WR99210. 
The construct was transfected into the 3D7 wild-type strain and WR99210 
resistant parasites were visible in Giemsa stained thin smears after 4-5 weeks. 
Genomic DNA (gDNA) was isolated from the parasites and used for Southern blot 
analysis of the genotype of the transfected parasites. 
In the meantime transfected parasites were taken through drug selection cycles. 
This means that the drug pressure was removed from the cultures for three 
weeks at a time. During this time, many parasites lose the episomal plasmid and 
thus the hdhfr gene and become sensitive to the drug again. However, if the 
plasmid has already integrated into the target gene locus it cannot be lost from 
the parasites and these parasites remain resistant. After three weeks the drug is 
added back to the cultures and as a consequence parasites that have lost the 
plasmid die, while parasites which retained the episomal plasmid or integrated 
the plasmid into their genome survive. It is thought that this procedure enriches 
for parasites that have integrated the plasmid into their genome and allows for 
faster isolation of knockout parasite lines.  
The transfected line 3D7pHH1-∆γgcs was taken through two drug selection cycles 
and after each cycle, when parasites were growing under drug pressure again, 
gDNA was isolated and analysed by Southern blotting. The schematic diagram in 
Figure 3-4A displays the expected banding pattern of the Southern blot after 
diagnostic digest with the enzymes NdeI and XhoI. The fragments expected to be 
visible with a gene specific probe are indicated by red arrows, while fragments 
expected with a probe specific for the hdhfr selectable marker are indicated by 
blue arrows. For the endogenous pfγgcs locus of 3D7 (Figure 3-4A, I) a single 
band at 3.69 kb is expected when a gene specific probe is used. This fragment 
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cannot be detected with the hdhfr probe. For the episomal plasmid pHH1-∆γgcs 
(Figure 3-4A, II) a single band at 2.59 kb is expected for both a pfγgcs gene-
specific probe and an hdhfr-specific probe. In the case of a recombination event 
and integration of the plasmid into the pfγgcs locus (Figure 3-4A, III), two bands 
at 1.19 kb and 5.08 kb are expected to appear with the pfγgcs-specific probe 
whereas only the 5.08 kb band is expected to be visible when a hdhfr probe is 
used. For the generation of the pfγgcs gene-specific probe used in this Southern 
blot, the insert of pHH1-∆γgcs was amplified by PCR and labelled as described in 
Chapter 2. For the hdhfr-specific probe the full length hdhfr ORF was amplified.  
Figure 3-4B shows a Southern Blot using the gene-specific probe for pfγgcs. Lane 
1 contains gDNA of untransfected 3D7 wild-type parasites and only one band at 
3.69 kb corresponding to the endogenous gene locus can be detected. Lanes 2 
and 3 contain gDNA isolated from 3D7pHH1-∆γgcs in drug selection cycles 0 and 2, 
respectively. In both lanes the wild-type band at 3.69 kb and the pHH1-∆γgcs 
plasmid band at 2.59 kb are detected. However, an additional band of 
approximately 3.4 kb is visible on the blot (Figure 3-4B, lanes 2 and 3) and this 
additional band does not correspond to either of the expected integration bands 
at 1.19 kb and 5.08 kb. 
To analyse this further, a second Southern Blot was performed using an hdhfr-
specific probe (Figure 3-4C). As expected, no signal is detected for non-
transfected wild-type parasites (Figure 3-4C, lane 1). For selection cycle 0 and 
cycle 2 of the transfected 3D7pHH1-∆γgcs parasites (Figure 3-4C, lanes 2 and 3, 
respectively) a 2.59 kb band corresponding to the episomal plasmid is visible, as 
well as the same additional band of approximately 3.4 kb that can be detected 
when a gene-specific probe is used. This additional band potentially indicates a 
random integration event of the pHH1-∆γgcs plasmid into the P. falciparum 
genome. No disruption of the target gene was observed. These results suggest 
that the pfγgcs gene is either essential or that the gene locus is refractory to 
integration. 
A second transfection of pHH1-∆γgcs into 3D7 wild-type parasites was 
performed, but no parasites could be detected in the cultures up to three 
months after transfection. Further attempts to generate a second 3D7pHH1-∆γgcs 
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parasite line were abandoned and I focused on the gene replacement strategy 
instead (see 3.5). 
 
Figure 3-4: Knockout studies of P. falciparum γgcs by gene disruption. 
For knockout studies by single crossover the plasmid pHH1 was used. Panel A displays a 
schematic diagram (not to scale) of the wild-type 3D7 pfγgcs locus (I), the pHH1-∆γgcs plasmid (II) 
and the gene locus following a single crossover recombination event (III). The plasmid (II) contains 
an 864 bp insert (II, blue box) homologous to a part of the pfγgcs ORF (I, green box). This insert 
lacks part of the 5’-end including the ATG start codon and contains an artificial stop codon (stop*) 
whilst lacking the 3’-end. The plasmid contains an hDHFR selectable marker cassette (yellow box) 
for positive selection of transfected parasites. Knockout is achieved by gene disruption following a 
single crossover event. This leads to a pseudo-diploid locus (III) with two truncated copies of the 
gene, one being truncated at the 3’-end by the artificial stop codon (III, stop*, green-blue box) and 
one being truncated at the 5’-end and lacking the ATG start codon (III, blue-green box). Restriction 
sites for NdeI and XhoI are indicated by black arrows and the expected fragments detected with a 
gene-specific probe are indicated by red arrows. Blue arrows indicate the expected fragments 
detected with a probe specific for the hdhfr gene in the hDHFR cassette. Panel B shows a 
Southern blot after digestion of gDNA with NdeI and XhoI probed with a pfγgcs specific probe. The 
red arrows in Panel A indicate the expected sizes. Lane 1 contains gDNA of untransfected 3D7 
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wild-type parasites. Lanes 2 and 3 contain gDNA isolated from 3D7pHH1-∆γgcs after drug selection 
cycle 0 and 2, respectively. In all three lanes a band corresponding to the endogenous pfγgcs locus 
(WT) at 3.69 kb can be detected. The transfected parasites (lanes 2 and 3) contain the plasmid and 
the corresponding band at 2.59 kb is visible. An additional band of unexpected size is also detected 
in these parasites. Panel C displays a Southern blot after diagnostic digest of gDNA with NdeI and 
XhoI probed with an hdhfr specific probe. Blue arrows in Panel A indicate the expected pattern and 
sizes. Lane 1 contains gDNA of untransfected 3D7 wild-type parasites. No bands can be detected 
in these parasites. Lanes 2 and 3 contain gDNA isolated from 3D7pHH1-∆γgcs after selection cycle 0 
and 2, respectively. A band corresponding to pHH1-∆γgcs can be detected at 2.59 kb in these 
lanes. In addition a second band is detected which does not correspond to the expected pattern. 
3.5 Knockout by gene replacement 
During this study several plasmids were generated by Maier et al. which permit 
the knockout of genes in P. falciparum by gene replacement and we obtained 
the plasmids pCC4 and pCC1 (Maier et al., 2006). The pCC4 plasmid contains a 
blasticidin-S-deaminase (bsd) selectable marker for positive selection of 
transfected parasites with Blasticidin-S-HCl (Bla) while pCC1 contains the 
selectable marker hdhfr for selection with WR99210. Only the pCC4 plasmid was 
used to create a construct for knockout studies on pfγgcs because I planned to 
use the construct for co-transfections with an expression construct containing an 
hdhfr selectable marker at a later stage (see section 3.8). In addition to the bsd 
marker for positive selection of transfected parasites the pCC4 plasmid contains 
a cytosine deaminase (cd) cassette to allow for negative selection with Ancotil®. 
The active component of Ancotil® is 5-fluorocytosine (5-FC) which is converted 
by CD into 5-fluorouracil. 5-Fluorouracil is toxic for cells due to its inhibition of 
RNA synthesis and of the thymidylate synthase (Maier et al., 2006). In case of 
recombination between a pCC4 construct and its target gene by double crossover 
the target gene is replaced by the bsd gene and the cd gene is lost. Whilst 
parasites can be Bla resistant by retaining the plasmid episomally, they can only 
be resistant to Ancotil® and Bla if the target gene has been replaced with the 
bsd marker in a double crossover event and the cd death gene has been lost. The 
double crossover is extremely rare in P. falciparum erythrocytic stages. The 
negative selectable marker is thought to select for parasites in which this rare 
event has occurred, as opposed to the much more frequent single crossover 
event which has been the basis of previous knockout studies.  
Two inserts were cloned into the pCC4 plasmid, a 485 bp insert homologous to 
part of the 5’-end of the pfγgcs ORF and a 522 bp insert homologous to part of 
the 3’-end (see Table 2-1). The inserts did not contain any part of the repetitive 
element and are thus homologous to both D10 and 3D7 parasites. The plasmid 
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was designed to contain regions homologous to the pfγgcs ORF rather than the 
5’- and 3’-UTRs because the flanking regions of pfγgcs are very AT rich and thus 
cloning is difficult. Because of the size of pfγgcs, it was possible to use part of 
the coding region for the generation of the pCC4 construct. The construct was 
named pCC4-∆γgcs and it was transfected once into D10 wild-type parasites and 
on two independent occasions into 3D7 wild-type parasites. Bla resistant 
parasites were detected in Giemsa stained thin smears four weeks after 
transfection for D10 and five to six weeks after transfection for 3D7. In case the 
parasites could compensate for the loss of PfγGCS by taking up extracellular 
GSH, cultures were supplemented with 2 mM GSH. 
The transfected parasite lines were named D10pCC4-∆γgcs, 3D7pCC4-∆γgcs-1 and 
3D7pCC4-∆γgcs-2. Similar as described for the 3D7pHH1-∆γgcs line in section 3.4, 
parasites were subjected to drug selection cycles by removing Bla from the 
cultures for three weeks before adding the drug again. Parasites took typically 
between 3 to 5 days before growing normally again after addition of the drug. 
Once their growth was normal, the cultures were divided into two independent 
cultures. One of the cultures was treated with Ancotil® at a concentration 
equivalent to 1 µM 5-FC, whilst the other was cultured without. The cultures 
that remained untreated were used for the isolation of gDNA and taken through 
the next Bla selection cycle. Parasites in the Ancotil® treated cultures typically 
died within the next 2 to 4 days and no living parasites were observed anymore 
after one week of treatment. For all three transfected lines Ancotil® resistant 
parasites were obtained after Bla selection cycle 3. 3D7pCC4-∆γgcs-1 was taken 
through one additional selection cycle to cycle 4 and again resistant parasites 
were obtained after selection with Ancotil®. It took approximately 4 weeks from 
the first day of Ancotil® treatment until Ancotil® and Bla resistant parasites were 
observed in Giemsa stained thin smears of the cultures. 
In order to analyse the genotype of the transfected parasites, gDNA was 
isolated, digested with NdeI and analysed by Southern blotting. In the diagram in 
Figure 3-5A the expected banding pattern for the Southern blot is shown. Gene 
specific probes were generated by amplification of both inserts of pCC4-∆γgcs by 
PCR and labelling as described in chapter 2. Due to the variations of the 
repetitive motif between 3D7 and D10 parasites, either a 3.69 kb or a 3.88 kb 
band is expected for the pfγgcs wild-type locus, respectively. For the plasmid 
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two bands are expected at 7.27 kb and at 0.65 kb with the same probes. The 
larger of the two fragments contains the cd death gene. In the case of double 
crossover recombination and replacement of the pfγgcs gene two bands at 2.18 
kb and 1.01 kb are expected for both 3D7 and D10 parasite lines. Red arrows in 
the diagram in Figure 3-5A indicate the respective fragments.  
Figure 3-5B shows a Southern blot analysis of D10pCC4-∆γgcs in Bla selection cycle 0 
(lane 2) and in cycle 3 (lane 3). Lane 4 contains gDNA of Ancotil® resistant 
parasites obtained after selection cycle 3. In lane 1 gDNA of untransfected D10 
wild-type parasites was loaded for comparison. In all four lanes of Figure 3-5B 
the 3.88 kb band corresponding to the endogenous D10 pfγgcs locus is present. 
The plasmid can be detected in D10pCC4-∆γgcs in selection cycle 0 and cycle 3 and 
is still present after Ancotil® treatment (Figure 3-5B, lanes 2-4). No integration 
into the pfγgcs gene locus had occurred; none of the diagnostic bands indicating 
recombination are visible. It is surprising that the plasmid is still present in the 
Ancotil® resistant line (Figure 3-5, lane 4) as the presence of the cd gene should 
make these parasites susceptible to the drug. 
In Figure 3-6 Southern blots of 3D7pCC4-∆γgcs-1 (Figure 3-6A) and 3D7pCC4-∆γgcs-2 
(Figure 3-6B) are displayed. The gDNA was again digested with NdeI prior to 
Southern blotting. In comparison to the transfected parasite lines 3D7 wild-type 
gDNA was analysed. On both blots, the wild-type gDNA was loaded in lane 1 and 
only a 3.69 kb band corresponding to the 3D7 wild-type pfγgcs locus is visible. In 
lane 2 of Figure 3-6A and B, gDNA of 3D7pCC4-∆γgcs-1 and 3D7pCC4-∆γgcs-2 in selection 
cycle 0 was loaded, respectively. Both parasite lines contained the plasmid in 
this selection cycle with the two diagnostic bands at 7.27 kb and 0.65 kb visible 
and they still contained the plasmid in cycle 3 (lane 3, Figure 3-6A and B, 
respectively). Ancotil® resistant parasites were obtained from both lines after 
selection cycle 3. Similar to D10pCC4-∆γgcs, Ancotil® resistant parasites obtained 
from 3D7pCC4-∆γgcs-1 and from 3D7pCC4-∆γgcs-2 after selection cycle 3 still contained 
the plasmid; both diagnostic bands at 7.27 kb and 0.65 kb were visible on the 
Southern blot (Figure 3-6A and B, lane 5). The 3D7pCC4-∆γgcs-1 line was taken 
through one additional drug cycle and Southern analysis of gDNA obtained after 
selection cycle 4 showed again the wild-type gene and the plasmid, albeit there 
appeared to be less plasmid present (Figure 3-6A, lane 4). No integration 
specific bands were visible at 2.18 kb and 1.01 kb. Like in the previous selection 
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cycle, Ancotil® resistant parasites were isolated again for 3D7pCC4-∆γgcs-1 in cycle 
4, but no bands diagnostic for integration were visible on the Southern blot and 
a band corresponding to the pfγgcs endogenous locus at 3.69 kb was still present 
(Figure 3-6A, lane 6). Interestingly, the smaller band at 0.65 kb corresponding to 
the plasmid was still detected while the larger 7.27 kb band was no longer 
visible. This potentially means that the plasmid has undergone some kind of 
recombination, albeit not with the target gene. As the cd death gene is located 
on the larger fragment of the plasmid it might be lost from these parasites, but 
this will need to be confirmed by reprobing the blot with a cd specific probe in 
the future. 
These results indicate again that the pfγgcs locus is either refractory to 
integration, or that the gene is essential for survival of intra-erythrocytic stages 
of P. falciparum. 
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Figure 3-5: Knockout studies by gene replacement of P. falciparum γgcs. 
For gene knockout by gene replacement the plasmid pCC4 was used. Panel A displays a diagram 
(not to scale) of the pfγgcs wild-type locus (I), the pCC4-∆γgcs plasmid (II) and the pfγgcs gene 
locus following a double crossover recombination event (III). The length of the pfγgcs ORF (green 
box) varies between the 3D7 and D10 strain due to a different number of repeats of a variable 
repetitive motif. The pCC4-∆γgcs plasmid contains two 485 bp and 522 bp inserts (blue boxes) 
homologous to regions of the 5’-and 3’-end of pfγgcs in both 3D7 and D10. For positive selection of 
transfected parasites the plasmid contains a BSD selectable marker cassette (yellow box). For 
negative selection against parasites maintaining the plasmid as episome the plasmid contains a 
CD cassette (orange box). Following a double crossover event the target gene is replaced with the 
BSD cassette and the CD cassette is lost. Diagnostic digests to analyse the genotype of 
transfected parasites were performed with NdeI. Restriction sites are indicated by black arrows. 
The lengths of the expected fragments detectable with pfγgcs specific probes homologous to the 
inserts of the plasmid are indicated by red arrows. Panel B: Southern blot of transfected parasite 
line D10pCC4-∆γgcs with a gene specific probe after diagnostic NdeI digest. Lane 1 contains gDNA of 
untransfected D10 wild-type. Lanes 2 and 3 contain gDNA of D10pCC4-∆γgcs in Bla selection cycle 0 
and 3, respectively. Lane 4 contains gDNA of Ancotil resistant parasites obtained form D10pCC4-∆γgcs 
after cycle 3. The 3.88 kb band corresponding to the pfγgcs wild-type gene (WT) is visible in all four 
lanes. In the transfected D10pCC4-∆γgcs parasite line the two bands corresponding to the plasmid at 
γ-Glutamylcysteine Synthetase  80 
 
7.27 kb and 0.65 kb are visible in cycle 0, cycle 3 and after Ancotil treatment in cycle 3 (lanes 2-4, 
respectively). No integration was observed, the diagnostic bands are absent. 
 
Figure 3-6: Knockout studies by gene replacement of γgcs in P. falciparum 3D7. 
Panel A shows a Southern blot of parasite line 3D7pCC4-∆γgcs-1 (lanes 2-6) in comparison to non-
transfected 3D7 wild-type parasites (lane 1). Expected fragments after a diagnostic NdeI digest are 
3.69 kb for the endogenous pfγgcs gene, 7.27 kb and 0.65 kb for the plasmid and 2.18 kb and 1.01 
kb for integration (see diagram in Figure 3-5A). The band corresponding to the wild-type (WT) can 
be observed in all samples. Lane 2 contains gDNA of 3D7pCC4-∆γgcs-1 in Bla selection cycle 0 with 
the endogenous gene fragment and the two plasmid bands visible. The plasmid is still present in 
selection cycles 3 and 4 in lanes 3 and 4, respectively. Lanes 5 and 6 contain gDNA of Ancotil 
resistant parasites obtained after Bla cycles 3 and 4, respectively. In lane 5 both bands 
corresponding to the plasmid are still detected while in lane 6 the higher 7.27 kb band is not visible. 
No bands indicating integration can be observed in any sample of 3D7pCC4-∆γgcs-1. Panel B displays 
a Southern blot of parasite line 3D7pCC4-∆γgcs-2 (lanes 2-4) in comparison to wild-type 3D7 parasites 
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(lane 1). As for 3D7pCC4-∆γgcs-1, expected fragments after diagnostic NdeI digest are 3.69 kb for the 
endogenous pfγgcs gene, 7.27 kb and 0.65 kb for the plasmid and 2.18 kb and 1.01 kb for 
integration (see diagram in Figure 3-5A). In the untransfected 3D7 parasites in lane 1 only the 3.69 
kb band corresponding to the wild-type pfγgcs gene (WT) is visible. The same band can be 
detected in 3D7pCC4-∆γgcs-2 in Bla selection cycle 0 (lane 2), cycle 3 (lane 3) and in Ancotil resistant 
parasites obtained after cycle 3 (lane 4). Both plasmid bands at 7.27 kb and 0.65 kb are visible in 
all samples of 3D7pCC4-∆γgcs-2 (lane 2-4). No integration specific fragments were detected. 
3.6 Knock-in control 
In order to analyse whether the pfγgcs gene locus can be targeted, a knock-in 
control construct based on the pHH1 plasmid (Reed et al., 2000) was generated. 
The pHH1-γgcscon plasmid contains a 1323 bp insert homologous to the 3’-end of 
the pfγgcs gene which includes the endogenous stop codon (Table 2-1). The 5’-
end of the gene is not part of the insert. Integration of this construct into the 
gene locus should lead to a pseudo-diploid locus with two copies of pfγgcs, one 
full length copy and one truncated copy lacking the 5’-end and ATG start codon. 
The plasmid was transfected into 3D7 wild-type parasites generating the parasite 
line 3D7pHH1-γgcscon. Live parasites were observed five weeks after transfection. To 
analyse the genotype of the transfected cell lines, gDNA was isolated and 
analysed by Southern blot after diagnostic digest with NdeI. 
The schematic diagram in Figure 3-7A describes the expected banding pattern of 
the Southern blot for the endogenous gene locus (I), the transfected plasmid (II) 
and the gene locus after a single crossover recombination event (III). Red arrows 
indicate the sizes of the expected fragments that can be detected with a pfγgcs 
specific probe. The probe was generated by amplifying the pfγgcs insert of 
pHH1-γgcscon by PCR and labelling as described in Chapter 2. For the wild-type 
pfγgcs locus of 3D7 a 3.69 kb band is expected and a 6.35 kb band is expected 
for the plasmid. Following integration, the recombined gene locus should appear 
as two bands at 6.70 kb and 3.34 kb.  
The 3D7pHH1-γgcscon parasite line was taken through one drug selection cycle as 
described in section 3.4. Once the selection cycle was completed, gDNA was 
prepared and analysed by Southern blotting. After one selection cycle 
integration specific bands were detectable in the Southern Blot and the 3D7pHH1-
γgcscon parasite line was subsequently cloned by limiting dilution. Figure 3-7B 
displays a Southern blot of one of the clones obtained (lane 2) in comparison to 
non-transfected 3D7 wild-type parasites (lane 1). The 3.69 kb band for the 
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endogenous pfγgcs gene is clearly visible in the wild-type in lane 1 but absent in 
the clone in lane 2. Instead two diagnostic bands at 6.70 kb and 3.34 kb 
corresponding to integration of pHH1-γgcscon into the pfγgcs gene locus are 
visible in this clone. Potentially this clone still contains some episomal plasmid. 
The expected plasmid band would be visible at 6.35 kb and thus relatively close 
to the 6.70 kb integration band. Indeed the signal in Figure 3-7 lane 2 at this 
position is very strong compared to the other bands and it is not possible to tell 
if there is a single or double band at this position. Due to the strong intensity in 
comparison to the other bands it seems likely that there are indeed two bands at 
this position. This can be tested by diagnostic PCR in the future. Episomal 
plasmids are sometimes still present following recombination events even though 
they are no longer essential to provide the hdhfr resistance marker for parasite 
survival, as there is already an integrated copy in the recombined target gene 
locus. Potentially the plasmids are maintained because multiple copies of the 
hdhfr gene provide a higher expression of hDHFR protein and thus an advantage 
for parasite survival. This clearly shows that the pfγgcs locus can be targeted 
and suggests that failure to generate a gene disruption or gene deletion is due to 
the pfγgcs gene being essential for the survival of intra-erythrocytic stages of P. 
falciparum in vitro.  
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Figure 3-7: Knock-in control studies on P. falciparum γgcs. 
Panel A shows a schematic diagram (not to scale) of the pfγgcs locus (I), the pHH1-γgcscon 
plasmid (II) and the gene locus following integration of the plasmid by single crossover 
recombination (III). The plasmid contains a 1323 bp insert (II, blue box) homologous to the 3’-end 
of the pfγgcs coding region (I, green box) including the endogenous stop codon (stop) and an 
hDHFR selectable marker cassette for selection of transfected parasites (II, III, yellow box). 
Following recombination between plasmid and endogenous gene, the locus is disrupted leading to 
one full length copy of pfgs (III, green-blue box) and one copy truncated at the 3’-end (III, blue-
green box). DNA was digested with NdeI prior to Southern blotting. Restriction sites are indicated 
by black arrows and the resulting fragments that can be detected with a pfγgcs specific probe are 
indicated by red arrows. Panel B displays a Southern blot of NdeI digested parasite gDNA probed 
with a gene specific probe (For expected sizes see red arrows in Panel A). Lane 1 contains gDNA 
of untransfected 3D7 wild-type parasites and a 3.69 kb band corresponding to the wild-type pfγgcs 
locus (WT) can be detected. In lane 2 an exemplary clone of the 3D7pHH1-γgcscon line is shown. In 
this clone the wild-type diagnostic band is absent and two integration specific bands at 6.70 kb and 
3.34 kb can be detected instead. It cannot be determined if there is a second band just below the 
6.70 kb integration band corresponding to the 6.35 kb plasmid band due to the intensity of the 
signal and overexposure of the film in this area. 
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3.7 Expression of PfγGCS-HA in P. falciparum 
3.7.1 Genotypic analysis 
The expression construct for C-terminally HA-tagged PfγGCS, pCHD-Hsp86-γGCS-
HA (see Table 2-1), was generated using MultiSite Gateway technology (van 
Dooren et al., 2005). The construct contained the full-length pfγgcs ORF of the 
3D7 strain cloned in frame with the sequence for an HA-tag under the control of 
the Hsp86 promoter. The Hsp86 promotor is a strong promotor and allows for 
high levels of expression of the fusion protein throughout the intra-erythrocytic 
parasite life cycle. This plasmid was used to express PfγGCS-HA in P. falciparum 
for phenotypical studies and at a later stage for co-transfection studies with a 
knock-out construct. The plasmid was first transfected into wild-type D10 
parasites on two independent occasions creating the parasite lines D10γGCS-HA-1 
and D10γGCS-HA-2. Transfected parasites were selected with WR99210 and were 
first observed four to five weeks after transfection. 
To determine whether the episomal plasmid was present, diagnostic Southern 
blot analyses were performed on the two parasite lines once parasites were 
observed in cultures after transfection. The diagram in Figure 3-8A displays the 
expected banding pattern of the Southern blot with a pfγgcs gene specific probe 
after a diagnostic digest with the enzyme NdeI. The probe used was identical to 
the probe used for the knock-in control studies (Section 3.6) and homologous to 
the pfγgcs insert of pHH1-γgcscon. For the endogenous D10 pfγgcs locus a 3.88 
kb band is expected and the size of the expected band diagnostic for the 
episomal plasmid is 9.89 kb. Even though the plasmid was not intended for 
recombination with the endogenous locus, such an event is possible due to the 
homologous pfγgcs sequence in the plasmid. Recombination between wild-type 
gene and plasmid would result in a pseudo-diploid locus with two functional 
copies of the gene. One copy would be under control of the endogenous 
promoter and be fused in frame with the HA-tag while the other copy would be 
under control of the Hsp86 promotor and untagged. Because the repetitive 
sequence motif of pfγgcs is present 9 times in the endogenous D10 locus and 
only once in the 3D7 pfγgcs sequence cloned into the expression plasmid, two 
variations are possible for the recombined locus. This depends on whether the 
D10 sequence motif is present in the first or the second copy following a single-
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cross over recombination. If a recombination event occurrs downstream of the 
motif, the 5’-copy of pfγgcs resembles the 3D7 sequence and the 3’-copy 
resembles the D10 sequence (Variation A). Should the recombination occur 
upstream of the repetitive motif, the 5’-copy will resemble the D10 pfγgcs and 
the 3’-copy the 3D7 form (Variation B). The sizes of the diagnostic bands for this 
recombination event are 6.66 kb and 7.08 kb for variation A and 6.85 kb and 
6.89 kb for variation B. 
To test whether the plasmid undergoes recombination with the endogenous gene 
locus, D10γGCS-HA-1 was taken through one drug selection cycle. Indeed, 
integration was observed in selection cycle 1 and the parasites were 
subsequently cloned by limiting dilution. Figure 3-8B shows two of the clones 
isolated after limiting dilution that were later used for phenotypical analyses. 
Clone 4 of D10γGCS-HA-1 still contains some episomal plasmid, indicated by the 
9.89 kb band as well as possessing a recombined pfγgcs locus (Figure 3-8B, lane 
2). Clone 5 only possesses the recombined locus indicated by a double band 
(Figure 3-8B, lane 3) whereas the diagnostic plasmid band cannot be detected in 
this clone, indicating the absence of episomal plasmid. Because of the size of 
the double band for the recombined locus and because the double band has not 
clearly separated, it can be assumed that the recombined locus resembles 
variation B in both clones. In case of variation B the two fragments are only 40 
bp different in size and thus unlikely to be properly segregated on this gel, 
whereas the two bands for variation A at 6.66 kb and 7.08 kb would be clearly 
separated. Therefore the sequence of the HA-tagged protein is expected to be a 
mixture of the 3D7 and D10 form of PfγGCS in Clone 4 possessing the plasmid 
and a recombined locus while only D10 PfγGCS-HA is expected in Clone 5 
possessing only the recombined locus. The recombination between the 
expression plasmid pCHD-Hsp86-γGCS-HA and the endogenous pfγgcs locus shows 
again that the gene locus can be targeted. 
The Southern blot in Figure 3-8C shows the genotype of the parasite line D10γGCS-
HA-2. This line possesses the endogenous pfγgcs locus and the episomal 
expression plasmid, indicated by the diagnostic bands at 3.88 kb and 9.89 kb, 
respectively. No integration specific bands are visible, showing that no single 
crossover recombination has occurred in this parasite line. 
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Thus three different PfγGCS over-expressing lines were generated: (1) Clone 5 
contains a pfγgcs gene under control of the endogenous promotor with an HA-tag 
and a second copy of the gene under control of the Hsp86 promotor and 
untagged; this should lead to a higher pfγgcs expression than observed in wild-
type parasites; (2) Clone 4 has the integrated gene locus as described for (1) 
plus the additional episomal HA-tagged version of the gene; presumably gene 
expression is higher than in the wild-type and in Clone 5; (3) D10γGCS-HA-2 only 
carries the episome in addition to the endogenous pfγgcs locus. 
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Figure 3-8: Genotypic analyses of D10γGCS-HA-1 and D10γGCS-HA-2. 
For expression of PfγGCS-HA in P. falciparum, parasites were transfected with the construct 
pCHD-Hsp86-γGCS-HA. Panel A shows a schematic diagram (not to scale) of the expected 
banding pattern for the endogenous D10 pfγgcs locus (I), the expression plasmid pCHD-Hsp86-
γGCS-HA (II) and the gene locus following recombination with the plasmid (III) after diagnostic 
digest of parasite gDNA with NdeI. To analyse transfected parasites, a pfγgcs- specific probe 
homologous to the 3’-end of the gene was used. This probe was also used for the analysis of 
parasites transfected with pHH1-γgcscon (see 3.6). The expected bands are indicated by red 
arrows. A 3.88 kb fragment is expected for the endogenous D10 pfγgcs locus (I) and for the 
expression plasmid a 9.89 kb fragment is expected. The plasmid contains the full length 3D7 
pfγgcs ORF (II, green box) in frame with an HA-tag (II, purple box) and an hDHFR cassette (II, 
yellow box) for selection of transfected parasites. Single crossover recombination between the 
plasmid and the endogenous locus results in a pseudo-diploid locus with two functional full length 
copies of the gene (III, green boxes). In case of a recombination event, the first copy of the gene is 
under control of the endogenous promotor and contains the HA-tag, whereas the second copy is 
untagged and under control of the Hsp86 promotor. Due to the differences in the repetitive motif 
present in the endogenous locus and the expression construct, two different variations are possible 
for an integration event. In variation A, the first copy of pfγgcs contains the motif as it is present in 
the 3D7 strain and the second copy contains the D10 motif. This would lead to two bands of 6.66 
kb and 7.08 kb. In variation B, the D10 motif is present in the first copy, while the second copy 
contains the 3D7 motif, leading to two bands of 6.85 kb and 6.89 kb, respectively. Panel B shows a 
Southern blot of two clones of the parasite line D10γGCS-HA-1 in comparison to wildtype D10 
parasites (lane 1). Prior to blotting, gDNA was digested by NdeI. The expected fragments are 
indicated in Panel A by red arrows. Only in lane 1 containing wild type gDNA the endogenous 
pfγgcs locus (WT) is present. Clone 4 (lane 2) possesses a recombined pfγgcs locus and the 
episomal expression plasmid. Clone 5 (lane 3) possesses the recombined gene locus and has lost 
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the plasmid. Panel C displays a Southern blot of the parasite line D10γGCS-HA-2. The expected 
banding pattern following diagnostic NdeI digest is indicated by red arrows in Panel A. D10γGCS-HA-2 
possesses the endogenous pfγgcs locus (WT) and the expression plasmid pCHD-Hsp86-γGCS-
HA. No recombination has occurred between the plasmid and the wild-type gene locus in this 
parasite line. 
3.7.2 Phenotypic analyses 
In order to determine whether PfγGCS-HA is expressed, protein was extracted 
from parasites and analysed by western blotting using an anti-HA antibody. The 
western blot displayed in Figure 3-9 was performed by L. Sveen under my 
supervision and shows protein extract of Clones 4 and 5 of D10γGCS-HA-1 (lanes 1 
and 2, respectively) and the non-clonal D10γGCS-HA-2 parasites (lane 3). The 
presence of protein in all lanes was confirmed by Ponceau-S staining of the 
membrane prior to blocking and incubation with antibodies. A band of the 
expected size for PfγGCS-HA between 129.9 kDa for the 3D7 and 130.8 kDa for 
the D10 variation was detected in all three transfected parasite lines (lanes 1-3). 
The two forms of the protein are too similar in size to be separated on this gel. 
In comparison, no signal was detected in protein extract of wild-type D10 
parasites (lane 4). For all lines 20 µg of total protein according to Bradford assay 
were loaded, but the signal strength varies between the three transfected lines, 
indicating different amounts of the HA-tagged fusion protein are present in the 
parasites. The signal is weakest in lane 2 (Figure 3-9), containing the protein 
extract of Clone 5 of D10γGCS-HA-1. For this line no episomal plasmid was detected 
on the Southern blot (Figure 3-8B), only the recombined pfγgcs locus was 
present. Clone 4 of D10γGCS-HA-1, which still contained episomal plasmid 
according to the Southern blot in Figure 3-8B appears to contain more of the 
PfγGCS-HA fusion protein, as indicated by the stronger signal detected in lane 1. 
This suggests that the amount of the HA-tagged protein present is dependent on 
the presence or absence of the episomal plasmid, as one would expect. Clone 4 
with the episomal plasmid possesses more than one copy of the tagged gene 
encoding for PfγGCS-HA. Thus this line contains more of the recombinant protein 
than Clone 5, which only possesses one copy of the tagged gene under control of 
the endogenous promotor in the recombined locus. The strongest signal is 
detected on the protein extract from the non-clonal D10γGCS-HA-2 parasites. 
D10γGCS-HA-2 does not have a recombined pfγgcs locus, only the episomal 
expression plasmid is present in this parasite line. Some smaller fragments than 
the expected size of 129.9 kDa indicate that some degradation of the fusion 
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protein occurs in this parasite line. Because more than one copy of the 
expression plasmid can be present per parasite cell, these parasites potentially 
contain several copies of the gene encoding for γGCS-HA which are under control 
of the strong Hsp86 promotor. This indicates that high level of PfγGCS-HA 
expression from an episomal plasmid is possible. 
Ideally this blot should be stripped and probed again with a “loading control” 
antibody recognising a protein not affected by the over-expression of PfγGCS, to 
confirm that equal amounts of protein were loaded. Because on this blot only 
the HA-tagged form of PfγGCS is detected, it does not allow any conclusions 
about the total amount of PfγGCS present in these parasite lines. Unfortunately 
no PfγGCS specific antibody is available to analyse the amount of total PfγGCS. 
 
Figure 3-9: Expression of PfγGCS-HA. 
Western blot analysis of protein extract from parasite lines transfected with pCHD-Hsp86-γGCS-HA 
was performed with an anti-HA antibody. Because of variations of a repetitive sequence element, 
two sizes are expected for recombinant PfγGCS-HA. The plasmid encodes for the 3D7 variation at 
a size of 129.9 kDa, whereas the recombined locus resembles the D10 variation and is larger at a 
size of 130.8 kDa. The two different sizes were not separated on this gel. For all samples 20 µg of 
total protein were loaded. Lane 1 contains protein extract of D10γGCS-HA-1 Clone 4. In lane 2 protein 
extract of D10γGCS-HA-1 Clone 5 was loaded. Both clones possess a recombined pfγgcs locus. In 
addition, Clone 4 still contains the episomal expression construct pCHD-Hsp86-γGCS-HA, which is 
absent in Clone 5. In lane 3 protein extract of the non-clonal D10γGCS-HA-2 line was loaded. This 
parasite line possesses the endogenous wild-type locus and the episomal expression construct. 
Protein extract of non-transfected wild-type D10 parasites was loaded in lane 4. This Western Blot 
was carried out by L. Sveen, IASTE student at the University of Glasgow, under my supervision. 
The susceptibility of D10γGCS-HA-2 to the specific inhibitor of γGCS, L-BSO, was 
tested and the concentration at which 50 % of growth inhibition of the parasites 
occurs (IC50 value) was determined (Meister, 1983). The IC50 assays were also 
performed in the presence of 5 mM N-acetylcysteine (NAC), because availability 
of L-cysteine might be a limiting factor for GSH biosynthesis and over-expression 
of PfγGCS may not be sufficient to increase the GSH levels in the cytosol of 
D10γGCS-HA-2, if there is a lack of available substrates. 
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The IC50 growth assay for the effect of L-BSO on D10
γGCS-HA-2 in comparison to 
D10 wild-type was performed once in duplicate by L. M. Laine under my 
supervision (Figure 3-10A). At 165 ±21 µM the IC50 determined for D10
γGCS-HA-2 
was approximately 2.5 times higher than the wild-type IC50 at 64 ±5 µM (Figure 
3-10). This suggests that there is indeed more target protein in this mutant line 
compared to the D10 wild-type. IC50 values determined in the presence of 5 mM 
NAC were 178 ±39 µM and 72 ±7 µM for D10γGCS-HA-2 and D10, respectively and 
thus only slightly higher, indicating that NAC does only marginally influence the 
susceptibility of the parasites to L-BSO. 
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Figure 3-10: Determination of IC50 values for L-BSO in D10 and D10γGCS-HA-2. 
Panel A: The inhibitory effect of L-BSO on parasite growth was determined in the presence and 
absence of 5 mM NAC for wild-type D10 and D10γGCS-HA-2. IC50 values were similar under both 
conditions with D10γGCS-HA-2 being 2.5 times less susceptible to the drug. The IC50 for L-BSO alone 
was 165±21 µM for D10γGCS-HA-2 (●) and 64±5 µM for D10 (■). IC50 values in presence of 5 mM 
NAC were 72±7 µM and 178±39 µM for D10 (▼) and D10γGCS-HA (▲), respectively. 
3.8 Co-transfection of PfγGCS knockout and expression 
plasmids 
After having shown that the pfγgcs gene locus can be targeted and that 
expression of PfγGCS-HA from an episomal plasmid is possible, I attempted to 
knockout the gene in presence of an episomal copy of pfγgcs. If the pfγgcs gene 
is indeed essential, it is anticipated that the presence of an episomal copy 
should result in sufficient generation of γGCS for parasite survival. The knockout 
construct pCC4-∆γgcs and the expression plasmid pCHD-Hsp86-γGCS-HA were co-
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transfected at the same time into wild-type D10 parasites to generate the line 
D10pCC4-∆γgcs/γGCS-HA. The transfected parasites were selected with Bla and 
WR99210 and were first observed 6 weeks after transfection. For drug selection, 
only Bla was omitted form the cultures while the WR99210 pressure was 
maintained to continuously select for the expression plasmid. Parasites were 
taken through 3 selection cycles and gDNA was isolated after each cycle and 
analysed by Southern blot. 
Figure 3-11 displays a schematic diagram of the expected banding pattern for a 
Southern blot after diagnostic NdeI digest of the gDNA. Red arrows indicate the 
fragments which can be detected with gene specific probes homologous to the 
two inserts of pCC4-∆γgcs. Blue arrows indicate those fragments which can be 
detected with probes for the selectable marker genes bsd and hdhfr. Digest with 
NdeI results in a 3.88 kb fragment for the endogenous locus of pfγgcs in D10, 
which can only be detected with the gene specific probes (Figure 3-11A, I). For 
the pCC4-∆γgcs plasmid (Figure 3-11A, II) two fragments at 7.27 kb and at 0.65 
kb are expected with the gene specific probes. Only the larger fragment is 
detectable with the bsd specific probe. A 9.89 kb fragment is expected for the 
pCHD-Hsp86-γGCS-HA plasmid for both gene- and hdhfr-specific probes (Figure 
3-11A, III). In the event of a gene replacement by pCC4-∆γgcs (Figure 3-11A, IV), 
two fragments at 2.18 kb and 1.01 kb are expected for the recombined locus 
with the gene specific probes while a bsd-specific probe can only detect the 2.18 
kb band. 
The Southern blot for D10pCC4-∆γgcs/γGCS-HA using pfγgcs specific probes is displayed 
in Figure 3-11B. In lane 1 gDNA of untransfected D10 wild-type parasites was 
loaded. Lane 2 contains gDNA of D10pCC4-∆γgcs/γGCS-HA isolated in drug selection 
cycle 0 when parasites were first obtained following transfection and lane 3 
contains gDNA isolated in drug selection cycle 3. The 3.88 kb band corresponding 
to the endogenous pfγgcs locus is present in the wild-type parasites and in 
selection cycles 0 and 3 of the D10pCC4-∆γgcs/γGCS-HA line (Figure 3-11B, lanes 1-3). 
In addition, two bands at 7.27 kb and 0.65 kb corresponding to the pCC4-∆γgcs 
plasmid can be detected in D10pCC4-∆γgcs/γGCS-HA in cycle 0 and cycle 3 in lanes 2 
and 3, respectively. Surprisingly, the diagnostic 9.89 kb band for the expression 
construct is not present in either cycle. Instead, an additional band not 
corresponding in size to either the expression plasmid or integration of pCC4-
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∆γgcs is visible just below the band for the endogenous gene in the D10pCC4-
∆γgcs/γGCS-HA line (Figure 3-11B, lanes 2 and 3). This additional band also does not 
correspond in size to a recombination event between the expression plasmid and 
the endogenous locus as described in 3.7.1. 
To closer investigate this pattern the membrane was stripped and re-probed 
with bsd- and hdhfr-specific probes (Figure 3-11C). As expected, no bands are 
recognized in lane 1, which contains gDNA of D10 wild-type parasites. In lanes 2 
and 3 (gDNA of D10pCC4-∆γgcs/γGCS-HA in selection cycle 0 and 3, respectively) two 
bands are visible. The top band at 7.2 kb corresponds to the pCC4-∆γgcs 
knockout construct. The bottom band appears to be the same additional band 
that was seen when the blot was probed with the gene specific probes in Figure 
3-11B. The 9.89 kb band diagnostic for the expression plasmid is not recognized, 
indicating loss or possibly recombination of the expression construct. This co-
transfection did not lead to a knockout of the pfγgcs target gene, probably 
because the expression plasmid was lost or altered through recombination and 
thus was no longer able to provide expression of functional PfγGCS protein to 
substitute for a pfγgcs knockout. 
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Figure 3-11: Knockout of pfγgcs by gene replacement in presence of an episomal copy. 
Panel A: Schematic diagram (not to scale) of the D10 pfγgcs locus (I), the pCC4-∆γgcs knockout 
plasmid (II), the pCHD-Hsp86-γGCS-HA expression plasmid (III) and the pfγgcs locus following 
recombination with the pCC4-∆γgcs plasmid by double crossover (IV). The pCC4-∆γgcs plasmid 
(II) containes two 485 bp and 522 bp inserts (blue boxes) homologous to regions of the 5’-and 3’- 
end of the pfγgcs coding region (green box). This plasmid contains a BSD selectable marker 
cassette (yellow box) for positive selection of transfected parasites and a CD cassette (orange box) 
for negative selection against parasites maintaining the plasmid as episome. The expression 
plasmid pCHD-Hsp86-γGCS-HA contains the full length pfγgcs coding region of the 3D7 strain (III, 
green box) cloned in frame with an HA-tag (purple box). The expression construct contains an 
hDHFR selectable marker cassette (III, yellow box) for positive selection of transfected parasites. 
Following recombination with pCC4-∆γgcs, the endogenous pfγgcs is replaced by the BSD 
selectable marker (IV). Diagnostic digests were performed with NdeI. Restriction sites are indicated 
by black arrows. Southern blot was performed with pfγgcs specific probes or probes specific for the 
selectable markers bsd and hdhfr. Fragments detected with gene-specific probes are indicated by 
red arrows. Fragments detected with the probes for selectable markers are indicated by blue 
arrows. Panel B: Southern blot using a pfγgcs-specific probe on untransfected D10 wild-type 
parasites (lane 1) and the D10pCC4-∆γgcs/γGCS-HA transfected parasite line in selection cycle 0 and 
cycle 3 (lanes 2 and 3, respectively). The 3.88 kb band corresponding to the endogenous pfγgcs 
gene (WT) is visible in both wild-type and transfected parasites (lane 1-3). In the transfected line 
the two bands corresponding to pCC4-∆γgcs are visible at 7.27 kb and 0.65 kb in drug selection 
cycle 0 and cycle 3 (lanes 2 and 3). An additional band is visible below the band corresponding to 
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the endogenous gene which does not correspond to any band expected for either pCHD-Hsp86-
γGCS-HA or integration of pCC4-∆γgcs. Panel C shows the same blot after re-probing with probes 
for the selectable markers bsd and hdhfr. No bands can be detected on the D10 wild-type gDNA. In 
lane 2 and 3 of the transfected parasites in cycle 0 and cycle 3, respectively, two bands are visible. 
The larger one corresponds to the 7.27 kb fragment of the pCC4-∆γgcs plasmid containing the 
BSD cassette. The smaller band at approximately 3.6 kb does not correspond to any expected 
band (see diagram in Panel A). 
To further investigate the possibility of recombination of the expression 
construct, isolated gDNA of D10pCC4-∆γgcs/γGCS-HA was used for bacterial 
transformation in order to recover any plasmids present in the parasites. This 
plasmid rescue was performed with gDNA of parasites in selection cycle 0 and 
cycle 1. However, only for the gDNA prepared in selection cycle 0 bacteria 
colonies were obtained. Nine of the colonies were picked for isolation of plasmid 
DNA and the obtained plasmids were analysed by restriction digest with PvuII. 
Using this enzyme, two fragments of 8.26 kb and 2.36 kb size are expected for 
the expression construct pCHD-Hsp86-γGCS-HA. Two smaller fragments of 3.60 
kb and 4.76 kb are expected for the knockout construct pCC4-∆γgcs. 
The restriction analysis showed that two different types of plasmids were 
obtained (Figure 3-12). One plasmid appeared to be present in higher copy 
number in the bacteria and gave a pattern of two bands at approximately 1.8 kb 
and 2.2 kb (Figure 3-12, lanes 1, 2, 4, 8 and 9). The other type of plasmid gave a 
pattern of five bands and appeared to be present at a low copy number. The 
fragments of the second plasmid had sizes of approximately 1.8 kb, 2.2 kb, 3.5 
kb, 4 kb and 5 kb (Figure 3-12, lanes 3, 5, 6 and 7). Neither of the two patterns 
observed for the isolated plasmids correspond to those expected for the 
plasmids pCHD-Hsp86-γGCS-HA and pCC4-∆γgcs. These results again indicate 
that the two plasmids have undergone recombination. Surprisingly, not even 
pCC4-∆γgcs which was detected on the Southern blot could be isolated. It is 
possible that the number of colonies screened was not large enough in order to 
find a clone containing this plasmid. 
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Figure 3-12: Plasmids isolated from D10pCC4-∆γgcs/γGCS-HA gDNA. 
D10pCC4-∆γgcs/γGCS-HA gDNA was used for bacterial transformation to recover plasmids present in the 
parasites. Nine colonies were selected for plasmid isolation and the plasmids were subsequently 
digested with PvuII (lanes 1-9). The expected sizes were 8.26 kb and 2.36 kb for pCHD-Hsp86-
γGCS-HA and 3.60 kb and 4.76 kb for pCC4-∆γgcs. None of the isolated plasmids corresponded to 
the expected patterns. 
3.9 Summary 
• The length of pfγgcs differs between different strains of P. falciparum 
due to the variable number of a repetitive motif of unknown purpose. The 
3D7 strain possesses only one copy of the motif. D10 possesses 9 repeats 
of the motif. 
• Localization studies with episomally expressed PfγGCS-GFP indicate that 
PfγGCS is cytosolic. 
• A knockout of pfγgcs could not be achieved by either gene disruption with 
the construct pHH1-∆γgcs or by gene replacement with the construct 
pCC4-∆γgcs. However, the gene locus was targeted with the knock-in 
control construct pHH1-γgcscon and it was also possible to tag the 
endogenous locus with an HA-tag. Together these results indicate that 
pfγgcs is essential for the survival of erythrocytic stages of P. falciparum 
in vitro. 
• Parasites transfected with an expression construct for PfγGCS-HA express 
the fusion protein. Recombination between the expression construct and 
the gene locus is possible and leads to a pseudo-diploid locus with two 
copies of the gene. Expression of PfγGCS-HA decreases the susceptibility 
of P. falciparum to the γGCS inhibitor L-BSO, but addition of NAC does not 
change the susceptibility of the parasites to L-BSO. 
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• The knockout of pfγgcs by gene replacement with pCC4-∆γgcs in presence 
of an episomal copy of the gene was not possible due to recombination of 
the expression construct pCHD-Hsp86-γGCS-HA. Transfected parasites did 
not contain the original constructs and no knockout was observed. 
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4 Glutathione Synthetase 
4.1 Introduction 
The second step of the biosynthesis of GSH, the addition of glycine to the 
dipeptide L-γ-glutamyl-L-cysteine (γGC), is catalysed by glutathione synthetase 
(GS) (Reaction 3). 
 
Reaction 3: The second step of GSH biosynthesis. 
The ATP-dependent ligation of glycine to γGC is catalysed by GS. 
In this chapter the subcellular localization of PfGS is investigated by expression 
of recombinant PfGS-GFP in erythrocytic stages of P. falciparum. The role and 
importance of PfGS for the survival of P. falciparum is analysed by reverse 
genetic approaches. Two different methods were used to attempt the knockout 
of pfgs, a gene disruption and a gene replacement strategy and it was further 
analysed whether the gene locus can be targeted by knock-in constructs. A third 
approach to assess the essentiality of PfGS was to express an inactive mutant of 
PfGS C-terminally tagged to the destabilization domain FKBP12 (Armstrong and 
Goldberg, 2007; Banaszynski et al., 2006). In the absence of the stabilising agent 
Shld1 the tagged protein is subject of immediate degradation and should thus 
not lead to the formation of inactive GS dimers and thus not affect viability of 
the parasites. In presence of Shld1 the PfGS mutant protein should be stabilized 
and dilute out the endogenously expressed active from of PfGS. Lastly, PfGS-HA 
was expressed in P. falciparum. 
4.2 Localization of PfGS 
The subcellular localization of PfGS was investigated expressing C-terminally 
GFP tagged PfGS from an episomal expression plasmid. Using MultiSite Gateway® 
technology the full-length pfgs ORF was cloned in frame with the sequence of 
the GFP-tag (van Dooren et al., 2005). The expression was under control of the 
Hsp86 promotor and the expression plasmid pCHD-Hsp86-GS-GFP (see Table 2-1) 
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was transfected on two independent occasions into D10 wild-type parasites, 
generating the parasite lines D10GS-GFP-1 and D10GS-GFP-2. Live parasites were 
observed in the transfected cultures after 3 weeks. Both parasite lines showed 
GFP-fluorescence in the cytosol. Images presented here were taken of parasite 
line D10GS-GFP-1 (Figure 4-1A). To ensure that the observed fluorescence was due 
to the full length PfGS-GFP fusion protein and not to a degradation product, 
protein was extracted from the parasites and analysed by Western blotting with 
an anti-GFP antibody (Figure 4-1B). A single band of the expected molecular size 
of the full-length PfGS-GFP fusion protein at 104.7 kDa was detected, 
demonstrating that the GFP-fluorescence observed in the transfected parasites is 
indeed the result of the expression of the full-length PfGS-GFP from the pCHD-
Hsp86-GS-GFP plasmid. These data show that PfGS is located in the parasite 
cytosol. 
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Figure 4-1: Subcellular localization of PfGS-GFP. 
Panel A: The subcellular localization of PfGS in erythrocytic stages was determined by expressing 
a PfGS-GFP fusion protein in the parasites. The full length pfgs ORF was cloned in frame with the 
sequence for a C-terminal GFP-tag and D10 parasites were transfected twice with an episomal 
expression construct for PfGS-GFP under control of the Hsp86 promotor. The fusion protein was 
localized in the parasite cytosol. Images were taken of the transfected line D10GS-GFP-1. Panel B: 
Western Blot analysis of protein extract of D10GS-GFP-1 parasites with an anti-GFP antibody showed 
the full length PfGS-GFP fusion protein. 
Glutathione Synthetase  100 
 
4.3 Knockout studies 
4.3.1 Knockout by gene disruption 
To assess whether PfGS is essential for the survival of intra-erythrocytic stages 
of P. falciparum, knockout studies by gene disruption were performed using the 
plasmid pHH1 (Reed et al., 2000). A 1000 bp DNA fragment homologous to a part 
of the target gene was cloned into the plasmid. The fragment lacked the 5’- and 
3’-end of pfgs and contained an artificial stop codon. The resulting plasmid was 
named pHH1-∆gs (Table 2-1) and was transfected into wild-type 3D7 parasites on 
two independent occasions. Transfected parasites were selected with the drug 
WR99210 because the pHH1 plasmid contains an hDHFR selectable marker 
cassette. It was expected that the plasmid leads to a knockout by integration of 
the vector into the target gene locus following a single cross-over event if pfgs is 
not essential. The target gene locus is disrupted into a pseudo-diploid locus with 
two truncated copies of the gene. One copy lacks the 3’-end and contains a 
premature stop codon while the second copy is truncated at the 5’-end and lacks 
the start codon. 
Transfected parasite lines were named 3D7pHH1-∆gs-1 and 3D7pHH1-∆gs-2 and 
parasites were observed in Giemsa stained thin smears four to five weeks after 
transfection. To select for parasites with a disrupted gene locus, cultures were 
subjected to drug selection cycles as outlined in section 3.4. Parasites 
transfected with the pHH1-∆gs construct were taken through four drug selection 
cycles and gDNA was isolated after each complete cycle and analysed by 
Southern blot after a diagnostic restriction digest with EcoRV and XhoI (Figure 
4-2). 
Figure 4-2A shows a diagram of the expected restriction pattern for the Southern 
blot. Using a pfgs specific probe generated from the insert of pHH1-∆gs, an 8.47 
kb band should be visible indicative of the endogenous pfgs locus. A 1.26 kb 
fragment is expected for the plasmid with this probe and in the case of a 
recombination event with the pfgs gene locus two bands at 1.93 kb and 7.80 kb 
are expected (Figure 4-2A). Black arrows indicate the restriction sites of EcoRV 
and XhoI. The sizes of the expected fragments are indicated by red arrows. 
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The Southern blot in Figure 4-2B shows gDNA isolated from 3D7pHH1-∆gs-1 and 
3D7pHH1-∆gs-2 in selection cycle 0 (lanes 2 and 4, respectively) and cycle 4 (lanes 3 
and 5, respectively) in comparison to gDNA extracted from 3D7 wild-type 
parasites (lane 1). No recombination of the plasmid was observed; in either of 
the transfected parasite lines only bands corresponding to the plasmid and the 
endogenous pfgs locus were detected (1.26 kb and 8.47 kb, respectively; Figure 
4-2B, lanes 2-5). For the untransfected wild-type parasites only the 8.47 kb band 
corresponding to the intact endogenous pfgs locus is visible. This suggests that 
either the gene is essential or that the gene locus cannot be targeted. 
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Figure 4-2: Knockout studies of P. falciparum gs by gene disruption. 
For knockout studies by single cross-over the plasmid pHH1 was used. Panel A displays a 
schematic diagram (not to scale) of the wild-type endogenous gene locus (I), the transfected pHH1-
∆gs construct (II) and the gene locus following recombination (III). The wild-type locus (I) was 
targeted with a pHH1-∆gs construct (II) containing a 1 kb insert (II, blue box) homologous to a part 
of the pfgs ORF (I, green box). The insert lacks the start ATG codon and part of the 5’-end and 
contains an artificial stop codon (stop*) whilst lacking the 3’-end. An hDHFR selectable marker 
cassette (yellow box) allows for selection of transfected parasites. Knockout of the gs gene is 
achieved through disruption of the gene locus following a single cross-over event between the 
plasmid and the wild-type locus. This leads to the formation of a pseudo-diploid locus (III) with two 
truncated copies of the gene, one truncated at the C-terminus by the artificial stop codon (III, stop*, 
green-blue box) and one truncated at the N-terminus lacking a start codon (III, blue-green box). 
Parasite lines were analysed by Southern blot following restriction digest of gDNA with EcoRV and 
XhoI. Red arrows indicate the expected fragment sizes detected with a gene specific probe. Panel 
B shows a Southern blot of two independently transfected parasite lines after diagnostic digest with 
NdeI and XhoI. The expected pattern is indicated by red arrows in Panel A. Lane 1 contains gDNA 
of untransfected 3D7 wild-type parasites. Lanes 2 and 3 contain gDNA of selection cycle 0 and 
cycle 4 of 3D7pHH1-∆gs-1, respectively. Lanes 4 and 5 contain gDNA of selection cycle 0 and cycle 4 
of 3D7pHH1-∆gs-2, respectively. In all five lanes the diagnostic wild-type band is present at 8.47 kb 
(WT). In lanes 2-5 the band corresponding to the plasmid is detected at 1.26 kb. No integration 
specific bands at 1.93 kb and 7.80 kb can be observed in lanes 2-5. 
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4.3.2 Knockout by gene replacement 
In a second approach to test whether pfgs is essential, knockout studies by gene 
replacement were performed using the plasmid pCC4 (Maier et al., 2006). Two 
0.48 kb inserts homologous to regions of the 5’- and 3’-ends of the pfgs gene 
were cloned into the plasmid, thus generating the construct pCC4-∆gs (see Table 
2-1). Recombination via double cross-over between the pCC4 construct and the 
gene locus results in replacement of the target gene with the blasticidin-S-
deaminase (bsd) selectable marker. In addition to the bsd selectable marker for 
selection of transfected parasites, the plasmid also contains a cytosine 
deaminase (cd) gene for negative selection against parasites maintaining the 
plasmid episomally and against parasites that integrated the plasmid by single 
crossover. This death gene is lost when the vector recombines with the target 
gene by double crossover. Transfections were performed independently in 3D7 
and D10 wild-type parasites. Transfected parasites were selected with 
Blasticidin-S-HCl (Bla) and to account for the possibility that parasites could 
survive the loss of PfGS by scavenging GSH, culture medium was supplemented 
with 2 mM GSH. 
Transfected parasites 3D7pCC4-∆gs and D10pCC4-∆gs were taken through drug 
selection cycles by removing Bla pressure for three weeks before adding the drug 
again as described previously. After each complete Bla selection cycle the 
cultures were divided into two independent cultures. One flask was cultured 
normally and taken through further drug selection cycles while the other was 
treated with Ancotil®. In case of a double crossover recombination between 
pCC4-∆gs and the pfgs gene the cd gene is lost and thus parasites become 
Ancotil® resistant. Ancotil® was added at a concentration equivalent to 1 µM 5-
fluorocytosine. Parasites in cultures treated with Ancotil® began to die within 2-
4 days, suggesting that Bla resistant parasites still contained the plasmid and the 
cd gene. No viable parasites were observed after one week, indicating the 
continued presence of the cd gene in the episomal plasmid. The Ancotil® drug 
pressure was maintained for several weeks. For 3D7pCC4-∆gs no Ancotil®-resistant 
parasites were obtained following Ancotil® treatment while for the D10pCC4-∆gs 
parasite line Ancotil®-resistant parasites were isolated after selection cycle 4. 
Ancotil®–resistant parasites were first detected in Giemsa stained thin smears 
after 4 weeks of culturing in the presence of Ancotil®. 
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To analyse the genotype of transfected parasites, gDNA was prepared of  
3D7pCC4-∆gs and D10pCC4-∆gs in Bla selection cycle 0 and after each subsequent cycle 
and analysed by Southern blotting (Figure 4-3, Panel B and C). The gDNA was 
digested in a diagnostic restriction digest with EarI. Figure 4-3A displays a 
schematic diagram depicting the expected pattern for the endogenous pfgs locus 
(AI), the pCC4-∆gs plasmid (AII) and the pfgs locus following a double crossover 
recombination event between the wild-type gene and the knockout construct 
(AIII). Gene specific probes homologous to the two inserts of pCC4-∆gs were used 
to analyse the parasite lines. The sizes of the expected fragments were 0.94 kb 
and 4.82 kb for the pfgs wild-type locus, 5.90 kb for the plasmid and 6.83 kb for 
a gene replacement. 
In Figure 4-3B and C Southern blots of D10pCC-∆gs and 3D7pCC4-∆gs are displayed. 
Both transfected parasite lines contained the plasmid in selection cycle 0 (Figure 
4-3B lane 2 and Figure 4-3C lane 2) and maintained the plasmid until cycle 3 
(lane 3B and lane 3C) as indicated by the presence of a 5.90 kb band. No band 
diagnostic for gene replacement at 6.83 kb was visible in either of the lines. The 
D10pCC4-GS parasites resistant to Ancotil® still contain the endogenous gene 
indicated by two bands at 0.94 kb and 4.82 kb and there is no indication of 
recombination of pCC4-∆gs with the endogenous gene locus (Figure 4-3C lane 4). 
However, it appears that the plasmid was lost from this parasite line as no 5.90 
kb band is visible on the Southern blot, suggesting that the parasites have 
maintained Bla resistance while losing the cd death gene. This possibility was 
not further analysed. Potentially the plasmid may have recombined, allowing the 
parasites to keep the part containing the bsd gene while losing the cd gene and 
the inserts homologous to the gs gene, which should have been detectable on 
the Southern blot. Performing Southern blot analysis with probes specific for the 
bsd and cd genes could elucidate for instance the fate of the plasmid. These 
results again indicate that the pfgs gene is essential for the survival of intra-
erythrocytic stages of P. falciparum. 
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Figure 4-3: Knockout studies by double cross-over of P. falciparum gs 
For knockout by gene replacement the plasmid pCC4 was used. Panel A displays a schematic 
diagram (not to scale) of the pfgs wild-type locus (I), the pCC4-∆gs construct (II) and the gene 
locus following recombination by double crossover (III). The plasmid contains two 0.48 kb inserts 
(II, blue boxes) homologous to the 5’- and the 3’-ends of the pfgs coding region (I, green box). 
Following double cross over recombination, the gene is replaced by the blasticidin-S-deaminase 
selectable marker cassette (II, III, yellow box). To analyse transfected parasite lines by Southern 
blotting, gDNA was digested with the restriction enzyme EarI. Red arrows indicate the sizes of the 
fragments for wild-type gene, plasmid and recombined locus that can be detected with a gene-
specific probe. Panel B shows a Southern blot of the transfected 3D7pCC4-∆gs parasite line in 
comparison to the 3D7 wild-type after diagnostic digest of gDNA with EarI. The expected pattern is 
described in Panel A. Lane 1 contains 3D7 wild-type gDNA. Two bands according to the wild-type 
(WT) gene locus at 0.94 kb and 4.82 kb can be observed. Lane 2 contains gDNA of 3D7pCC4-∆gs in 
cycle 0. In addition to the wild-type gene (WT), a 5.90 kb band corresponding to the plasmid is 
visible. Lane 3 shows the same parasite line after selection cycle 3. Again only the bands 
corresponding to the endogenous gene and the plasmid are present. Panel C shows a Southern 
blot of the D10pCC4-∆gs parasite line in comparison to the untransfected D10 wild-type after 
diagnostic digest of gDNA with EarI. The expected pattern is described by the diagram in Panel A. 
Lane 1 contains D10 wild-type gDNA. Only two bands at 0.94 kb and 4.82 kb corresponding to the 
wild-type gene locus are detected. Lane 2 and 3 contain gDNA of D10pCC4-∆gs in drug selection 
cycle 0 and cycle 3, respectively. In both the wild-type gene specific bands (WT) are visible as well 
as the 5.90 kb band corresponding to the plasmid. Lane 4 contains gDNA of the Ancotil® resistant 
parasites that were obtained after cycle 3. The wild-type gene is still present in this line. The 
plasmid band has disappeared. 
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4.3.3 Knockout control studies 
To rule out the possibility that the pfgs gene locus cannot be targeted parasites 
were transfected with the construct pHH1-gscon (Reed et al., 2000). Similar to 
the knockout construct, the pHH1-gscon control construct targets the pfgs gene 
locus in a single cross-over event. The 1.08 kb insert homologous to the target 
gene in this construct is truncated at the 5’-end but contains the full length 3’-
end including the endogenous stop codon of the pfgs coding region (see Table 
2-1). Integration of the construct into the wild-type locus creates a pseudo-
diploid locus with a full-length and a truncated copy of the gene (Figure 4-4A). 
Thus parasites still have a functional copy of the gene despite disruption of the 
pfgs gene locus. 3D7 wild-type parasites were transfected with the pHH1-∆gs 
control plasmid and selected with WR99210. Parasites resistant to WR99210 
were obtained 4 weeks after transfection. 
Transfected parasites 3D7pHH1-gscon were taken through two drug selection cycles 
as described previously and for each cycle gDNA was prepared and analysed by 
Southern blotting after digestion with EcoRI and XhoI. The expected fragments 
detectable with a pfgs gene specific probe corresponding to the insert of pHH1-
gscon are 6.40 kb for the endogenous wild-type locus (Figure 4-4A, I) and 3.30 kb 
for the plasmid (Figure 4-4A, II). Two fragments of 1.80 kb and 7.90 kb size are 
expected for an integration event (Figure 4-4A, III). 
After two drug selection cycles, the gene locus had been targeted and parasites 
were cloned by limiting dilution. Figure 4-4B shows a Southern blot of the 
untransfected 3D7 wild-type (lane 1) and the transfected parasite line in cycle 0, 
prior to integration (lane 2), and a clone isolated after cycle 2 (lane 3). A band 
corresponding to endogenous pfgs at 6.40 kb is visible in wild-type 3D7 (Figure 
4-4B, lane 1) and in 3D7pHH1-gscon in cycle 0 (lane 2). In the transfected parasites 
(lane 2) a band corresponding to the plasmid at 3.30 kb can be seen in addition 
to the endogenous wild-type band. Lane 3 shows an exemplary clone with two 
bands at 1.80 kb and 7.90 kb visible diagnostic for homologous recombination of 
the pfgs gene locus with the plasmid. The band corresponding to the wild-type 
gene locus is absent (Figure 4-4B). This demonstrates that the pfgs gene locus 
can be targeted. The cloned parasite line still contains the episomal plasmid as 
indicated by the presence of a 3.30 kb band. Since the selectable marker has 
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integrated into the gene locus the plasmid is no longer essential for the survival 
of the parasites. However, sometimes plasmids are maintained even after 
integration, possibly because this means higher expression level for the hDHFR 
selectable marker and an advantage for parasite survival. 
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Figure 4-4: Knock-in control studies of P. falciparum gs 
Panel A displays a schematic diagram (not to scale) of the pfgs wild-type locus (I), the pHH1-gscon 
construct (II) and the pfgs locus after recombination by single cross-over (III). The pHH1 construct 
contains a 1077 bp insert (II, blue box) homologous to the 3’-end of the coding region of the pfgs 
target gene (I, green box) and a hDHFR selectable marker (yellow box). The insert of the knock-in 
construct is truncated at the 5’-end, but it contains the full 3’-end of pfgs. Following recombination 
between plasmid and wild-type locus, the target gene is disrupted (III) and two copies of pfgs 
result, one full length copy (green-blue box) and one copy truncated at the 5’-end (blue-green box). 
gDNA of transfected parasites was digested with restriction enzymes EcoRI and XhoI for analysis 
by Southern blotting. Black arrows indicate restriction sites. The expected fragments detectable 
with a gene specific probe are indicated by red arrows. Panel B shows a Southern blot of EcoRI 
and XhoI digested gDNA of untransfected 3D7 wild-type parasites (lane 1), transfected parasites in 
cycle 0 (lane 2) and an exemplary clone following integration in selection cycle 2 (lane 3). The 
expected sizes of the restriction fragments are 6.40 kb for the endogenous pfgs locus, 3.30 kb for 
the plasmid and 1.80 kb and 7.90 kb for an integration event. The 6.40 kb band for the wild-type 
gene locus (WT) is visible in the 3D7 wild-type (lane 1) and in cycle 0 of the transfected line 
3D7pHH1-gscon (lane 2). The latter also shows a 3.30 kb band corresponding to the plasmid. The 
clone in lane 3 shows two integration specific bands at 1.80 kb and 7.90 kb in addition to the 
plasmid at 3.30kb. The 6.40 kb fragment corresponding to the wild-type gene is absent in this 
clone. 
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4.4 Expression of GSE206K/N208A-FKBP12 
The previous experiments have established that the pfgs gene locus can be 
targeted by a knock-in construct. However, neither a single crossover construct 
nor a double crossover construct in the presence of negative selection leads to a 
gene disruption or replacement, respectively. These results suggest an important 
if not essential function for PfGS. To further elucidate this possibility, the 
expression of a dominant-negative PfGS mutant protein in the erythrocytic 
stages of the parasites was considered a possibility to down-regulate internal 
PfGS activity. This approach was taken because PfGS is active as a dimer. The 
presence of a PfGS dead mutant next to the active form should result in the 
formation of inactive-active hybrid dimers as well as to active-active and 
inactive-inactive dimers and thus dilute the endogenous PfGS. This should 
decrease the overall PfGS activity in the parasite and potentially lead to a 
decrease in the intracellular GSH level in transfected parasite lines. To control 
the level of mutant PfGS present in the parasites, the gene was cloned in frame 
with the sequence for a C-terminal destabilization domain. The destabilization 
domain is a mutant form of the human FKBP12 protein (hereafter referred to as 
FKBP12) which leads to rapid proteasomal degradation of the fusion protein 
(Armstrong and Goldberg, 2007; Banaszynski et al., 2006). Shld1 is a ligand for 
FKBP12 and binds with high affinity to the destabilization domain thereby 
stabilizing the tagged protein. Thus cellular levels of any FKBP12 fusion protein 
can be regulated by adjusting the concentration of available ligand. 
4.4.1 Sequence considerations 
Alignment of PfGS with the HsGS reveals an overall sequence identity of 18.2 %. 
However, several domains appear to be highly conserved (Meierjohann et al., 
2002a). Recent studies on mutant forms of the human enzyme identified the role 
and importance of four amino acid residues within the ATP-binding domain of 
the human enzyme for enzyme activity (Dinescu et al., 2004). In particular the 
negatively charged Glu-144 residue was shown to have a major role in catalysis 
and is presumably involved in the stabilization of the γ-glutamylcysteinyl-
phosphate intermediate. Mutation of this amino acid to Lys completely abolished 
the activity of HsGS. Other residues shown to be of importance for activity of 
the human enzyme were Asn-146, Lys-305 and Lys-364. All four residues are 
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conserved in the PfGS (Figure 4-5). To generate an inactive form of PfGS, Glu-
206 and Asn-208 corresponding to Glu-144 and Asn-146 in the human enzyme 
were both mutated to Lys and Ala, respectively, thus generating PfGSE206K/N208A. 
Mutagenesis was performed using the pJC40-PfGS expression construct available 
in our laboratory (Meierjohann et al., 2002a) as template, generating the 
construct pJC40-GSE206K/N208A. The pJC40-GSE206K/N208A construct was then used as 
template for cloning of PfGSE206K/N208A into the pCHD-3/4 vector using the 
MultiSite Gateway® system for expression of PfGSE206K/N208A-FKBP12 in P. 
falciparum. The expression was controlled by the Hsp86 promotor to allow high 
levels of expression throughout the parasite intra-erythrocytic cycle. The 
expression construct was named pCHD-Hsp86-GSE206K/N208A-FKBP12 (see Table 
2-1). 
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Pf3D7GS         MERKVDEFYKVIEKEVLNYFTCPNGKNEYLSYERIKSLIKDMIAFLNTESYYIFTNSYKN 
HsGS            --------------------MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPT 
                                     ..*  .   . ::::.* :: :    :*.  : *..  . 
 
Pf3D7GS         EYNIDFLYNPKLFSFTLLPHRLDKKLLELCKYSTLLYSELFDNMVCDLSYLLSIFENIKE 
HsGS            SSEV-VSYAP----FTLFPSLVPSALLEQAYAVQMDFNLLVDAVSQNAAFLEQTLSSTIK 
                . :: . * *    ***:*  : . *** .    : :. *.* :  : ::* . :..  : 
 
Pf3D7GS         HDFFVKKMLEVCKKVYGDNSDNSDNSDNSNNSNNSNNSNNFRNIKDDIRCVIGRSDYMTN 
HsGS            QDDFTARLFDIHKQVLKE------------------------GIAQTVFLGLNRSDYMFQ 
                :* *. ::::: *:*  :                        .* : :   :.***** : 
 
Pf3D7GS         RNNDIIDDKEKIDDENINDKDIKQIEYNTISVAFGNLSSILFNGHKYILKQIYKEYFPYI 
HsGS            RSAD-------------GSPALKQIEINTISASFGGLASRTPAVHRHVLSVLSK------ 
                *. *             ..  :**** ****.:**.*:*     *:::*. : *       
 
Pf3D7GS         GNEEEQKEVNDILDKKFDNNFVQGIITCFKKCHDIYISEYKPLLGSHKVIMMSILHEDDF 
HsGS            -----TKEAGKIL----SNNPSKGLALGIAKAWELY--------GSPNALVLLIAQEKER 
                      **...**    .**  :*:   : *. ::*        ** :.::: * :*.:  
 
Pf3D7GS         NSFDKYKTTNELNKININQKALTINEIKLLFESKKLFLNYKDETLIDSLKRIKNKEYNPY 
HsGS            NIFDQRAIENELLARNIHVIRRTFEDI-----SEKGSLDQDRRLFVDGQ----------- 
                * **:    ***   **:    *:::*     *:*  *: . . ::*.             
 
Pf3D7GS         NEIFKPGKLLIDLNDLEDILNVDCININDILKNINKYERNIFEISVLYFRALYTPNHFNE 
HsGS            ------------------------------------------EIAVVYFRDGYMPRQYSL 
                                                          **:*:***  * *.::.  
 
Pf3D7GS         NIWKIREMFEFSDAIKIPSLPYQLVGSKKIQMLLLDNDILKKYISLNLNKEKKSDEQITK 
HsGS            QNWEARLLLERSHAAKCPDIATQLAGTKKVQQELSRPGMLEMLLP-------GQPEAVAR 
                : *: * ::* *.* * *.:. **.*:**:*  *   .:*:  :.        . * ::: 
 
Pf3D7GS         DMTLLKKTFALQVDPSQNINAHIIQDAINNENNYLLKPQREGGKNNLHGNQVKQKLKLFY 
HsGS            LRATFAGLYSLDVGEEGD---QAIAEALAAPSRFVLKPQREGGGNNLYGEEMVQALKQLK 
                  : :   ::*:*. . :   : * :*:   ..::******** ***:*::: * ** :  
 
Pf3D7GS         DHNKKQTLSHYVLMQRLFPSTFTAIHCRTQEMKNEICTTNISNEQQKKKPSHLIQFSPEK 
HsGS            DSEERAS---YILMEKIEPEPF------------ENCLL------RPGSPARVVQ----- 
                * ::: :   *:**::: *..*            * *        :  .*::::*      
 
Pf3D7GS         SISEFSLFHNFIFYKNKNILNEQKGYLVRTKNYTEKEGGAICGISSLDSFFLTEH 
HsGS            CISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVAAGVAVLDNPYPV-- 
                .***:.:*  ::  ::. ::*:: *:*:***   . :**. .*:: **. : . 
Figure 4-5: Alignment of the PfGS amino acid sequence with the human GS amino acid 
sequence. 
PfGS was aligned with HsGS using the programme T-Coffee showing identical residues (*), 
conserved residues (:) and homologous residues (.). For maximal alignment several gaps were 
introduced (-). The sites Glu-206, Asn-208, Lys-448 and Lys-517 in PfGS that are homologous to 
Glu-144, Asn-146, Lys-305 and Lys-364 in HsGS are highlighted in yellow. 
4.4.2 Recombinant expression of GSwt and GSE206K/N208A in E.coli 
In order to assess whether the mutations that were introduced into PfGS affect 
the activity, both wild-type and mutant forms of the enzyme were 
recombinantly expressed in E. coli, purified and activity assays performed. To 
confirm the optimal expression conditions described by Meierjohann et al. 
(Meierjohann et al., 2002a) for PfGSwt and to establish them for PfGSE206K/N208A in 
E. coli BLR (DE3), small scale test expressions at different temperatures were 
performed using the pJC40 constructs. The temperatures tested were 18°C, 
25°C, 30°C and 37°C. Samples of bacteria cultured after induction with 1 mM 
IPTG were prepared using the BugBuster extraction protocol and insoluble and 
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soluble fractions were analysed by western blotting using an  
anti-His-tag antibody. Figure 4-6A shows a western blot for the PfGSwt 
recombinant protein after expression over night. A band of the expected size 
(77.5 kDa) corresponding to the recombinant protein can be seen in the soluble 
fractions at 18°C, 25°C and 30°C (Figure 4-6A, lanes 5,6 and 7, respectively). No 
PfGSwt was detected in the soluble fractions after expression at 37°C (Figure 
4-6A, lane 8). The largest amount of soluble protein was found to be expressed 
at 25°C over night. Bands of the expected size for PfGS are also visible in the 
insoluble fraction (Figure 4-6A, lanes 1-4). The PfGSwt recombinant protein was 
expressed overnight at 25°C for purification. Figure 4-6B shows a western blot 
analysis of the PfGSE206K/N208A test expression. Protein was expressed for either 
four hours (Figure 4-6B, lanes 1-4) or over night (Figure 4-6B, lanes 5-8). Only 
the soluble fractions were loaded for this blot. Again, the temperatures tested 
were 18°C (lanes 1 and 5), 25°C (lanes 2 and 6), 30°C (lanes 3 and 7) and 37°C 
(lanes 4 and 8). Small amounts of the recombinant protein were detected after 
expression for 4 h at 18°C and 37°C (Figure 4-6B, lanes 1 and 4, respectively). 
Overnight incubation leads to expression of PfGSE206K/N208A recombinant protein 
at all four temperatures (Figure 4-6B, lanes 5-8). However, some smaller 
fragments detected suggest degradation or premature termination of protein 
translation, especially at 18°C (lane 5). The lowest number of smaller fragments 
can be detected after expression at 30°C (Figure 4-6B, lane 7). Thus the best 
expression condition for PfGSE206K/N208A appears to be incubation at 30°C 
overnight. 
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Figure 4-6: Western blot analysis of PfGS test expression. 
Panel A: PfGSwt protein was expressed overnight after induction with 1 mM IPTG at 18°C (lanes 1 
and 5), 25°C (lanes 2 and 6), 30°C (lanes 3 and 7) and 37°C (lanes 4 and 8) and samples were 
extracted using the BugBuster method. Lanes 1-4 contain the insoluble fractions and lanes 5-8 
soluble fractions. The expected size for PfGSwt is 77.5 kDa. Equal amounts of protein were loaded 
for insoluble and soluble fractions. Panel B: Mutant PfGSE206KN208A was expressed after induction 
with 1 mM IPTG for four hours (lanes 1-4) and over night (lanes 5-8) at 18°C (lanes 1 and 4), 25°C 
(lanes 2 and 5), 30°C (lanes 3 and 7) and 37°C (lanes 4 and 8). Equal amounts of the soluble 
fractions were loaded for this blot. 
PfGSwt and PfGSE206K/N208A were purified using the Ni2+-NTA affinity batch method. 
Both forms of the protein could be enriched, but the preparation was not very 
clean and numerous additional bands were observed on a SDS-PAGE (Figure 
4-7A). A double band was prominent at the expected size of the PfGS protein 
(77.5 kDa) and the larger band was confirmed to be either (His)10-GS
wt or (His)10-
GSE206K/N208A protein by western blotting using an anti-His-tag antibody (Figure 
4-7B). Some of the additional bands visible on the SDS-PAGE gel were also 
detected on the western blot, suggesting they are breakdown products of the 
recombinant proteins. 
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Figure 4-7: Expression and purification of (His)10-tagged GS. 
Panel A: Coomassie stained gel of purified PfGSwt (lane 1) and PfGSE206K/N208A (lane 2). Panel B: 
Western Blot of the purified protein PfGSwt (lane 1) and PfGSE206K/N208A (lane 2) using anti His-tag 
antibody. 
The activity of the recombinant enzymes was determined as previously 
described (Huang et al., 1995; Meierjohann et al., 2002a). Briefly, ADP produced 
by PfGS or PfGSE206K/N208A is used by pyruvate kinase to produce pyruvate and ATP 
from phosphoenolpyruvate. Lactate dehydrogenase in the assay uses NADH 
present in the reaction mix to convert pyruvate to lactate. The activity is 
measured by following the change of absorbance at 340 nm when NADH is 
oxidized to NAD+. As a substrate, γ-glutamyl-α-aminobutyrate (γ-GluAbu) was 
used rather than γ-GC in order to avoid thiol oxidation (Huang et al., 1995; 
Meierjohann et al., 2002a). 
In preliminary tests enzymatic activity was detectable for the wild-type form of 
PfGS but not for the PfGSE206K/N208A mutant (Figure 4-8). The measured activity of 
PfGSwt was proportional to the amount of protein used. No activity was detected 
if the substrate γ-GluAbu was omitted from the reaction mix, indicating that the 
PfGSwt and not one of the contaminating proteins were responsible for the 
detected activity. The activity measured for PfGSwt was 0.42 µmol / min / mg.  
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Figure 4-8: Activity of recombinant PfGS. 
The enzyme activity was determined spectrophotometrically by coupling the release of ADP by 
PfGS to oxidation of NADH to NAD+ through pyruvate kinase and lactate dehydrogenase. PfGSwt 
was active and the detected activity was proportional to the amount of enzyme. The activity of 
PfGSwt was dependant on the presence of the substrate γ-GluAbu. The mutant protein 
PfGSE206K/N208A was not active. This assay was only performed once. 
The specific activity was approximately ten times lower than previously reported 
for the homogenous protein (5.24 ±0.7 µmol / min /mg) (Meierjohann et al., 
2002a). This is likely due to the fact that the purified protein preparation still 
contains multiple contaminants that affect the overall specific activity 
determined. However, the purification was not further optimized for this study 
due to time limitations. Future work will be to purify the proteins further and to 
repeat the activity assays. Since no activity was detected for PfGSE208K/N208A it 
can be presumed that the Glu-206 and Asn-208 residues are important for not 
only HsGS but also for PfGS enzyme activity. 
4.4.3 Phenotypic analyses of P. falciparum expressing 
PfGSE206K/N208A-FKBP12 
P. falciparum D10 wild-type parasites were independently transfected twice 
with the pCHD-Hsp86-GSE206K/N208A-FKBP12 expression construct (see Table 2-1) 
creating the parasite lines D10GS-E206K/N208A-FKB12-1 and D10GS-E206K/N208A-FKBP12-2. It 
was first established that both lines express the PfGSE206K/N208A-FKBP12 fusion 
protein and whether the protein can be stabilized by addition of Shld1. Parasites 
were cultured in presence of 0.25 µM Shld1 for 8 hours and 24 hours prior to 
protein extraction and western blot analyses using an anti-FKBP12 antibody 
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(Figure 4-9). As a control, protein was extracted from parasites grown in the 
absence of Shld1 and from non-transfected D10 wild-type parasites. For each 
sample, 20 µg of total protein were loaded according to Bradford assay. The 
presence of protein in each lane was confirmed by staining of the membrane 
with Ponceau-S. 
No PfGSE206K/N208A-FKBP12 protein was detected in non-transfected D10 wild-type 
parasites (Figure 4-9, lane 1). Neither was the tagged protein detected in D10GS-
E206K/N208A-FKBP12-1 and D10GS-E206K/N208A-FKBP12-2 in the absence of the stabilising 
compound Shld1 (Figure 4-9, lanes 2 and 5, respectively), indicating complete 
degradation of the recombinant fusion protein due to the destabilization 
domain. Addition of Shld1 to the cultures only had an effect in the line D10GS-
E206K/N208A-FKBP12-1. The PfGSE206K/N208A-FKBP12 protein was detected after 8h and 
24 h (Figure 4-9, lanes 3 and 4, respectively). No protein was detectable in 
D10GS-E206K/N208A-FKBP12-2 after addition of 0.25 µM Shld1 to the culture medium for 
8 or 24 hours (lanes 6 and 7). This suggests that only D10GS-E206K/N208A-FKBP12-1 
expresses the tagged mutant protein and it is stabilized by Shld1. The second 
parasite line D10GS-E206K/N208A-FKBP12-2 seems to not express the fusion protein and 
therefore it cannot be stabilized. All further analyses were performed using only 
D10GS-E206K/N208A-FKBP12-1. 
 
Figure 4-9: Stabilization of PfGSE206K/N208A-FKBP12 in D10GS-E206K/N208A-FKBP12-1 and D10GS-
E206K/N208A-FKBP12
-2 in presence of 0.25 µM Shld1. 
Western analysis was performed using an anti-FKBP12 antibody. No recombinant protein was 
present in the untransfected D10 wild-type negative control (lane 1). Equally, no protein was 
detected in the PfGSE206K/N208A-FKBP12 expressing parasite lines D10GS-E206K/N208A-FKBP12-1 and 
D10GS-E206K/N208A-FKBP12-2 in the absence of Shld1 (lanes 2 and 5, respectively). In the presence of 
0.25 µM Shld1 GS-FKBP12 is expressed and stabilized in D10GS-E206K/N208A-FKBP12-1 after 8 (lane 3) 
and 24 hours (lane 4). No stabilized protein can be detected in D10GS-E206K/N208A-FKBP12-2 protein 
extract under these conditions after 8 (lane 6) and 24 hours (lane 7). 
To investigate if increasing the Shld1 concentration in the culture medium 
increases the amount of PfGSE206K/N208A-FKBP12 in D10GS-E206K/N208A-FKBP12-1, mixed 
stage parasites were cultured in the presence of 0.25 µM, 0.5 µM and 1 µM Shld1 
for 8 hours prior to protein extraction and Western analyses (Figure 4-10A, lanes 
2, 3 and 4, respectively). To investigate if the presence of Shld1 had any obvious 
effect on the parasite appearance, parasites were visually inspected (Figure 
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4-10B). Western blots were performed using the FKBP12 antibody and an 
antibody against the α-subunit of P. falciparum casein kinase 2 (PfCK2α) as a 
loading control. As a negative control, protein extract of parasites grown in the 
absence of Shld1 was loaded (Figure 4-10A, lane 1). Upon addition of Shld1 the 
PfGSE206K/N208A-FKBP12 protein is present at all drug concentrations tested. 
Surprisingly, differing from the result of the western blot shown in Figure 4-9, 
this time a double band was observed with the anti-FKBP12 antibody. Potentially 
this indicates the presence of a smaller degradation product. The levels of 
PfGSE206K/N208A-FKBP12 do not increase when the Shld1 concentration is doubled 
from 0.25 µM to 0.5 µM (lanes 2 and 3). This suggests that the amount of 
stabilized PfGSE206K/N208A-FKBP12 is already at a maximum at a concentration of 
0.25 µM Shld1 and cannot be increased any further. Probably the overall 
expression level of the tagged protein is limiting its stabilization and the 
PfGSE206K/N208A-FKBP12 protein present is already saturated with Shld1 at the 
lower concentration. Interestingly, increasing the Shld1 concentration even more 
to 1 µM has a reverse effect, lowering the amount of GSE206K/N208A-FKBP12 present 
in the parasites. No obvious effect of the drug on the morphology of the 
parasites was observed in Giemsa stained thins smears during the course of this 
experiment. All stages of parasite development were present in the mixed 
cultures and looked healthy at the three Shld1 concentrations tested. No dead 
parasites were observed. 
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Figure 4-10: Effect of varying Shld1 concentrations on stabiliztion of PfGSE206K/N208A-FKBP12. 
Panel A: Western blot of D10GS-E206K/N208A-FKBP12-1 protein extracted after parasites were cultured for 
8 hours without Shld1 (lane 1), in presence of 0.25 µM Shld1 (lane 2), 0.5 µM Shld1 (lane 3) and 1 
µM Shld1 (lane 4). An antibody against FKBP12 was used to detect PfGSE206K/N208A-FKBP12. An 
antibody against the Casein Kinase 2 α-subunit (PfCK2α) was used as loading control. Panel B: 
Thin smears of the cultures prior to harvesting showed healthy looking parasites in different stages 
for all tested concentrations of Shld1. 
To assess whether the presence of Shld1 and hence the stabilization and 
presence of PfGSE206K/N208A-FKBP12 affects growth and survival of D10GS-E206K/N208A-
FKBP12-1, a drug assay was performed to determine the IC50 concentration of Shld1 
for wild-type D10 parasites and for D10GS-E206K/N208A-FKBP12-1 (Figure 4-11). Growth 
of both parasite lines, D10 and D10GS-E206K/N208A-FKBP12-1, was unaffected at 
concentrations of Shld1 up to 0.2 µM. At higher concentrations the growth rate 
was affected in both parasite lines. The IC50 concentrations were determined to 
be 1.6 µM and 2.5 µM for D10 and D10GS-E206K/N208A-FKBP12-1, respectively. Because 
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the IC50 test was only performed twice in duplicate for D10 and D10
GS-E206K/N208A-
FKBP12-1 a full statistic analysis was not possible. The inhibition of the D10 wild-
type parasites by Shld1 indicates unspecific toxicity of the compound. Because 
of this unspecific toxicity, the IC50 assay was repeated once in duplicate with 
3D7 wild-type parasites. Again toxicity of Shld1 was found at concentrations 
higher than 0.2 µM (Figure 4-11). 
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Figure 4-11: Effect of Shld1 on the proliferation of D10 and 3D7 wild-type parasites and 
D10GS-E206K/N208A-FKBP12-1.
 
IC50 concentrations were determined twice in duplicate for D10 (●) and D10GS-E206K/N208A-FKBP12-1 (■) 
and once in duplicate for 3D7 parasites (▲). The IC50 concentrations for Shld1 were 1.6 µM for 
D10, 2.5 µM for D10GS-E206K/N208A-FKBP12-1 and 1.9 µM for 3D7. Results are presented as mean ± 
S.D. 
It was further investigated if an extended exposure to Shld1 during which the 
parasites undergo their intra-erythrocytic developmental cycle repeatedly 
affects parasite growth. Over a seven day period tightly synchronized D10GS-
E206K/N208A-FKBP12-1 parasites were cultured in the absence and in the presence of 
0.25 µM Shld1 (Figure 4-12). This concentration was chosen because it was the 
highest non-toxic concentration (Figure 4-11) which leads to stabilization of the 
fusion protein according to western analyses (Figure 4-10A). It was presumed 
that maximal stabilization of PfGSE206K/N208A-FKBP12 was achieved whilst 
minimising unspecific toxicity of Shld1. Parasites were diluted to an initial 
parasitemia of 0.5 % and their growth was monitored by counting Giemsa stained 
thin smears. Every second day cultures were diluted 1:5. No difference was 
found between the different treatments. D10GS-E206K/N208A-FKBP12-1 grew at the 
same rate in the presence and absence of 0.25 µM Shld1. The overall growth rate 
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was however rather low, regardless of the presence of Shld1, with the parasites 
struggling to reach a parasitemia higher than 2 % and the experiment was 
terminated after seven days. This shows that the stabilization and presence of 
the mutant PfGSE206K/N208A protein in the parasites did not affect their growth. 
However, it suggests that the presence of the plasmid itself negatively affects 
parasite growth regardless of stabilization of PfGSE206K/N208A-FKBP12. 
Day
1 2 3 4 5 6 7 
pa
ra
s
ite
m
ia
 
[%
]
0
2
4
- Shld 1
+ 0.25 µM 
Shld 1
 
Figure 4-12: Growth rate of D10GS-E206K/N208A-FKBP12-1 in presence and absence of Shld1. 
The growth of D10GS-E206K/N208A-FKBP12-1 in the absence (-Shld1, blue bars) and in the presence of 
0.25 µM Shld1 (red bars) was monitored over a seven day period. Tightly synchronized ring stage 
parasites were diluted to 0.5 % parasitemia on day 0 and their growth was monitored from the 
following day by counting Giemsa stained blood smears. Every second day cultures were diluted 
1:5. Results of one experiment performed in duplicate are presented as mean ± S.D. 
Overall the phenotypic analyses of parasites expressing PfGSE206K/N208A-FKBP12 
revealed no phenotype that can be related to the presence of the inactive fusion 
protein. The level of the stabilized recombinant protein was low in D10GS-
E206K/N208A-FKBP12-1 and undetectable in D10GS-E206K/N208A-FKBP12-2, which may mean 
that there is not enough of PfGSE206K/N208A-FKBP12 present to dilute the active 
form of PfGS. The unspecific toxicity that was observed for Shld1 makes further 
studies with this system difficult, as a phenotype that might be observed in the 
presence of this compound is potentially related to its toxicity and not the 
stabilization of PfGSE206K/N208A-FKBP12 in the parasites. 
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4.4.4 Genotypic analyses of transfected parasite lines 
Genotypic analyses of D10GS-E206K/N208A-FKBP12-1 and D10GS-E206K/N208A-FKBP12-2 were 
performed in order to determine if recombination of the expression plasmid is 
the reason for poor expression of the PfGSE206K/N208A-FKBP12 protein in P. 
falciparum. Even though the plasmid pCHD-HSP86-GSE206K/N208A-FKBP12 is not 
designed for recombination with the pfgs wild-type gene, recombination 
between the two is possible due to the homologous pfgs sequence. 
Recombination between the expression construct and the endogenous gene locus 
can explain the low expression of the recombinant PfGSE206K/N208A-FKBP12 protein 
in P. falciparum. To determine the genotype of the transfected parasite lines, 
gDNA was isolated and analysed by Southern blotting after a diagnostic 
restriction digestion with PacI and BamHI (Figure 4-13). 
The expected Southern blot pattern when using a pfgs specific probe is depicted 
in Figure 4-13A. The expected size of the fragment corresponding to the wild-
type pfgs locus is 4.84 kb (Figure 4-13A, I). For the expression plasmid a band of 
9.67 kb is expected (Figure 4-13A, II). Should recombination occur, two bands of 
6.77 kb and 7.76 kb are expected (Figure 4-13A, III). Such a recombination event 
leads to a pseudo-diploid locus with two copies of the gene, one under control of 
the endogenous promotor and possessing the FKBP12-tag and the other under 
control of the Hsp86 promotor. It not possible to predict which copy would 
contain the mutation. If a single cross-over occurred towards the 5’-end of pfgs, 
the first copy of the gene under control of the endogenous promotor and 
possessing the FKBP12-tag would also contain the mutation. However, if a single 
cross-over occurred between sequences downstream of the mutated site, the 
second copy under control of the Hsp86-promotor would contain the mutation. 
In order to determine the position of the mutation after a homologous 
recombination event, the recombined locus needs to be sequenced. 
Southern blot analysis revealed that both transfected parasite lines D10GS-
E206K/N208A-FKBP12-1 and D10GS-E206K/N208A-FKBP12-2 contained the plasmid, as indicated 
by a diagnostic band at 9.67 kb (Figure 4-13B, lanes 2 and 3, respectively). 
There appears to be less plasmid present in D10GS-E206K/N208A-FKBP12-2, which 
potentially is the reason why no recombinant protein can be detected in this 
parasite line. 
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However, both parasite lines also showed an additional band not corresponding 
to the expected pattern. The additional bands differed in size between the two 
parasite lines, being approximately at 7.0 kb for D10GS-E206K/N208A-FKBP12-1 (Figure 
4-13B, lane 2) and 7.5 kb for D10GS-E206K/N208A-FKBP12-2 (Figure 4-13B, lane 3). Single 
cross over recombination between the wild-type pfgs locus and the transfected 
plasmid should result in the appearance of two diagnostic bands at 6.77 kb and 
7.76 kb in a Southern blot. The additional band seen in D10GS-E206K/N208A-FKBP12-1 
(Figure 4-13B, lane 2) may correspond to the smaller one of the two, while the 
additional band in D10GS-E206K/N208A-FKBP12-2 (Figure 4-13B, lane 3) potentially 
corresponds to the 7.76 kb band. However, if the plasmid recombined with the 
endogenous pfgs locus both bands should be detectable. It is possible that 
integration into a random gene locus of the genome has occurred leading to the 
single additional band in each line. The wild-type diagnostic band can be 
detected in both parasite lines, though it appears less pronounced in D10GS-
E206K/N208A-FKBP12-1, further indicating a recombination event in which the wild-
type gene is lost or altered. As the parasite lines represent a non-clonal 
population it cannot be concluded with certainty that the additional bands 
detected are corresponding to recombination of the plasmid with the 
endogenous gene locus. In the case of an integration event into the pfgs locus it 
would be possible to isolate clones without the wild-type gene that only possess 
a recombined gene. The cloning of the D10GS-E206K/N208A-FKBP12-1 and  
D10GS-E206K/N208A-FKBP12-2 lines in order to further analyse their genotype will be 
part of future work. The results of the genotypic analyses do possibly provide an 
explanation for the observed low levels of expression for the recombinant 
PfGSE206K/N208A-FKBP12 protein as expression levels of PfGSE206K/N208A-FKBP12 may 
be affected through a recombination of the expression plasmids. 
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Figure 4-13: Genotypic analyses of PfGSE206K/N208A-FKBP12 expressing parasite lines D10GS-
E206K/N208A-FKBP12
-1 and D10GS-E206K/N208A-FKBP12-2. 
Panel A displays a schematic diagram (not to scale) of the pfgs wild-type gene locus (I), the 
expression construct pCHD-Hsp86-GSE206K/N208A-FKBP12 (II) and the recombined locus (III) should 
single cross-over recombination between the plasmid and the endogenous gene occur. The 
expression construct contains the full length pfgs ORF (green box) in frame with a C-terminal 
FKBP12 tag (blue box) and a hDHFR cassette as selectable marker (yellow box). Should 
recombination by single cross over between the wild-type locus and the expression construct occur 
(III), it would lead to a pseudo- diploid locus containing two copies of the pfgs gene, one encoding 
for a GS-FKBP tagged fusion protein under control of the endogenous promoter and one for the 
untagged protein under control of the Hsp86 promoter. It cannot be predicted which copy will 
contain the mutations. Southern analysis was performed using the restriction enzymes PacI and 
BamHI. Restriction sites are indicated by black arrows. The expected sizes of the resulting 
fragments are indicated by red arrows. Panel B shows the Southern analyses after diagnostic 
digest with PacI and BamHI of the parasite lines D10GS-E206K/N208A-FKBP12-1 (lane 2) and D10GS-
E206K/N208A-FKBP12
-2 (lane 3) in comparison to non- transfected D10 wild-type parasites (lane 1). The 
expected pattern is depicted in Panel A. In all three lanes the endogenous pfgs specific band is 
present at 4.84 kb (WT). The two transfected lines contain the expression construct visible as a 
diagnostic band at 9.67 kb (lanes 2 and 3). For the D10GS-E206K/N208A-FKBP12-1 line (lane 2) an 
additional band at approximately 7 kb is visible and for the D10GS-E206K/N208A-FKBP12-2 line (lane 3) an 
additional band at approximately 7.5 kb was detected. The additional bands possibly correspond to 
either the smaller or larger of the expected integration bands. However, in both parasite lines the 
second expected integration band is missing. 
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4.5 Expression of PfGSwt-HA in P. falciparum 
4.5.1 Genotypic analyses 
In order to continuously express recombinant C-terminally HA-tagged wild-type 
PfGS in erythrocytic stages of P. falciparum, the expression construct pCHD-
Hsp86-GS-HA was cloned using MultiSite® Gateway technology (van Dooren et al., 
2005). The Hsp86 promotor in the plasmid allows for high level expression of 
PfGS-HA in the parasites throughout the intra-erythrocytic stages. The full 
length ORF of pfgs was cloned in frame with the sequence for the C-terminal HA-
tag. Wild-type D10 parasites were transfected once with pCHD-Hsp86-GS-HA and 
transfected parasites were selected with WR99210. Resistant parasites were 
observed in the culture 5 weeks after transfection and the parasite line was 
named D10GS-HA. To analyse the genotype of the transfected parasites, gDNA was 
extracted and analysed by Southern blotting after diagnostic digest with PacI and 
BamHI. 
The diagram in Figure 4-14A describes the expected banding pattern following 
PacI and BamHI digest if a pfgs gene specific probe is used. A single fragment of 
4.84 kb is expected for the endogenous pfgs locus. Likewise, a single band is 
expected for the plasmid at 9.40 kb. The plasmid is not intended for integration 
studies, but single crossover recombination between the homologous pfgs 
sequence of plasmid and endogenous locus is possible. In the case of such a 
recombination event, two fragments of 6.50 kb and 7.76 kb are expected for the 
recombined locus. To analyse the transfected parasites, the same probe that 
was also used for analysis of the knock-in control parasite line described in 
section 4.3.3 was used. 
Figure 4-14B displays a Southern blot of D10GS-HA (lane 2) in comparison to wild-
type D10 parasites (lane 1). The 4.84 kb band corresponding to the endogenous 
pfgs gene locus is visible in both lanes. In the transfected parasites (Figure 
4-14B, lane 2) a second 9.40 kb fragment corresponding to the expression 
construct pCHD-Hsp86-GS-HA can be detected. In addition to the wild-type locus 
and the plasmid the presence of a third band at approximately 7.0 kb was 
observed in the D10GS-HA line (Figure 4-14B, lane 2). This additional band does 
not correspond to the expected pattern for a recombination event between the 
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plasmid and the endogenous gene locus. For this case, two bands at 6.50 kb and 
7.76 kb are expected. Potentially some unspecific recombination of the plasmid 
has occurred, leading to the detection of this single band. This will have to be 
analysed in greater detail in the future. 
 
Figure 4-14: Genotypic analysis of D10GS-HA. 
Panel A: Schematic diagram (not to scale) of the pfgs wild-type locus (I), the expression plasmid 
pCHD-Hsp86-GS-HA (II) and the gene locus in case of a single crossover recombination event 
between the plasmid and the endogenous gene (III). Following diagnostic digest with PacI and 
BamHI, a 4.84 kb fragment is expected for the endogenous pfgs locus and a 9.40 kb fragment for 
the plasmid. A single crossover event between plasmid and wild-type gene leads to two fragments 
of 6.50 kb and 7.76 kb. Black arrows indicate restriction sites for BamHI and PacI. Red arrows 
indicate the sizes of the expected fragments which can be detected with a pfgs-gene specific 
probe. Panel B: Southern blot analyses of wild-type D10 (lane 1) and D10GS-HA (lane 2) gDNA after 
diagnostic digest with PacI and BamHI. The red arrows in Panel A indicate the expected fragments. 
A 4.84 kb band visible in both lanes corresponds to the endogenous pfgs locus (WT). In lane 2 a 
9.40 kb band indicates the presence of the expression plasmid pCHD-Hsp86-GS-HA. An additional 
band is present in this lane at approximately 7 kb that may correspond to one of the two expected 
bands diagnostic for integration of the plasmid into the gene locus. However, the second expected 
band is not visible. 
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4.5.2 Phenotypic analyses 
The phenotypic analyses of D10GS-HA were performed by M. L. Laine under my 
supervision. In order to determine whether the PfGS-HA fusion protein is 
expressed and present in D10GS-HA, protein was extracted from the parasites and 
5 µg were analysed by western blotting with an anti-HA antibody (Figure 4-15). A 
signal detected in the extract at the predicted size of PfGS-HA at 82.9 kDa shows 
the recombinant protein is expressed in the parasites. Three smaller bands 
indicate some degradation of the recombinant protein. 
 
Figure 4-15: Western analysis of D10GS-HA. 
Protein extract of D10GS-HA was analysed with an anti-HA antibody. 5 µg of extracted protein were 
loaded on a 10% SDS-PAGE gel. This Western blot was performed by M. L. Laine. 
After it was shown that D10GS-HA parasites are expressing the recombinant 
protein, it was analysed whether the presence of PfGS-HA influences the 
susceptibility of the parasites to the GSH depleting inhibitor of γGCS, L-BSO. The 
IC50 value for the drug was determined in the absence and in the presence of 5 
mM NAC, because it is possible that the availability of cysteine is limiting the 
GSH biosynthesis rate. Therefore, parasites over-expressing PfGS-HA may not 
have altered GSH levels due to a lack of available γGC substrate. NAC increases 
γGC and thus GSH biosynthesis by providing cysteine. 
In Figure 4-16A, the effect of L-BSO on the survival of D10 and D10GS-HA is 
displayed. In the absence of NAC, D10GS-HA is more susceptible to L-BSO than 
wild-type D10 parasites. The IC50 value for the PfGS-HA expressing parasite line 
was determined at 48.1 ±2.2 µM, whereas the wild-type parasites had an IC50 of 
63.3 ±5.3 µM. Addition of 5 mM NAC only shows a marginal effect on wild-type 
D10 parasites and the IC50 value at 72.1 ±7.2 was similar to the IC50 determined 
in the absence of NAC. In the D10GS-HA line the addition of 5 mM NAC increased 
the L-BSO IC50 by approximately 57 % to 75.6 ±6.8 µM, which is similar to the IC50 
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of the wild-type. These experiments were only performed once in duplicate. 
Therefore it cannot be concluded if the observed differences are significant. 
BSO [µM]
1 10 100 1000
Pa
ra
s
ite
 
gr
o
w
th
 
[%
]
0
20
40
60
80
100
120
140
160
 
Figure 4-16: Determination of IC50 values for L-BSO for D10 and D10GS-HA. 
The effect of L-BSO on parasite survival was measured in the presence and absence of 5 mM 
NAC. In the absence of NAC, the L-BSO IC50 for D10 (■) was slightly higher at 63.6±5.3 µM than 
for D10GS-HA (●) at 48.1 ±2.2 µM. In presence of 5 mM NAC, the IC50 values were similar at 75.6 
±6.8 µM and 72.1±7.2 µM for D10GS-HA (▲) and D10 (▼), respectively. 
4.6 Summary 
• Localization studies with episomally expressed PfGS-GFP showed the 
fusion protein is present in the parasite cytosol of erythrocytic stages of 
P. falciparum. 
• A knock out of the pfgs gene was not achieved by gene disruption using 
the plasmid pHH1-∆gs. Targeting the gene locus with a pHH1 control 
construct was possible, indicating that the pfgs gene may be essential for 
erythrocytic stages in vitro. 
• Knock-out by gene replacement using the plasmid pCC4-∆gs while 
supplementing cells with extracellular GSH was also not possible. 
Negative selection with Ancotil® against parasites maintaining the 
episomal construct lead to death of the parasites except for one occasion 
were parasites had lost the plasmid and acquired Bla and Ancotil® 
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resistance without replacement of the target gene. This further indicates 
that the gene is essential. 
• Alignment of PfGS and human GS revealed four conserved sites that are 
involved in ATP binding in the human enzyme. A PfGS mutant 
PfGSE206K/N208A was generated mutating two conserved sites to abolish the 
activity of the enzyme. Preliminary data show that recombinant 
PfGSE206K/N208A protein has no detectable activity while recombinantly 
expressed GSwt is active, indicating that the two residues are of 
importance for enzyme activity in PfGS. 
• In P. falciparum episomal expression of inactive PfGSE206K/N208A from the 
expression construct pCHD-Hsp86-GSE206K/N208A-FKBP12 is possible. 
Expression of the mutant PfGSE296K/N208A-FKBP12 fusion protein in P. 
falciparum was confirmed in one transfected parasite line. The fusion 
protein is fully degraded and undetectable in absence of the stabilizing 
agent Shld1 and can be detected upon addition of Shld1. Increasing Shld1 
concentrations do however not increase the amount of PfGSE296K/N208A-
FKBP12 in the parasites and unspecific toxicity of the compound was 
observed at concentrations higher than 0.25 µM. Shld1 equally affects 
proliferation in the wild-type strains D10 and 3D7 at higher 
concentrations. No effect on parasite survival and growth rate could be 
observed upon stabilization of PfGSE296K/N208A-FKBP12 with 0.25 µM Shld1. 
Genotypic analyses showed potential recombination of the construct, 
possibly explaining the low expression level observed. 
• Parasites transfected with an expression construct for C-terminally HA-
tagged active wild-type PfGS express the recombinant protein at high 
levels. The presence of the fusion protein seems to lead to a slight 
increase in the susceptibility of the parasites to L-BSO compared to wild-
type D10 parasites. Addition of 5 mM NAC does not affect the L-BSO IC50 in 
wild-type parasites, but increases the IC50 in the PfGS-HA expressing 
parasites to wild-type level. 
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5 Glutathione and chloroquine resistance 
5.1 Introduction 
In this chapter, the potential role of GSH in chloroquine (CQ) resistance is 
analysed. CQ prevents the detoxification of heme, which is released during the 
breakdown of host cell hemoglobin in the parasites’ digestive vacuoles (DV), 
leading to an increase of toxic free heme, which is eventually lethal for the 
parasites (Banyal and Fitch, 1982; Chou et al., 1980; Fitch, 1989; Fitch et al., 
1982). In CQ resistant P. falciparum parasites, reduced accumulation of CQ 
within the DV has been linked to mutations in the parasites chloroquine 
resistance transporter (pfcrt) gene. Other factors are also likely to contribute to 
CQ resistance such as other transporters like the P-glycoprotein homologue 1 
(Pgh1, encoded by pfmdr1) and the multidrug resistance protein-1 (PfMRP1) 
(Foote et al., 1989; Mu et al., 2003; Reed et al., 2000). 
Another mechanism that has been put forward, was that GSH contributes to CQ 
resistance by competing with the drug for free heme and by destroying heme 
non-enzymatically (Ginsburg et al., 1998; Ginsburg and Golenser, 2003). Indeed, 
elevated GSH levels were found in the CQ resistant strain Dd2 in comparison to 
the sensitive strain 3D7 (Meierjohann et al., 2002b). However, these parasite 
lines differed widely in their genetic background. Dd2 is not only resistant to CQ, 
but indeed multi-drug resistant (Gonzales et al., 2008) and it remains unclear, 
whether the elevated GSH levels are not related to a compensating mechanism 
that emerged in response to the various mutations in several genes such as pfcrt 
and pfmdr1 that occurred in order to establish multi-drug resistance. Another 
difficulty with the hypothesis that GSH can contribute to CQ resistance is that 
heme is generated in the DV and GSH biosynthesis takes place in the cytosol as 
shown in chapters 3 and 4 of this study. Ginsburg and colleagues suggested that 
free heme can escape from the DV and therefore suggests that cytosolic GSH can 
contribute to protection of the parasites. However, a later study found that 
more than 90 % of heme remains in the food vacuole (Egan et al., 2002; Ginsburg 
et al., 1998). These controversial findings make it difficult to fully understand 
how cytosolic GSH would be able to contribute to CQ resistance. 
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In this study I investigated the GSH metabolism and the influence of 
modifications to the GSH metabolism on CQ resistance in three isogenic parasite 
lines, which only differ in their pfcrt allele (Sidhu et al., 2002). These parasite 
lines were a kind gift of D. Fidock, Albert Einstein College, New York, USA. They 
were generated by Sidhu et al. through allelic exchange of the endogenous pfcrt 
carried by the wild-type line GC03 with alleles of the CQ resistant strains Dd2 
and 7G8, thus generating the CQ resistant lines C3Dd2 and C67G8 (Sidhu et al., 
2002). GC03 is the progeny of a genetic cross between the CQ resistant Dd2 and 
CQ sensitive HB3 line and carries the sensitive pfcrt allele of HB3 (Wellems et 
al., 1990). As a control for any influence of the insertion of the transfected 
construct the C2GC03 parasite line was generated, which possesses the original 
sensitive pfcrt allele of GC03. Table 5-1 displays the respective haplotypes of 
PfCRT in these lines. Because these parasite lines share the same genetic 
background, it is possible to investigate the influence of GSH on CQ resistance 
without having the complications that arise when comparing field isolates of 
different genetic backgrounds. 
Clone Name 
of 
pfcrt 
allele 
CQ 
sensitivity 
Functional PfCRT haplotype 
 
 
Amino acid position 
   72 74 75 76 220 271 326 356 371 
GC03 HB3 sensitive C M N K A Q N I R 
C2GC03 HB3 sensitive C M N K A Q N I R 
C3Dd2 Dd2 resistant C I E T S E S T I 
C67G8 7G8 resistant S M N T S Q D L R 
Table 5-1: PfCRT haplotype of recombinant parasite lines used in this study. 
The Dd2 haplotype represents commonly found haplotypes of Africa and Asia, while the 7G8 
haplotype represents those commonly found in South America. The recombinant parasite lines 
were a kind gift of D. Fidock. Table adapted from Sidhu et al. (Sidhu et al., 2002). 
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5.2 Influence of extracellular glutathione on chloroquine 
susceptibility 
In order to investigate a potential influence of extracellular GSH on the 
susceptibility of P. falciparum to CQ, IC50 values were determined for each 
parasite line in the absence and presence of 1 mM extracellular GSH (Figure 
5-1). The average IC50 concentrations determined in normal IC50 medium without 
additional GSH (Figure 5-1, - symbol) were 17.2 ±1.9 nM and 11.3 ±1.9 nM for the 
sensitive parasite lines GC03 and C2GC03, respectively. The resistant lines C3Dd2 
and C67G8 were 20- and 8.5-fold less sensitive to the drug than GC03 and C2GC03 
with IC50 values of 272.3 ±41.0 nM and 118.4 ±15.1 nM, respectively. 
Upon addition of 1 mM GSH to the medium, the IC50 for CQ did not change 
significantly in any of the four parasite lines (Figure 5-1, + symbol). The average 
IC50 values determined for GC03 and C2
GC03 were 15.0±2.6 nM and 15.4±2.0, 
respectively. In the CQ resistant parasite lines C3Dd2 and C67G8 the average IC50 
values in the presence of 1 mM extracellular GSH increased marginally and were 
determined to be 302.3 ±12.0 nM and 146.8 ±10.3 nM, respectively. 
For statistical analysis of the effect of extracellular GSH on the CQ IC50 of each 
individual parasite line, unpaired two-tailed student t-tests were performed, 
comparing the IC50 values measured in the absence of GSH to the IC50 in the 
presence of 1 mM GSH. The P values for all four parasite lines were >0.2, 
showing that there is not significant effect of 1 mM extracellular GSH on the 
susceptibility of the parasites to CQ in any of the lines investigated. 
The results are summarised in Table 5-2. These IC50 data indicate that if there is 
a correlation between increased GSH levels and a decreased susceptibility to CQ, 
this cannot be influenced by increasing the extracellular GSH concentration in 
the medium. The reason for this lack of an effect potentially is related to 
insufficient uptake of GSH. 
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Figure 5-1: Influence of extracellular GSH on CQ IC50 of CQ sensitive and resistant parasite 
lines. 
CQ IC50 values were determined for four isogenic parasite lines in normal IC50 medium (-) and in 
medium supplemented with 1 mM GSH (+). The parasite lines C3Dd2 and C67G8 possessing mutant 
pfcrt alleles are highly resistant to CQ regardless of the presence of extracellular GSH. No 
significant change was observed after addition of 1 mM GSH for both sensitive and resistant lines. 
The IC50 values were determined in triplicate on 2-6 independent occasions. Results are presented 
as mean ± standard error of the mean (S.E.M). 
Parasite 
line 
CQ IC50 [nM] CQ IC50 with 1 mM GSH 
[nM] 
t test comparison of 
CQ and CQ+GSH IC50 
GC03 17.2 ± 1.9 (n=2) 15.0 ± 2.6 (n=3) P=0.59 
C2GC03 11.3 ± 1.9 (n=6) 15.4 ± 2.0 (n=3) P=0.22 
C3Dd2 272.3 ± 41.0 (n=6) 302.3 ± 12.0 (n=3) P=0.64 
C67G8 118.4 ± 15.1 (n=6) 146.8 ± 10.3 (n=3) P=0.26 
Table 5-2: Average CQ IC50 in absence and in presence of 1 mM extracellular GSH. 
IC50 values were determined in triplicate on several independent occasions. The number of repeats 
(n) for each parasite line is given in brackets. The IC50 values are presented as mean ± S.E.M. For 
each individual parasite line, the CQ IC50 values in the absence and presence of GSH were 
compared in an unpaired two-tailed student t test. 
It is possible that increasing the extracellular GSH concentration beyond 1 mM 
affects the parasites’ susceptibility to CQ. It was however noted that increasing 
extracellular GSH concentrations further had an adverse effect on parasite 
growth. The adverse effect of GSH was related to decreased buffer capacity of 
the medium and rapid acidification of the medium which is not supportive of 
parasite growth. 
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5.3 Glutathione levels and susceptibility to glutathione 
depleting agents 
Using a spectrophotometric assay, the total GSH levels in the three isogenic 
parasite lines C2GC03, C3Dd2 and C67G8 and the wild-type parasite line GC03 were 
determined. Initially GSH levels were measured after enriching the cultures to 
~90-95 % parasitemia with Miltenyi Biotec MACS® columns. However, it was 
noticed that this method altered GSH levels negatively. Because blood cell 
suspension and buffers enter the columns by gravity flow when using this 
method, it is very difficult to standardize the experimental setup. It was 
noticeable that longer binding of the parasites to the columns led to a decrease 
in the measured GSH levels (Figure 5-2). Therefore the method of sample 
preparation was changed and tightly synchronized parasite cultures containing 
young trophozoite stages (approximately 28-32 hours after invasion) were used 
instead without purification of infected red blood cells prior to saponin lysis. It 
was presumed that the modified method minimized the stress the parasites were 
subjected to. In Figure 5-2 data obtained by the two different methods of 
sample preparation are compared. GSH levels determined in the parasite lines 
C2GC03 and C67G8 without initial enriching of infected red blood cells are 2.5- to 
3.5-fold higher than the levels determined after MACS purification. Therefore, 
GSH levels were measured for all four parasite lines without initial purification 
of infected RBC. 
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Figure 5-2: Influence of sample preparation on parasite GSH levels. 
Two different methods were used to generate samples or the spectrophotometric determination of 
total GSH in isolated parasites. In one method, tightly synchronized, trophozoite infected red blood 
cells were used directly for saponin lysis (C2GC03 and C67G8). In the second method, trophozoite 
infected RBCs were enriched with MACS columns prior to saponin lysis (C2GC03 MACS and C67G8 
MACS). Results are presented as mean ±S.E.M. of 3-5 independent determinations. 
GSH levels determined for the three isogenic parasite lines C2GC03, C3Dd2 and 
C67G8 and for the wild-type GC03 line differed between the lines (Figure 5-3). 
The differences between C2GC03 and C67G8 were detected regardless which 
method was used (Figure 5-2). Comparing all four isogenic parasite lines, GSH 
levels were determined to be 0.71 ±0.20 µmol/ 1010 cells and 0.93 ±0.05 µmol/ 
1010 cells for the CQ resistant lines C3Dd2 and C67G8, respectively, and 1.55 ±0.10 
µmol/ 1010 cells and 1.27 ±0.07 µmol/ 1010 cells for the CQ sensitive lines C2GC03 
and GC03, respectively (Figure 5-3). 
One way ANOVA showed that these differences are significant (F3,8= 8.50, P< 
0.01). Post hoc Newman-Keuls analysis shows that there is no significant 
difference between the two sensitive lines GC03 and C2GC03. Equally, there was 
no significant difference between C3Dd2 and C67G8. However, both resistant lines 
are significantly different to C2GC03 (P <0.01 and <0.05) and C3Dd2 contained 
significantly less GSH than GC03 (P <0.05). 
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Figure 5-3: GSH levels in isogenic P. falciparum lines. 
Total GSH levels were determined using tightly synchronized trophozoite stages after saponin lysis 
to remove RBC contaminations. The GSH levels of the CQ resistant strains C3Dd2 (0.71±0.2 µmol/ 
1010 cells) and C67G8 (0.93±0.05 µmol/ 1010 cells) are significantly lower than those determined for 
the CQ sensitive line C2GC03 (1.55±0.10 µmol/ 1010 cells) (*: P<0.05; **: P<0.01). The GSH level 
determined for GC03 was 1.27±0.07 µmol/ 1010 cells. Results are presented as average of three 
independent measurements ± S.E.M. 
To elucidate whether the four parasite lines are differently affected by the 
specific γGCS inhibitor L-buthionine sulfoximine (L-BSO), the IC50 concentrations 
for this compound were determined. In order to further analyse whether P. 
falciparum can utilize extracellular GSH added to the culture medium, the IC50 
concentrations for L-BSO in the presence and the absence of 1 mM GSH in the 
medium were determined (Figure 5-4). 
In the absence of additional extracellular GSH, the L-BSO IC50 values for the CQ 
resistant strains are lower than those for the sensitive lines (59.1 ±4.1 µM and 
66.6 ±7.4 µM for GC03 and C2GC03 and 33.0 ±3.5 µM and 36.5 ±7.7 µM for C3Dd2 
and C67G8, respectively), (see Figure 5-4). This result corresponds to the 
observed lower GSH levels in the resistant lines and is consistent with 
differences in the GSH levels between the four isogenic parasite lines. 
A one way ANOVA test shows that these differences are significant (F3,11= 6.76, P 
<0.01) and a Newman-Keuls post hoc analysis showed that C3Dd2 and C67G8 were 
significantly different to both C2GC03 and GC03 (P <0.05). No significant 
differences were found between GC03 and C2GC03 or between C3Dd2 and C67G8.  
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Upon addition of 1 mM GSH to the medium, the effect of L-BSO is alleviated in 
all four parasite lines. In the CQ sensitive lines GC03 and C2GC03 the addition of 1 
mM GSH led to an increase of the IC50 value for L-BSO by 20-50 % to 89.1 ±9.9 µM 
and 80.1 ±12.6 µM, respectively. In the CQ resistant cell lines the IC50 values 
increased by 70- 120 % to 73.2 ±0.8 µM and 64.3 ±8.7 µM for C3Dd2 and C67G8, 
respectively. Thus, the L-BSO IC50 values for all four parasite lines analysed were 
in a similar range upon addition of 1 mM GSH. The IC50 values for BSO are 
summarized in Table 5-3. 
One way ANOVA analysis followed by Newman-Keuls post-test showed that no 
significant differences exist between the four parasite lines for their 
susceptibility to BSO if 1 mM GSH is added to the medium. However, the only 
significant increase for the L-BSO IC50 in the presence of 1 mM GSH was found for 
the parasite line C3Dd2 (P <0.05). 
This suggests that extracellular GSH is taken up into infected red blood cells 
albeit not with high enough efficiency to fully compensate for the effects of L-
BSO. Whether this effect is attributable to uptake of GSH into the host 
erythrocyte or the parasite is not clear from these experiments. 
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Figure 5-4: L-BSO IC50 of isogenic CQ resistant and CQ sensitive parasite lines. 
IC50 values for L-BSO were determined in triplicate on at least three independent occasions in 
absence and in the presence of 1 mM GSH. Without addition of GSH, the CQ resistant parasite 
lines C3Dd2 and C67G8 are significantly more susceptible to L-BSO than the CQ sensitive lines 
GC03 and C2GC03 (*: P<0.05). In the presence of 1 mM GSH, the effect of L-BSO is alleviated in all 
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four lines and there is no significant difference between the parasite lines. Results are presented as 
mean ±S.E.M. The respective IC50 values are summarized in Table 5-3. 
The effect of another GSH depleting agent, 1-chloro-2,4-dinitrobenzene (CDNB), 
was tested on the four parasite lines in absence and presence of 1 mM GSH 
(Figure 5-5). CDNB is a substrate for the enzyme glutathione-S-transferase (GST) 
and a less specific way to deplete GSH. The IC50 values for CDNB in the absence 
of GSH are in the low µM range between 9.5 µM and 13 µM for all four parasite 
lines (see Table 5-3) and one way ANOVA analysis showed that differences 
between the lines under these conditions are not significant (F3,10= 0.22, 
P=0.88). 
With addition of 1 mM GSH to the culture medium, the IC50 values increased 5 to 
10 fold, suggesting again that GSH enters infected red blood cells. The effect of 
1 mM GSH was most pronounced in the C2GC03 parasite line. 
One way ANOVA analysis indicated significant differences with F7,11= 9.51 and 
P<0.001. Newman-Keuls post hoc analyses showed that the increase of the CDNB 
IC50 in presence of 1 mM GSH is significant in all four parasite lines (P<0.05 for 
GC03, C3Dd2 and C67G8 and <0.01 for C2GC03). Comparison between the parasite 
lines indicate that in presence of 1 mM GSH the IC50 values of the lines C2
GC03 and 
C3Dd2 are significantly different (P <0.01). However, no significant differences 
exist between C2GC03 and the other two parasite lines GC03 and C67G8 and there 
are equally no significant differences between C3Dd2 and GC03 and C67G8. 
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Figure 5-5: CDNB IC50 in the absence and presence of 1 mM GSH. 
CNDB IC50 values were determined in triplicate on at least three independent occasions. There 
was no significant difference between the four parasite lines in the absence of GSH. IC50s were 
significantly higher in the presence of 1 mM GSH (*: P<0.05; **: P<0.01). Results are presented as 
mean ±S.E.M. 
The influence of higher extracellular GSH concentrations was tested once with 
10 mM GSH, but this concentration was found to be detrimental to parasite 
survival in absence of any drug. It was noted that the pH of the medium was 
greatly acidified by addition of GSH and had to be very carefully re-adjusted to 
pH 7.4. Most likely GSH affects the buffer capacity of the medium and thus leads 
to a rapid acidification if used in the cultures. This is potentially the reason for 
the observed negative growth effect of GSH at higher concentrations. In order to 
support the addition of high GSH concentrations, the medium composition needs 
to be changed and optimized, which was beyond the scope of this study. 
Glutathione and chloroquine resistance  139 
 
 
Parasite 
line 
BSO IC50 BSO IC50 with 
1mM GSH 
CDNB IC50 CDNB IC50 with 
1mM GSH 
GC03 59.1±4.1  
(n=4) 
89.1±9.9  
(n=3) 
13.4±5.1  
(n=4) 
56.7±11.9 * 
(n=4) 
C2GC03 66.6±7.4 
 (n=4) 
80.1±12.6 
(n=3) 
11.8±4.6 
(n=4) 
83.8±11.5 ** 
(n=4) 
C3Dd2 33.0±3.5  
(n=3) 
73.2±0.8 * 
(n=3) 
9.5±1.1  
(n=3) 
33.6±6.8 * 
(n=4) 
C67G8 36.5±7.7  
(n=4) 
64.3±8.7  
(n=3) 
9.5±1.4  
(n=3) 
59.3±15.1 * 
(n=4) 
Table 5-3: IC50 of GSH depleting agents. 
IC50 values for L-BSO and CDNB were determined in triplicates on at least three independent 
occasions. The number of repeats (n) is given in brackets. Asterisks indicate significant increases 
of IC50 values in the presence of 1 mM GSH (*: P<0.05; **: P<0.01). Results are presented as 
mean ±S.E.M. 
5.4 Susceptibility to oxidative stressors 
In order to determine if the decreased GSH levels affected the susceptibility of 
the parasite lines to oxidative stress, the IC50 values for two inducers of 
intracellular oxidative stress, phenazine methyl sulphate (N-
methylphenanzonium methyl sulphate) and juglone (5-hydroxy-1,4-
naphthoquinone), were determined for GC03, C2GC03, C3Dd2 and C67G8. The IC50 
values for both compounds are listed in Table 5-4. 
For phenazine methyl sulphate the determined IC50s for GC03 and C2
GC03 were 
0.76 ±0.11 µM and 0.90 ±0.13 µM, respectively (Figure 5-6A). The IC50 for C3
Dd2 
was slightly higher at 1.13 ±0.19 µM and the IC50 for C6
7G8 was the lowest at 0.4 
±0.01 µM. The differences were however not significant according to one-way 
ANOVA analysis (F3,8= 3.90, P =0.055). 
Equally, no significant difference was found between the IC50s for GC03, C2
GC03, 
C3Dd2 and C67G8 for juglone (Figure 5-6B). The CQ sensitive lines GC03 and C2GC03 
had IC50 values of 17.1±3.3 µM and 15.7±5.0 µM, respectively. The IC50 for C3
Dd2 
was 18.0±2.1 µM. Again, C67G8 was most susceptible to the stressor with an IC50 
at 10.8±2.1 µM, albeit this is not significantly lower. The results of one way 
ANOVA analysis were F3,8= 1.02, P= 0.44. 
These results show that despite containing different GSH levels, the four 
parasite lines analysed do not differ significantly in their susceptibility to 
compounds inducing oxidative stress. 
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Parasite line Phenazine methyl 
sulphate [µM] 
Juglone IC50 [µM] 
GC03 0.76±0.11  17.1±3. 
C2GC03 0.90±0.13  15.7±5.0 
C3Dd2 1.13±0.19 18.0±2.1 
C67G8 0.47±0.10 10.8±2.1 
Table 5-4: IC50 values for oxidative stress inducing compounds. 
The IC50 concentrations for phenazine methyl sulphate and juglone were determined in triplicates 
on three independent occasions. Results are presented as mean ± S.E.M. 
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Figure 5-6: IC50 values of oxidative stress inducing compounds. 
IC50 values for phenazine methyl sulphate and juglone were determined in triplicate on three 
independent occasions. No significant differences were found between the CQ sensitive parasite 
lines GC03 and C2GC03 and the resistant lines C3Dd2 and C67G8 for either drug. Results are 
presented as mean of three independent determinations ±S.E.M. 
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5.5 Expression of glutathione producing and consuming 
enzymes 
A possible explanation for the observed differences in GSH levels and 
susceptibility to L-BSO are differences in the expression levels of the proteins 
producing or consuming GSH. Therefore the expression levels of the biosynthesis 
enzymes PfγGCS and PfGS, the GSH reducing enzyme glutathione reductase 
(PfGR) and the GSH consuming enzyme PfGST were determined. In addition, 
expression levels of PfCRT were analysed because earlier studies had reported 
reduced expression of PfCRT in the genetically modified lines (Sidhu et al., 
2002). 
Because there is currently no antibody available for PfγGCS and PfGS, the 
expression of these two enzymes could only be determined on mRNA level by 
quantitative real time PCR. We have not been able to express and purify 
recombinant PfγGCS in previous attempts in our laboratory and previous 
attempts to raise an antibody against recombinant expressed PfGS did not yield 
a specific antibody. 
Only slight variations were observed in the mRNA levels for pfγgcs and pfgs 
between the parasite lines and the differences were not significant (One way 
ANOVA, P >0.05). This indicates no changes in transcription of the expression of 
the two genes responsible for GSH biosynthesis. Thus, changes in GSH 
biosynthesis do not appear to be responsible for the differential GSH levels. 
The transcription levels of pfcrt were equally analysed by quantitative real-time 
PCR and appeared to be similar between the four parasite lines. 
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Figure 5-7: Relative expression of γgcs, gs and crt. 
The relative expression of γgcs, gs and crt was determined by quantitative real time PCR relative to 
C2GC03. As a housekeeping gene control, seryl-tRNA-synthetase was used. The results are shown 
as mean ± S.E.M. of five independent determinations. 
The abundances of the GSH reducing enzyme PfGR and of PfGST, the major GSH 
consuming enzyme, were determined by western blotting using specific 
antibodies against both enzymes (Figure 5-8). The expression of PfCRT was also 
determined on protein level. For all three western analyses, equal amounts of 
protein extracts of tightly synchronized trophozoites were loaded. An antibody 
against the α-subunit of the P. falciparum casein kinase 2 (PfCK2α) was used as 
loading control. Both PfGR and PfGST appeared to be present in equal amounts 
in the four investigated parasite lines and did not appear to be either up- or 
down-regulated. These results indicate that PfGR or PfGST are not the likely 
cause for the differential GSH levels and their expression does not appear to be 
changed in response to the observed differences in GSH levels either. However, 
the western analyses do not allow any conclusions about their activities which 
may be influenced by the available amount of substrates. 
The amounts of PfCRT present are similar in the four parasite lines, in line with 
the results obtained by the real-time PCR analysis. 
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Figure 5-8: Western analysis of the expression levels of PfGR, PfGST and PfCRT. 
Western blots were performed on lysates of the two CQ sensitive and two CQ resistant lines. 5 µg 
of protein were loaded per lane and the blots were probed with anti-PfGR, anti-PfGST or anti-
PfCRT antibodies to assess the level of expression of each protein. The blots were then stripped 
and re-probed with an anti-PfCK2α antibody to control for equal loading. 
5.6 Glutathione uptake 
None of the previous results give an explanation for the observed differences in 
GSH levels in the analysed parasite lines. Alterations in the uptake of substrates 
required for GSH biosynthesis or even in uptake of GSH itself are another 
potential explanation why GSH levels differ and are lower in parasite lines 
possessing a mutant form of PfCRT. 
To account for differences in GSH uptake, the uptake of GSH into infected RBC 
was investigated. The uptake of radio-labelled GSH in infected RBC was 
measured using MACS purified infected red blood cells. Uptake was measured 
over the course of 20 min and samples were taken at 5 min intervals. Uptake 
was rather slow and no significant differences were observed between 
uninfected RBC and trophozoite infected RBC during the first ten minutes. After 
15 min, more radioactive GSH was measured in infected RBC than in uninfected 
RBC. A baseline level of radioactivity was measured for the RBC control, which 
did not increase over time. Because this baseline activity can already be 
detected at t=0 at the beginning of the experiment, this is likely to be 
background due to unspecific binding of the labelled GSH to the cells which was 
not completely removed by the oil. Uptake was not followed for longer than 20 
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min because the quality of purified infected RBC rapidly declines after 30 min 
due to the high parasitemia of >90 %. Parasitized RBC could not be maintained 
under these conditions for long and lysis of the parasitized cells was indicated by 
the presence of free hemoglobin in the uptake solution. 
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Figure 5-9: Uptake of GSH into trophozoite infected red blood cells. 
MACS column enriched C2GC03 parasites (90-95 % parasitemia) and uninfected RBC were 
incubated in EBSS solution containing 3 mM GSH and 1 µCi/ml [3H]-GSH. Aliquots were taken in 
five minute intervals to determine the cell-associated radioactivity. Results are mean of 3 
independent experiments ±S.D. 
In order to determine whether GSH uptake is dependent on the extracellular 
GSH concentration, uptake of [3H]-GSH was measured in the presence of 
different concentrations of cold GSH in the uptake solution (Figure 5-10). The 
concentrations tested were 1 mM, 2 mM and 3 mM GSH. Indeed, GSH uptake was 
proportional to the concentration of total GSH in the uptake solution. 
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Figure 5-10: GSH uptake in increasing extracellular GSH 
GSH uptake into MACS purified C2GC03 trophozoite infected RBC in EBSS solution containing 1 
mM, 2 mM or 3 mM GSH with 1 µCi/ml [3H]-GSH. Cell-associated radioactivity was measured after 
uptake for 20 min. This experiment was only performed once. 
No difference could be observed in GSH uptake between the CQ sensitive line 
C2GC03 and the CQ resistant line C67G8. Over a 20 min period both parasite lines 
took up similar amounts of GSH if being incubated in 3 mM GSH and 1 µCi/ml 
[3H]-GSH. At the start of the experiment (t=0) the amount of radioactivity 
measured for the infected RBC was similar to the uninfected RBC. After 20 min 
only a very slight increase was found for the uninfected RBC, but in infected RBC 
the detected radioactivity showed an increase from 194 ±10 pmol/ 2x107 cells to 
339 ±34 pmol/ 2x107 cells for C2GC03 and from 165 ±46 pmol/ 2x107 cells to 367 
±19 pmol/ 2x107 cells in C67G8 infected RBC, respectively. There was no apparent 
difference between the sensitive and the resistant line, indicating the mutations 
in PfCRT7G8 do not alter GSH uptake into infected RBC. 
One way ANOVA showed differences were significant (P<0.0001, F5,6=26.63), and 
Newman-Keuls post hoc analyses showed that after 20 min radio-labelled GSH 
was significantly increased in the infected RBC (P<0.001), but not in uninfected 
RBC. No significant differences were found between C2GC03 and C67G8 infected 
RBC (P>0.05). 
Future work will need to establish the compartmentalization of GSH taken up in 
the host-parasite unit. The current data do not indicate whether GSH reaches 
the parasite compartment or if it is only taken up into the host cell. 
Glutathione and chloroquine resistance  146 
 
G
SH
 
u
pt
a
ke
 
[p
m
o
l /
 
2x
10
7  
c
e
lls
]
0
200
400
RBC
C2GC03
C67G8
0 min 20 min  
Figure 5-11: Uptake of GSH in C2GC03 and C67G8. 
GSH uptake into MACS purified trophozoite infected RBC of CQ sensitive C2GC03 and CQ resistant 
C67G8 parasites was measured before and after 20 min incubation in EBSS solution containing 3 
mM GSH and 1 µCi/ml [3H]-GSH. At the start of the incubation (t=0) GSH measured for uninfected 
RBC was 106 ±10 pmol/ 2x107 cells and 194 ±10 pmol/ 2x107 cells and 165 ±46 pmol/ 2x107 cells 
for C2GC03 and C67G8, respectively. After 20 min, GSH measured was 155 ±13 pmol/ 2x107 cells for 
RBC and 339 ±34 pmol/ 2x107 cells and 367 ±19 pmol/ 2x107 cells for C2GC03 and C67G8, 
respectively. Data is presented as mean of 3 independent experiments ±S.E.M. 
5.7 Data obtained by collaborators 
The following results were not generated by me but by our collaborators at the 
Liverpool School of Tropical Medicine. I am listing them here in order to 
complete the data set on our analyses of the relation between of mutations of 
pfcrt, CQ resistance and GSH metabolism. 
5.7.1 Effect of N-acetylcysteine on chloroquine susceptibility 
Earlier studies found that the addition of N-acetylcysteine (NAC) to the culture 
medium decreased the sensitivity of parasites to CQ (Ginsburg et al., 1998). 
These findings were confirmed in this study. Addition of 5 mM NAC in the CQ 
resistant line C3Dd2, significantly increased the CQ IC50 by 2-3 folds from 56.0 
±2.4 nM to 153.0 ±7.3 nM. Interestingly, on the CQ sensitive line C2GC03 the 
addition of 5 mM NAC had a much smaller effect and the CQ IC50 changed only 
marginally from 6.6 ±0.9 nM to 8.5 ±0.9 nM. 
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Figure 5-12: Effect of NAC on CQ IC50. 
The presence of 5 mM NAC increases the CQ IC50 in the resistant parasite line C3Dd2 from 56.0 
±2.4 nM to 153.0 ±7.3 nM, but has only a marginal effect on the CQ IC50 for sensitive line C2GC03, 
where 5 mM NAC led to an increase of the IC50 from 6.6 ±0.9 nM to 8.5 ±0.9 nM. These IC50 values 
were determined at the Liverpool Tropical School of Medicine. 
5.7.2 Chloroquine accumulation and chloroquine binding 
Previous studies showed that GSH depletion made parasites more susceptible to 
CQ while increasing GSH levels made them less susceptible (Ginsburg et al., 
1998). These observations were linked to heme degradation by GSH; decreased 
GSH levels were suggested to increase free heme and thus elevate CQ binding 
and the susceptibility of the parasites to the drug. 
This was tested by measuring the accumulation of [3H]-CQ while depleting GSH 
in the parasites with increasing concentrations of CDNB in the CQ sensitive line 
C2GC03 and the resistant line C3Dd2 (Figure 5-13A). CQ accumulation was hardly 
affected in the sensitive line, while CDNB markedly stimulated CQ accumulation 
in the resistant parasites. The increase of the CQ cellular accumulation ratio 
(CAR) in C3Dd2 was most pronounced at a CDNB concentration of 10 µM and was 
comparable to the effect of 10 µM verapamil, a known CQ resistance reversing 
agent. 
A similar experiment testing a single CDNB concentration was performed with 
two other parasite lines N3D7 and R2B8 (Figure 5-13B). Both parasite lines are 
derived from the CQ resistant parent line Dd2. In N3D7 the K76T mutation of 
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resistant PfCRT was converted back to T76K, making this line again sensitive to 
CQ (Lakshmanan et al., 2005). The line R2B8 carries the original Dd2 allele of 
pfcrt and is resistant to the drug. 10 µM CDNB has a similar effect on the 
resistant line as it has on C3Dd2; R2B8 parasites accumulate more CQ in the 
presence of 10 µM CDNB than in the absence of the drug. This effect is again 
comparable to the reversal of CQ resistance by verapamil (Figure 5-13B, black 
bars). In contrast, the presence of 10 µM CDNB does not affect the CQ CAR in the 
sensitive line N3D7 (Figure 5-13B, white bars). This indicates that the effect of 
CDNB on CQ accumulation is directly linked to the K76T mutation in PfCRT. 
The data so far indicate that GSH potentially has access to heme in the DV and is 
therefore able to destroy it. This would reduce the amount of free heme in the 
DV of resistant parasites. Because the concentration of free heme cannot easily 
be measured directly it was estimated by analysis of CQ equilibrium binding 
experiments on intact infected erythrocytes (Figure 5-13C) (Bray et al., 1998; 
Chou et al., 1980{Bray, 1999 #279)}. In the Scatchard plot (Figure 5-13C), the 
apparent affinity of binding is calculated from the reciprocal of the slope and 
the X-axis intercept gives the approximated equilibrium binding capacity. 
Least squares analysis of the CQ binding isotherms estimates the CQ equilibrium 
binding capacities of C2GC03 at 35 ±1.1 µmol / l and of C3Dd2 and C67G8 at 30 ±0.8 
µmol / l and 29 ± 1.7 µmol / l, respectively. The CQ resistant lines have an 
approximately 15 % reduced binding capacity for CQ in comparison to the 
sensitive line. These changes are consistent with a modest reduction in the 
concentration of free heme in the resistant lines analysed. 
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Figure 5-13: CQ accumulation and CQ equilibrium binding studies. 
Panel A displays the differential effect of CDNB on the cellular accumulation ratio (CAR) for [3H]-
CQ in trophozoites of the CQ sensitive C2GC03 line (black bars) and the CQ resistant C3Dd2 line 
(white bars). Increasing CDNB concentrations markedly affect the resistant line, but hardly affect 
the sensitive line. CQ uptake in the presence or absence of various CDNB concentrations was 
measured by collaborators of the Liverpool School of Tropical medicine as previously described 
(Lakshmanan et al., 2005{Bray, 1998 #276)}. Over a 20 min period, steady state CQ uptake was 
measured at a concentration of 5 nM [3H]-CQ. Panel B displays CQ uptake in the isogenic lines 
N3D7 and R2B8. Both parasite lines are derived from the Dd2 parental line. In N3D7 the K76T 
mutation in PfCRT has been converted back to T76K, thus making this line CQ sensitive. R2B8 
carries the original K76T mutation and is CQ resistant. Again, steady state CQ uptake was 
measured at the Liverpool School of Tropical medicine at a concentration of 5 nM [3H]-CQ over a 
20 min period as previously described (Bray et al., 1998; Lakshmanan et al., 2005). Panel C shows 
the Scatchard plot analysis of CQ equilibrium binding studies on C2GC03, C3Dd2 and C67G8. These 
studies were performed at a concentration of 2 nM [3H]-CQ and a range of concentrations of 
unlabelled CQ and the results were corrected for nonspecific uptake as described in Bray et al 
(Bray et al., 1998). The number of CQ binding sites for each parasite line was interpolated from the 
graph. 
5.7.3 Expression of PfCRT in Xenopus laevis oocytes 
To test the possibility that PfCRT is directly responsible for the translocation of 
GSH across the membrane of the digestive vacuole, the X. laevis heterologous 
expression system was used to express wild-type and mutant forms of PfCRT and 
to test the uptake of GSH by this system (Figure 5-14). The PfCRT alleles 
expressed were the wild-type HB3 allele, which is also found in GC03 and C2GC03, 
the CQ resistant Dd2 allele that is present in C3Dd2 and a K76T mutant form of 
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the HB3 wild-type, which is not naturally found in parasite isolates. As a positive 
control the A. thaliana Chloroquine-like-transporter-1 (AtCLT1) protein was 
used, which was recently shown to transport GSH and γGC (Maughan et al., 
submitted).  
To demonstrate the correct localization of PfCRT on the oocyte plasma 
membrane, indirect immunofluorescence was performed (Figure 5-14A). The 
results show that all three forms of PfCRT are expressed and present in the 
plasma membrane. In the water-injected control group of oocytes hardly any 
fluorescence is detected. 
The uptake studies show that there is a basal level of GSH uptake in the water 
injected negative control oocytes, which is presumably due to a low activity of 
endogenous transporters in the oocytes’ plasma membrane. The uptake in the 
oocytes expressing the HB3 allele of PfCRT is not significantly different from the 
negative control (Mann-Whitney U-test), suggesting that HB3 PfCRT does not 
transport GSH (Figure 5-14B). However, the oocytes expressing either of the 
mutant forms of PfCRT, the Dd2 allele and the K76T mutant, show significantly 
increased GSH uptake (P<0.01), similar to the uptake observed in oocytes 
expressing AtCLT1. These results confirm a role of mutant PfCRT in the transport 
of GSH. 
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Figure 5-14: Expression of PfCRT in X. laevis oocytes. 
Panel A: Indirect immunofluorescence studies on oocytes expressing different alleles of pfcrt and 
on water injected control oocytes using anti-PfCRT antibodies. Images are presented for oocytes 
expressing the HB3, Dd2 and K76T variants of PfCRT and for the negative control water injected 
oocytes. Panel B: Uptake of [3H]-GSH by Xenopus oocytes expressing wild-type or mutant PfCRT 
or AtCLT1. Oocytes were incubated with 52 nM GSH for 30 min. Data is presented as mean 
±S.E.M. of five independent experiments. For each experiment at least seven oocytes were used 
which were obtained each time from a different batch of oocytes from a different frog. Oocytes 
expressing mutant forms of PfCRT, PfCRTK76T or PfCRTDd2 and oocytes expressing the positive 
control AtCLT-1 were significantly different from the negative control oocytes injected with water. 
The differences were significant for each group of experiments as well as for the pooled data. 
Oocytes expressing the HB3 variant of PfCRT are not significantly different from water injected 
oocytes. Data is presented as mean ±S.E.M. Statistical significance was assessed by Mann-
Whitney U test. 
Glutathione and chloroquine resistance  152 
 
Mature female X. laevis were purchased from Xenopus Express (Vernassal, Haute-Loire, France) 
and oocytes were obtained after immersing frogs in euthanasic concentration of MS-222 (ethyl 3-
aminobenzoate methanesulfonate, Sigma, 0.5 % w/v) in 5 mM Tris base, pH 7.4. After removal, 
ovary lobes were divided into smaller sacs and individual oocytes were manually isolated. After 2 
washes oocytes were kept at 18°C for 2 hours in complete modified Barth’s solution (MBS) (88 mM 
NaCl, 1 mM KCl, 15 mM HEPES pH 7.6, 0.82 mM MgSO4, 0.3 mM Ca(NO3)2, 1 mM CaCl2, 1 ml/l of 
10000 U penicillin/ 10000 U streptomycin solution, Sigma). Stage IV-V oocytes were selected for 
injection of 50 nl DEPC-treated water or capped complementary RNA (cRNA) solutions at 1 µg/µl 
with a semi-automatic injector (Drummond, Nanoject, Broomall, PA, USA). Pfcrt gene cDNA was 
synthesized from total mRNA using Thermoscript (Invitrogen) and amplified by PCR with Taq High 
Fidelity polymerase (Invitrogen) following manufacturer’s instructions. Pfcrt genes of the HB3 and 
Dd2 strains and a mutant form of HB3 carrying the K76T mutation were cloned into the plasmid 
pSP64T using the XhoI-NcoI sites. AtCLT1 was cloned into the plasmid pT7TS (pGEM4Z modified 
vector, Promega Madison, WI, USA) using BglII-SpeI sites. In vitro transcription of cRNA was 
performed using EcoRI-linearized pSP64T plasmids or SalI-linearized pT7TS plasmids with the 
SP6 or T7 message machine kits (Ambion, Austin, TX, USA), respectively. Following injection of 
oocytes with cRNA or water, enzymatic dissociation and defolliculation was completed after four 
days by 30 min collagenase treatment (1mg/ml, Sigma) in MBS without calcium. Uptake assays 
were performed at 2 µCi/ml of [3H]-GSH (38.6 Ci/mmol, American Radiolabelled Chemicals, St 
Louis, MO, USA) corresponding to 52 nM GSH. Seven to ten oocytes were incubated in 1 ml 
Ringer solution with 5 % DTT at room temperature. Oocytes were washed 12 times on ice before 
being individually collected and immersed in 1 ml scintillation fluid. Oocytes were incubated 
overnight and radioactive decay was counted in a Wallac 1450 Microbeta scintillation counter. For 
indirect immunofluorescence, oocytes were immersed in 1 ml OCT medium (RA Lamb Ltd., 
Eastbourne, UK) before freeze down in 2-methylbutane in liquid N2 and immersion in liquid N2 for 
30 sec. 10 µm sections were prepared on coated glass slides and fixed in cold acetone for 10 min. 
The slides were blocked in 4 % BSA in PBS (w/v) for one hour before incubation with primary 
antibody in 4 % BSA in PBS (w/v) for one hour at room temperature. Slides were washed three 
times with PBS and the secondary antibody was applied in 4 % BSA in PBS (w/v) for one hour. 
Sides were washed again three times with PBS and glass cover slips were mounted with a drop of 
Hard Vector Shield (Burlingame, CA). Slides were dried for 30 min before examination under a 
confocal microscope. 
5.8 Summary 
• Analysis of three isogenic lines and their parental parasite line only 
differing in their pfcrt allele shows that IC50 values for CQ are not 
changed by the presence of 1 mM extracellular GSH. However, data of 
collaborators show an effect of N-acetylcysteine on the CQ IC50 
predominantly in a CQ resistant parasite line, but not in a sensitive line. 
• Determination of GSH levels in the four parasite lines showed a reduction 
of total GSH in the CQ resistant parasite lines compared to the sensitive 
lines. These parasite lines are also more susceptible to the γGCS inhibitor 
L-BSO, while no differences in their susceptibility to the GST substrate 
CDNB was observed. 
• Extracellular GSH alleviates the effect of L-BSO and CDNB, indicating that 
extracellular GSH can be utilized in the infected red blood cell. This 
effect is more pronounced for CDNB. 
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• Changes in expression levels of enzymes responsible for GSH biosynthesis, 
GSH reduction or GSH consumption were not found between the four 
parasite lines and are unlikely to be the reason for the observed 
differences in GSH levels. 
• Uptake of GSH was observed in infected red blood cells and the uptake 
ratio was not different between a CQ sensitive and a CQ resistant parasite 
line. 
• Cellular accumulation ratios of CQ determined in the presence of CDNB by 
collaborators at the Liverpool School of Tropical Medicine show a similar 
effect of CDNB on the CQ uptake in CQ resistant parasites as the 
resistance reverting agent verapamil. No effect of CDNB on the 
accumulation of CQ in sensitive parasites was observed. 
• CQ resistant parasites analysed by our collaborators in this study showed a 
reduced binding capacity for CQ, indicating reduced levels of free heme 
in resistant lines in comparison to the sensitive line C2GC03. 
• Data of collaborators at the Liverpool School of Tropical Medicine also 
show that X. laevis oocytes expressing mutant but not wild-type PfCRT 
take up radio-labelled GSH. This means that mutant, but not wild-type 
PfCRT transports GSH. 
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6 Discussion 
The tripeptide GSH serves a variety of important functions in many prokaryotic 
and eukaryotic organisms. Previously it has been suggested to be of particular 
importance for the malaria parasite P. falciparum, which lives in an environment 
of increased oxidative stress. Studies with L-BSO, an inhibitor of the first step of 
GSH biosynthesis, have shown the importance of the tripeptide for the survival 
of the parasites (Lüersen et al., 2000; Meierjohann et al., 2002b). However, it is 
still unclear to what extent the parasites depend on GSH de novo biosynthesis, 
since L-BSO equally affects the parasite’s host cell. To answer some of the 
remaining questions about GSH biosynthesis and its significance for survival of 
intra-erythrocytic stages of P. falciparum I determined the cellular localization 
of the GSH biosynthesis pathway and investigated whether this pathway is 
essential for the blood stage development of the parasite. 
Furthermore, I investigated the hypothesis that GSH is involved in resistance 
against the antimalarial drug CQ. Because of its ability to destroy FPIX, the 
intracellular target of CQ, a role for the tripeptide in the resistant phenotype of 
Plasmodium has previously been implicated. Altering intracellular GSH levels 
with various compounds such as L-BSO and NAC can modulate sensitivity of 
Plasmodium to CQ. Increasing GSH levels caused an increase in CQ resistance 
while depleting or decreasing GSH levels had the opposite effect. It was 
suggested that the higher GSH levels resulted in an increase of FPIX degradation, 
after FPIX escaped from the DV into the parasite cytosol. In fact the resistant P. 
falciparum field isolate Dd2 has been shown to contain higher GSH levels than 
the CQ sensitive isolate 3D7, giving some credence to this hypothesis (Atamna 
and Ginsburg, 1995; Deharo et al., 2003; Ginsburg et al., 1998; Ginsburg and 
Golenser, 2003; Meierjohann et al., 2002b). However, the escape of FPIX to the 
cytosol is controversially discussed (Atamna and Ginsburg, 1995; Egan et al., 
2002; Ginsburg et al., 1998; Ginsburg and Golenser, 2003) and thus the 
mechanism by which GSH potentially contributes to CQ resistance needs to be 
further clarified. 
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6.1 Localization of the glutathione biosynthesis pathway 
The GSH biosynthesis pathway, consisting of γGCS and GS is localized in the 
cytosol in mammals and other non-plant eukaryotes analysed so far. In plants 
GSH biosynthesis is found in the plastids and the cytosol, with γGCS localized in 
the plastids and GS predominantly localized in the cytosol and to a smaller 
extent in the plastids (Hell and Bergmann, 1988; Hell and Bergmann, 1990; Lash, 
2006; Meister, 1988; Pasternak et al., 2008; Radyuk et al., 2009). PfγGCS and 
PfGS are homologues to the enzymes of non-plant eukaryotes and therefore it 
has been postulated that they are both cytosolic. Indeed, I found the 
recombinant fusion proteins PfγGCS-GFP and PfGS-GFP were localized in the 
parasite cytosol, consistent with their predicted localization (Becker et al., 
2003b; Müller, 2004). 
This indicates that GSH is synthesized in the cytosol in P. falciparum and has to 
be imported into several organelles such as the endoplasmatic reticulum (ER), 
the mitochondrion and possibly the apicoplast as has been previously reported 
for yeast and mammalian cells (Banhegyi et al., 1999; Chakravarthi and Bulleid, 
2004; Hwang et al., 1992; Lash, 2006; Meister, 1988; Molteni et al., 2004). Most 
studies on intra-organelle GSH transport have been performed on mitochondria. 
Because GSH is negatively charged at the physiological pH of the cytosol, it 
cannot enter the equally negative lumen of mitochondria by passive diffusion 
and thus organic anion transporters were suggested to be responsible for the 
import of GSH into the organelle (Chen and Lash, 1998). In yeast mitochondria 
the GSH uptake rate is not altered by removal of the outer membrane, 
suggesting that either transport through the inner membrane is rate limiting or 
that the responsible transporter is a “connected” transporter through both 
membranes (Cummings et al., 2000). In mammalian mitochondria cis-inhibition 
and trans-stimulation of GSH transport by malate and succinate has been 
observed, suggesting a role for the dicarboxylate carrier and the 2-oxoglutarate 
carrier as transporters of GSH across the mitochondrial membrane (Chen and 
Lash, 1998). In Plasmodium species homologues of a putative oxoglutarate/ 
malate transporter protein exist (PF08_0031 in P. falciparum, 
http://plasmodb.org/plasmo/), but it is not known, whether the transporter is 
functional and localizes to the parasite’s mitochondrion. Future studies are 
needed to determine if malate and succinate influence GSH transport into the 
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mitochondrion of malaria parasites. GSH uptake into mitochondria is very 
efficient in plants and mammals. Mutants of A. thaliana containing 
approximately 80 % less of the tripeptide than wild-type plants display severely 
depleted GSH levels in the cytosol, while the levels in the mitochondria are 
almost normal (Zechmann et al., 2008). This also emphasizes the special need 
for the mitochondrion to maintain its reducing environment. GSH levels in the 
nucleus also remained high despite depletion of total GSH levels, indicating that 
the nuclear GSH pool is discretely regulated from the cytosol and that 
mechanisms controlling nuclear GSH levels exist (Zechmann et al., 2008). Similar 
results for organelle-specific GSH pools were obtained with mouse fibroblasts, 
where mitochondria and nuclear GSH pools are more resistant to depletion with 
L-BSO (Green et al., 2006). So far only total GSH levels have been determined in 
Plasmodium parasites, no studies have been performed on mitochondrial and 
nuclear GSH pools. 
A recent study showed that in the fruit fly Drosophila melanogaster the 
catalytic, but not the regulatory subunit of γGCS undergoes nuclear shuttling 
and can move from the predominant site of GSH biosynthesis in the cytosol into 
the nucleus in order to increase GSH concentration in the nucleus (Radyuk et al., 
2009). This nuclear shuttling appears to be regulated in response to oxidative 
stress and is mainly observed in dividing cells of the fly. Although a classical 
bipartite nuclear localization signal has been found in the γGCS of S. cervisiae by 
in silico analyses, such a motif is absent from mammalian homologues (Radyuk 
et al., 2009) and studies on mice fibroblasts did not detect γGCS in nuclear 
extracts (Markovic et al., 2007) . We did not investigate the possibility of 
nuclear shuttling of γGCS in P. falciparum, but no nuclear localization signal is 
predicted in PfγGCS. 
6.2 Uptake of extracellular glutathione 
In mammalian cells uptake of extracellular GSH depends on the action of γ-
glutamyl transpeptidase. The transpeptidase is able to cleave the γ-glutamyl 
linkage between glutamate and cysteine and transfers the glutamyl residue onto 
other amino acids. The highest affinity acceptor is the cysteine dimer cystine, 
thus γ-glutamylcystine is predominantly generated and taken up. Inside the 
cells, reduction of γ-glutmaylcystine leads to the formation of γGC, which then 
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feeds into GSH biosynthesis (Dalton et al., 2004). RBCs lack γ-glutamyl 
transpeptidase, thus uninfected RBC do not take up the tripeptide. 
Previous studies, as well as the present study, have however shown uptake of 
radio-labelled GSH by P. falciparum infected red blood cells (Atamna and 
Ginsburg, 1997; Raj et al., 2008). During the course of the present study, GSH 
uptake was investigated primarily to measure potential differences between CQ 
resistant and sensitive parasite lines rather than to characterize GSH transport. 
GSH uptake by infected RBC was similar between RBCs infected with CQ 
resistant C67G8 and sensitive C2GC03 parasites. 
Over a 20 min period, the amounts of GSH taken up in the presence of 3 mM 
extracellular GSH were in a similar range to those reported by Atamna and 
Ginsburg in the presence of 5 mM GSH (Atamna and Ginsburg, 1997). Converting 
the GSH uptake in both studies to nmol/ 1010 cells, Atamna and Ginsburg 
measured approximately 150 nmol/ 1010 cells, compared to 250 nmol/ 1010 cells 
found in the present study. In a recently published study, Raj et al. reported a 
much lower uptake ranging between 0.01 and 0.02 nmol/ 1010 cells, which is 
likely due to the low, 1-6 nM, extracellular GSH concentration used in their 
experiments and is corresponding to the dependence of the GSH uptake on the 
extracellular GSH concentration. The findings of Raj et al. are however in 
contrast to the findings by Atamna and Ginsburg, who reported that GSH uptake 
is only observed in the presence of high extracellular GSH concentrations 
(Atamna and Ginsburg, 1997; Raj et al., 2008). 
The rate of GSH uptake I observed was slow at the beginning of a 20 min period, 
whereas previous reports showed a much faster initial uptake. This is likely 
related to technical reasons. I kept parasites on ice prior to uptake and 
presumably it took some time to adjust the incubation mix to 37°C. For future 
experiments a longer equilibration step should be included prior to addition of 
GSH to allow more time for parasites to recover to physiological temperature. 
Because lysis of infected RBC was observed after 30 min of incubation, I did not 
follow the GSH uptake beyond that. Raj et al. reported a peak of GSH uptake at 
20 min, while in the study by Atamna and Ginsburg, GSH uptake reached a 
constant level after approximately 60 min (Atamna and Ginsburg, 1997; Raj et 
al., 2008). 
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The study by Atamna and Ginsburg showed that GSH is taken up by P. falciparum 
infected red blood cells, but uptake does not occur when free parasites are 
examined. This suggests that a permeability pathway exists in infected RBCs, but 
parasites do not possess a transporter for GSH in their plasma membrane 
(Atamna and Ginsburg, 1993). A possible alternative pathway for GSH uptake is 
the endocytosis of host cell cytosol containing GSH (Platel et al., 1999) and the 
subsequent uptake into the parasite’s cytosol through transporters in the 
parasite’s DV membrane. However, because extracellular GSH has been shown to 
increase the GSH level within the host cell compartment but not in the parasite 
itself, it has been previously concluded that the tripeptide does not enter the 
parasites (Atamna and Ginsburg, 1997). 
However, GSH biosynthesis may be regulated by feedback inhibition of γGCS in 
P. falciparum as it is in other organisms (Huang et al., 1988; Lueder and Phillips, 
1996). Thus, an increased uptake of the tripeptide possibly leads to down-
regulation of biosynthesis and the overall GSH level remains unchanged. Raj et 
al. presume that GSH is entering the parasite compartment, because the knock-
out of the parasite’s multi-drug resistance protein PfMRP increases the 
accumulation of radio-labelled GSH in infected RBC to almost twice the level 
observed in the parental line (Raj et al., 2008). They hypothesized that PfMRP 
plays a role in the efflux of GSH and that the loss of the protein in the parasite’s 
plasma membrane leads to a decrease in GSH efflux and thus causes an increase 
in GSH accumulation (Raj et al., 2008). This indicates a high and rapid turnover 
of GSH in the parasite. A rapid turnover of GSH has also been suggested for 
infected RBC by Atamna and Ginsburg, who hypothesized that the rapid 
oxidization and excretion in the form of GSSG is the reason why GSH uptake was 
not observed at low concentrations of the tripeptide (Atamna and Ginsburg, 
1997). Lüersen et al. also reported rapid GSSG efflux from infected RBC (Lüersen 
et al., 2000). The efflux of GSSG offers another possible explanation why total 
GSH levels do not increase despite uptake of the tripeptide by the parasites. 
However, the observation that extracellular GSH cannot rescue P. falciparum 
parasites in the case of a γgcs or gs knockout indicates that the tripeptide is 
either not or only at insufficient levels taken up. 
It remains an open question whether GSH taken up into infected RBC is also 
taken up into the parasite. Future studies are needed to further investigate the 
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subcellular localization of radio-labelled GSH following uptake into infected RBC. 
Rather than measuring GSH levels in the different compartments, the 
distribution of the radioactive label can be analysed in order to trace the fate of 
GSH in the infected RBC. 
6.3 Knockout of Glutathione biosynthesis 
Homologues of γgcs have previously been shown to be essential in various 
eukaryotic organisms, but not in prokaryotes such as E. coli. Several studies on 
γgcs employing a variety of methods showed that the gene is essential in S. 
cerevisiae, C. albicans, T. brucei and D. discoideum (Baek et al., 2004; Grant et 
al., 1996; Huynh et al., 2003; Kim et al., 2005; Lee et al., 2001). In all these 
cases, the loss of a functional γGCS enzyme could be compensated when cells 
were supplemented with GSH, GSSG or γGC and in some cases with other thiols 
such as DTT and NAC. 
The fact that the gene is not essential for the survival of blood stages of P. 
berghei and only essential in the mosquito stages is unusual for a eukaryotic 
organism (Vega-Rodriguez et al., 2009). However, GSH was still detected at 
approximately 5-14 % of the wild-type GSH levels in the blood stages of the 
pbγgcs knockout lines, showing that despite the loss of a functional biosynthesis 
pathway, the product is still present in the parasite cells (Vega-Rodriguez et al., 
2009). 
The possibility of an alternative pathway of γGC biosynthesis, independent of 
γGCS has previously been described in yeast. A deletion mutant of S. cerevisiae 
lacking γGCS has been shown to survive under both aerobic and anaerobic 
conditions because trace amounts of GSH are synthesized due to additional 
mutations in the pro2 gene of the proline biosynthesis pathway (Lee et al., 2001; 
Spector et al., 2001). Pro2 encodes for glutamylphosphate reductase, which 
converts γ-glutamylphosphate, provided by glutamate-5-kinase in the previous 
step, to L-glutamate-γ-semialdehyde. Mutation of the glutamylphosphate 
reductase allows the condensation of γ-glutamylphosphate with cysteine and 
thus synthesis of γGC in this step, but it is not understood if the mutant 
glutamylphosphate reductase alone is involved or if additional enzymes play a 
role (Spector et al., 2001). Homologues of glutamate-5-kinase and 
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glutamylphosphate reductase are absent from the P. falciparum genome 
(Gardner et al., 2002) and have not been identified in other Plasmodium species 
either (http://plasmodb.org/plasmo/), thus suggesting that a similar mechanism 
is not possible in malaria parasites. Residual GSH in pbγgcs knockout parasites is 
likely derived from the host cell and was attributed to endocytic uptake of GSH 
from the host cell cytosol into the food vacuole (Vega-Rodriguez et al., 2009). 
Neither the pfγgcs nor the pfgs gene could be disrupted or replaced in two 
different strains of P. falciparum by the strategies employed in this study. This 
is surprising, given that the knockout of the γgcs gene in P. berghei was possible 
(Vega-Rodriguez et al., 2009).  
However, there are several significant differences between P. falciparum and P. 
berghei parasites. There have been previous reports where orthologous genes 
were found to be essential in one parasite species, but not the other. For 
example the mitogen-activated protein kinase 2 (map2) has an essential function 
in erythrocytic stages of P. falciparum and a knockout is impossible to generate 
in these parasites, while the protein is only required for formation of male 
gametocytes in P. berghei and a knockout in the blood stages can be achieved 
(Dorin-Semblat et al., 2007; Rangarajan et al., 2005; Tewari et al., 2005). 
The gene loci of both genes were targeted in P. falciparum, showing they are 
not refractory to recombination and that the changes to the gene loci through 
the integration of the transfection plasmids are not deleterious. This implies 
that null mutants for either gene are not viable and thus both genes are 
essential in P. falciparum. The loss of GSH biosynthesis in the human parasite 
cannot be compensated for by either uptake of the tripeptide or by redundancy 
between the GSH system and other antioxidant systems such as the thioredoxin 
system. 
In case of the pHH1-∆γgcs construct, non-homologous integration into a non-
related gene locus was observed. We have previously observed random 
integrations of other pHH1-based knockout constructs targeting different 
unrelated genes in our laboratory. Random integrations were predominantly 
observed with knockout constructs targeting essential genes, where parasites 
were not viable, if integration into the correct gene locus occurred, and less 
frequently for knock-in control constructs which leave target genes functional. 
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Thus random integration of this plasmid appears to occur fairly regularly, albeit 
at a lower rate than integration into the destination locus and seems to be 
selected for when integration into the target locus is lethal or leads to a growth 
defect (Günther et al., 2009). 
The use of the pCC4-based constructs should avoid this problem due to the 
presence of the negative selectable marker cd. The presence of this gene allows 
selection against random integration as well as against episomal plasmids (Maier 
et al., 2006). However, in the present study parasites frequently became 
resistant to Ancotil®, despite the continued presence of the plasmids and thus 
the cd death gene in most transfected lines, as shown by Southern analyses. Of 
all three parasite lines transfected with the plasmid pCC4-∆γgcs and one 
parasite line transfected with pCC4-∆gs, Ancotil® resistant parasites were 
isolated. Resistance consistently occurred after transfectants had been taken 
through at least three drug selection cycles with Bla, while the cultures were 
sensitive to Ancotil® immediately after transfection and in the earlier Bla cycles. 
This shows that the parasites had not been resistant to Ancotil® when they were 
originally transfected and changes conferring resistance to Ancotil® were 
established in these lines.  
Ancotil® resistance has previously been reported on various occasions for anti-
fungal therapy. In clinical use, the active component of Ancotil®, 5-FC, is not 
used as monotherapy because resistance rapidly develops. Fungal resistance to 
5-FC is established in two ways. Deficiency in the uptake or metabolism of 5-FC, 
due to changes in the fungal pyrimidine salvage pathway, causes a decrease in 
the toxic metabolite 5-FU, and thus a decrease in inhibition of fungal DNA and 
RNA synthesis (Chapeland-Leclerc et al., 2005; Papon et al., 2007). Changes in 
the pyrimidine biosynthetic pathway causes increased prevalence of pyrimidines 
which compete with 5-FU for binding to its targets. (Sanglard, 2002; Vermes et 
al., 2000).  
Ancotil® resistant parasites were isolated frequently and emerged after a 
comparably short time period of three to four weeks of continuous Ancotil® 
pressure, indicating that it is unlikely that several changes in multiple genes 
were established in order to generate resistance. P. falciparum relies solely on 
pyrimidine biosynthesis (Reyes et al., 1982), thus changes to the parasite salvage 
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pathway are not possible. It is unknown how 5-FC is taken up by the parasite, 
but mutations in a transporter responsible for the uptake of the drug or a 
substantial down-regulation of its expression are potential mechanisms how 
resistance may have been established in the transfected parasite lines. Equally, 
expression of the cd gene from the pCC4 plasmids may be down-regulated 
through changes and mutations in the promoter region of the cd gene and 
pyrimidine biosynthesis is potentially up-regulated in the Ancotil® resistant 
parasites. Indeed, the plasmid or the part of the plasmid containing the cd gene 
was absent in two of the resistant lines, pointing to changes in the transfected 
plasmid rather than any parasite genes being responsible for the development of 
resistance. In the other lines generated for this study the respective part of the 
plasmid containing the cd gene was present according to Southern blot analyses, 
but it is possible that no active CD enzyme was expressed. These possibilities 
can be analysed in the future by assessing the presence of CD protein in the 
parasites and investigating the expression levels of genes involved in pyrimidine 
biosynthesis. 
The knockout of pfγgcs in presence of an episomal copy of the gene could not be 
achieved due to recombination of the plasmids. This is a technical problem 
which will need to be solved in the future. One possibility to minimize 
recombination of the expression plasmid with the endogenous gene locus or the 
knockout plasmid is to express a homologous γGCS protein of another 
Plasmodium species such as P. berghei. 
The knockout of thioredoxin reductase in presence of an additional copy of the 
gene has previously been achieved after both plasmids were simultaneously 
transfected (Krnajski et al., 2002). However, in the thioredoxin reductase study 
recombination between the two plasmids also occurred prior to integration. 
Potentially transfection of a knockout plasmid into a parasite line already 
expressing the recombinant enzyme from an episomal plasmid is more efficient 
and can be attempted in the future with the PfγGCS-HA expressing line D10γGCS-
HA-2 generated for this study. This line has been shown to contain only the 
episomal expression plasmid and the endogenous gene, while expressing 
recombinant protein. No such line has yet been generated for PfGS-HA, as the 
line presented in this study showed signs of recombination of the plasmid with 
the parasite genome. 
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6.3.1 Possible differences between P. berghei and P. falciparum 
glutathione metabolisms 
There are two possibilities why the γgcs gene is not essential for the intra-
erythrocytic stages of P. berghei, but is indispensable for the survival of P. 
falciparum in this stage: (1) P. berghei is able to scavenge GSH from its host at 
higher levels than P. falciparum (2) P. berghei requires less GSH for its survival 
than P. falciparum and the amounts taken up from the host cell are sufficient 
for the survival of the rodent parasite. 
Vega-Rodriguez et al. reported GSH levels of only 5-14 % of the wild-type level in 
pbγgcs knockout lines despite absent GSH biosynthesis and only observed a slight 
growth defect in the RBC stages (Vega-Rodriguez et al., 2009). It has previously 
been reported for P. falciparum that after short term GSH depletion, with 0.5 -2 
mM CDNB for 15 min, to 12 % of the normal wild-type levels, parasites showed no 
apparent growth defect in vitro (Ayi et al., 1998). It is not known if P. 
falciparum parasites are also able to survive with these depleted GSH levels for 
a longer period of time and as shown in the present study long term exposure to 
CDNB is lethal for the parasites at much lower concentrations, albeit it is not 
known to what extent the prolonged CDNB exposure decreases the parasite’s 
GSH levels before its death. Thus it cannot be concluded if P. falciparum 
requires higher GSH levels than P. berghei for intra-erythrocyte survival. 
As discussed above, it is generally thought that Plasmodium parasites do not 
take up GSH from their host cell. However, this was only tested in P. falciparum 
and not in P. berghei parasites (Atamna and Ginsburg, 1997). The presence of 
GSH in the pbγgcs knockout line indicates that P. berghei parasites are indeed 
capable of its uptake and this will have to be investigated in the future to 
uncover how precisely GSH enters these parasites. Possibly GSH present in the 
host cell is taken up into vesicles and eventually reaches the DV along with other 
contents of the host cell such as hemoglobin (Platel et al., 1999; Vega-Rodriguez 
et al., 2009). Without a transport mechanism allowing GSH to leave the DV, it 
would presumably be degraded by peptidases present in this organelle and the 
resulting amino acids taken up into the parasite cytosol or excreted as waste 
products. It has not been determined if P. berghei can recover GSH from its DV 
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and it is possible that P. berghei possesses a transporter for GSH in the DV that is 
absent in P. falciparum. 
In collaboration with Dr Bray and colleagues at the Liverpool School of Tropical 
Medicine it was shown in the present study that point mutations in PfCRT, a 
potential transporter or channel in the DV membrane, allow the translocation of 
GSH across the DV membrane in P. falciparum. For reasons discussed below we 
believe this flux may be concentration dependent and in parasites with a 
functional GSH biosynthesis pathway directed into the DV due to the higher GSH 
concentration in the parasite cytosol. The loss of GSH biosynthesis might reverse 
the flow and may allow GSH to enter the parasites. This offers the possibility for 
a knockout of pfγgcs or pfgs in CQ resistant lines of P. falciparum possessing a 
mutant pfcrt allele. The capability for the transport of GSH by the CRT 
homologue may already be present in P. berghei and further mutational changes 
may not be required in order to allow the parasites to take up GSH. These 
possibilities will be studied in detail in the future to fully understand the role of 
CRT in GSH homeostasis. 
The problem of insufficient GSH uptake by P. falciparum can potentially be 
avoided by using GSH-esters to supplement transfected cultures, as these esters 
can easily cross cell membranes (Lüersen et al., 2000; Meister, 1988). However, 
the release of GSH from methyl- or ethyl-esters leads to the release of toxic 
methanol and ethanol and thus provides a different problem for parasites. 
There are further differences between the human and the rodent parasite, 
which may determine whether PfγGCS is an essential enzyme or not. P. berghei 
preferentially infects reticulocytes which contain almost two times higher GSH 
levels than the mature erythrocytes infected by P. falciparum (Cromer et al., 
2006; Janse et al., 1989; McNally et al., 1992; Sailaja et al., 2003). Therefore 
the rodent parasite is provided by its reticulocyte host cell with a larger GSH 
pool to allow for compensation of the loss of biosynthesis. Another difference 
between reticulocytes and mature erythrocytes is that the latter have lost the 
activity of multiple enzymes and no longer possess a nucleus and the machinery 
for the translation of proteins (Geminard et al., 2002; Thorburn and Beutler, 
1991). Therefore mature RBC are unable to respond to decreasing GSH levels in 
the same way as reticulocytes, which are still able of increasing the expression 
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of γGCS and GS and potentially compensate a loss of GSH to the parasite by up-
regulation of their own GSH biosynthesis. 
Even if GSH only reaches the DV of P. berghei and does not reach the cytosol, 
the DV is one of the major sites for the generation of oxidative stress because of 
the degradation of hemoglobin. Therefore any GSH taken up can maintain the 
redox balance within this organelle and detoxify reactive oxygen species 
generated in this environment. Within the cytosol other components of the 
parasite antioxidant and redox system may take over other functions of GSH. 
Differences in the antioxidant system between P. berghei and P. falciparum may 
be responsible for greater redundancy in the rodent parasite’s antioxidant 
system and thus allow compensation for the loss of GSH biosynthesis in this 
organism and not in the human parasite. 
Redundancy between the thioredoxin and the GSH system is the reason why null 
mutants of the γGCS encoding gene gshA of E. coli are viable albeit showing 
reduced growth (Gardner and Fridovich, 1993). In contrast, double mutants for 
thioredoxin reductase and γGCS or thioredoxin reductase and GR are barely 
viable under aerobic conditions (Prinz et al., 1997). Similar results are seen for 
an E. coli triple mutant for both thioredoxins (trxA and trxC) and glutaredoxin 1 
(grxA), which is only viable when cultured anaerobically (Stewart et al., 1998). 
The thioredoxin reductase of P. falciparum has previously been shown to be 
essential for the erythrocytic stages of the parasite, indicating that the GSH and 
thioredoxin system are not redundant in this species and cannot easily replace 
each other (Krnajski et al., 2002). However, the thioredoxin reductase of P. 
berghei appears to be non-essential (K. Becker, personal communication), again 
emphasizing the distinct metabolic requirements of the two parasites. 
6.3.2 γ-Glutamylcysteine as glutathione substitute 
The observation that the second gene of the GSH biosynthesis pathway encoding 
for PfGS is equally essential in P. falciparum shows that the GSH precursor γGC 
is not sufficient for the survival of the parasites and cannot compensate for the 
loss of GSH in this organism. 
Previous findings that S. cerevisiae can survive in the presence of only γGC 
indicate that some functions of GSH can be adopted by γGC (Grant et al., 1997). 
Discussion  166 
 
The dipeptide has some similar properties to GSH and possesses the thiol group 
important for many of the functions of GSH. However, γGC is more prone to 
oxidation and therefore needs to be efficiently reduced by the organisms GSSG 
reductase. The marine bacterium Halobacterium halobium depends entirely on 
γGC as its primary low molecular weight thiol and does not synthesize GSH 
(Sundquist and Fahey, 1989). H. halobium is specialized for the use of γGC and 
enzymes, which are normally GSH-dependent, are γGC-dependent in this 
organism. It possesses a γGC reductase and efficiently maintains a high reduced 
γGC to oxidized γGC ratio (Sundquist and Fahey, 1989), which is likely to be one 
of the problems encountered by organisms specialized for the use of GSH if the 
gs gene is lost. As well as in P. falciparum, the loss of active GS is lethal for the 
plant A. thaliana and the yeast S. pombe. A. thaliana gs insertion mutants show 
a seedling lethal phenotype and S. pombe gs knockout cells are GSH auxotroph 
(Chaudhuri et al., 1997; Pasternak et al., 2008). Interestingly, the S. cervisiae 
mutant described by Grant et al. showed poor growth on minimal medium 
despite γGC hyper-accumulation. The growth defect could be alleviated by 
supplementing the cells with even more γGC, indicating that despite the already 
five times higher levels of γGC, the dipeptide is not used as efficiently as GSH 
and is needed at far higher concentrations to support wild-type growth rates 
(Grant et al., 1997). Seedling lethality of homozygous A. thaliana gs insertion 
mutants occurs in a stage, where residual GSH, provided in the seed by the 
paternal heterozygous plant, can still be detected at significant levels 
(Pasternak et al., 2008). This led the authors to the hypothesis that hyper-
accumulation of γGC itself may be deleterious to cells.  
Probably P. falciparum cannot utilize γGC with the same efficiency as GSH and 
although the non-enzymatic functions of GSH can be taken over by γGC, the 
dipeptide is likely to be a poor substrate for GSH-dependent enzymes. Inefficient 
reduction of oxidized γGC by PfGR probably cause changes to the cytosolic redox 
potential and leads to a decreased buffer capacity. The mechanism of 
maintaining a high GSH:GSSG ratio through export of GSSG is likely to be 
inefficient for the excretion of oxidized γGC (Lüersen et al., 2000). Decreased 
import of γGC into organelles where GSH is normally required may have an 
immense impact on the function of these organelles. γGC is also more prone to 
auto-oxidation under conditions found in the parasite cytosol, while the high salt 
concentrations in H. halobium can protect γGC (Sundquist and Fahey, 1989). 
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To further analyse the importance of PfGS, I attempted the regulated dominant-
negative expression of a mutant PfGS protein to down-regulate endogenous PfGS 
activity in the parasites. Because PfGS functions as a dimer (Meierjohann et al., 
2002a), the presence of an inactive dead mutant should cause the formation of 
inactive-active heterodimers as well as active-active and inactive-inactive 
homodimers. Overall this should decrease the PfGS activity in the parasites and 
reduce GSH levels. Sequence alignment of the PfGS and HsGS amino acid 
sequences revealed the presence of four conserved residues that are of great 
importance for the activity of the human enzyme (Dinescu et al., 2004). PfGS 
residues Glu-206 and Asn-208 correspond to HsGS Glu-144 and Asn-146 and are in 
a region highly conserved between the two species. The mutation to Lys and Ala, 
respectively, abolished the activity of PfGS, as has previously been reported for 
the human enzyme (Dinescu et al., 2004). The results for the activity of 
recombinant PfGSE206K/N208A are preliminary at this stage and have to be 
confirmed after optimization of the purification protocol for the recombinant 
proteins. However, despite similar contamination with other proteins, 
recombinant wild-type PfGS is active, thus suggesting that the activity of the 
mutant is greatly reduced in order to be undetected. In the human enzyme Glu-
144 participates in the formation and stabilization of the γ-glutamylcysteinyl-
phosphate intermediate while coordinating the Mg2+ ions involved in the 
catalysis. Asn-146 is also involved in the coordination of a Mg2+ ion and possibly 
takes part in catalysis (Dinescu et al., 2004). Probably both residues serve 
similar functions in PfGS. 
Two independent parasite lines transfected with the expression construct for 
PfGSE206K/N208A-FKBP12 were generated. In one parasite line no FKBP12-tagged 
GSE206K/N208A was stabilized by Shld1, despite the presence of the expression 
plasmid. However, in the second line the recombinant protein was stabilized 
with Shld1, while being undetectable in the absence of the compound, indicating 
its destabilization by the FKBP12-tag and complete degradation. This is in 
contrast to previous reports that C-terminally tagged fusion proteins are less 
efficiently degraded than N-terminal fusion proteins and are still present in the 
cells in the absence of Shld1 (Armstrong and Goldberg, 2007; Banaszynski et al., 
2006; Maynard-Smith et al., 2007). 
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The stabilization of PfGSE206K/N208A did however not result in a growth phenotype. 
There are three possible explanations for this observation: (a) reducing PfGS 
activity and the reduction in GSH levels does not have an adverse effect on the 
parasites; (b) PfGS activity is not decreased by the presence of the stabilized 
recombinant protein; (c) PfGS activity is decreased, but GSH levels are not 
reduced below a level that causes an adverse effect in the parasites.  
Because the knockout studies suggest that PfGS is an essential enzyme, the first 
possibility is unlikely. Potentially the activity of PfGS is not decreased to an 
extent that significantly affects GSH levels and the parasite’s growth. The 
reason for this could be either that the level of stabilized PfGSE206K/N208A-FKBP12 
is not high enough to sufficiently dilute the active enzyme or that the 
recombinant protein is not able to form heterodimers with the active form. In 
the human enzyme the corresponding mutations do not affect the folding of 
HsGS; single mutants of the human enzyme for either residue are inactive, but 
show no affected tertiary structure (Dinescu et al., 2004), suggesting that PfGS 
is folded correctly despite the mutations. Therefore the introduced mutations 
should not prevent the formation of heterodimers with wild-type PfGS. 
Expression studies of recombinant wild-type PfGS in E. coli show that N-
terminally His-tagged recombinant PfGS forms dimers (Meierjohann et al., 
2002a), but the presence of the C-terminal FKBP12-tag can potentially influence 
dimer formation. Future studies can determine the GSH levels of the parasites in 
the presence of stabilized PfGSE206K/N208A-FKBP12 and the GS activity in the 
parasites treated with Shld1. 
Low expression levels of C-terminally FKB12-tagged proteins are a common 
problem when this system is used in T. gondii (D. Soldati, personal 
communication). Indeed, the relative expression of wild-type PfGS tagged with 
either C-terminal GFP- or HA-tags using the same pCHD-plasmid and Hsp86-
promotor, appears to be higher than the levels of stabilized PfGSE206K/N208A-
FKBP12 as determined by western blotting. This is potentially due to the 
specificity of the different antibodies against the tags. However, increasing 
concentrations of Shld1 from 0.25 µM to 0.5 µM and 1 µM did not increase the 
amount of stabilized protein in this study, suggesting a saturation of the 
recombinant protein in the parasites already at the lower concentration of the 
compound. This also indicates low expression levels of PfGSE206K/N208A-FKBP12, 
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since other authors reported a constant increase of stabilized protein if the 
Shld1 concentration was raised (Armstrong and Goldberg, 2007; Banaszynski et 
al., 2006). Potentially low expression levels of the recombinant protein are 
linked to recombination of the plasmid. However, in the line that appears to 
contain more of the original transfected plasmid, no expression was detected at 
all, suggesting that a recombination event alone is not responsible for low 
expression. 
Another problem encountered during the dominant-negative expression of 
PfGSE206K/N208A-FKBP12 is the toxicity of the Shld1 ligand in wild-type parasite 
lines. The growth effect of the compound was obvious after 48 hours at 
concentrations higher than 0.2 µM and toxicity of Shld1 has also been reported 
independently in a recent study (Russo et al., 2009). It is not clear what the 
cause of Shld1 toxicity is. In a study on mammalian cells, Shld1 changed the 
expression levels of several genes, but because at various concentrations 
different genes were found to be affected, the authors assumed that off-target 
effects of Shld1 were too random to cause any general harmful effect in 
mammalian cells (Maynard-Smith et al., 2007). P. falciparum may however be 
more susceptible to Shld1 than mammalian species. 
Unspecific toxicity makes the use of high Shld1 concentrations problematic and 
should be taken into account for future studies. Therefore the FKBP12 system 
may not be a good tool for over-expression studies which require high 
concentrations of Shld1 in order to achieve high levels of stabilized recombinant 
proteins in the parasites. In a recent study a FKBP12-based method was used for 
the regulated knockdown of an endogenous protein (Russo et al., 2009). In case 
of a regulated knockdown, the endogenous gene is tagged with the sequence for 
the destabilization domain and the encoded protein is continuously stabilized by 
constant presence of Shld1 in the cultures. Because the levels of a stabilized 
protein required for parasite survival are lower than the levels required for a 
mutant form to efficiently dilute the active protein, the stabilization of an 
endogenous active enzyme requires less Shld1 than the over-expression of a 
dead mutant. For future studies constructs can be designed to tag the 
endogenous gene with the degradation domain sequence following single cross-
over recombination, thus ensuring that the protein will be degraded once Shld1 
is withdrawn from the cultures. 
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6.3.3 An essential function for glutathione 
The observation that both pfgγcs and pfgs are essential for erythrocytic stages of 
P. falciparum raises the question which essential function GSH serves in the 
parasites. 
The GSH deficient strains of S. cerevisiae can survive with as little as 0.5-1 % of 
the normal wild-type levels of GSH, either because it is supplemented in the 
medium or because trace amounts of GSH are synthesized due to additional 
mutations in the pro2 gene of the proline biosynthesis pathway (Lee et al., 2001; 
Spector et al., 2001). Interestingly, low GSH levels are still required for the 
survival of S. cerevisiae under anaerobic conditions, indicating that the lethal 
phenotype is not related to oxidative stress (Grant et al., 1996; Lee et al., 2001; 
Spector et al., 2001). The P. berghei γgcs null mutants are also surviving in RBC 
stages despite severely reduced GSH levels and showed only a slight growth 
defect (Vega-Rodriguez et al., 2009). 
Several authors have suggested the role of GSH for the maintenance of 
mitochondrial function (Martensson et al., 1989; Martensson and Meister, 1989; 
Vega-Rodriguez et al., 2009). This is also likely to be the case in P. falciparum, 
where the active electron transport chain is required for maintenance of the 
electrochemical gradient across the inner mitochondrial membrane and as an 
electron acceptor for dihydrofolate dehydrogenase, an essential component of 
the pyrimidine biosynthesis pathway (Painter et al., 2007). A functional electron 
transport chain potentially leads to the generation of ROS, which have to be 
detoxified to avoid damage to the organelle. Several systems were suggested to 
be involved in the removal of ROS in the mitochondrion (Müller, 2004) and the 
maintenance of the mitochondrial redox state is likely to be crucial for the 
integrity of the organelle. 
Treatment of mice and rats with L-BSO needs to cause a marked decrease of GSH 
in the organelle, before mitochondrial damage occurs. Mitochondrial swelling as 
well as rupture of cristae and disintegration of mitochondrial membranes is 
observed in several tissues such as skeletal muscle, lungs, epithelia of jejunum 
and colon following GSH depletion through L-BSO treatment (Martensson et al., 
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1989; Martensson et al., 1990a; Martensson et al., 1991; Martensson et al., 
1990b; Martensson and Meister, 1989).  
S. cerevisiae strains with a deleted gsh1 gene encoding γGCS are often 
respiratory deficient (petite) strains lacking functional mitochondria and are 
unable to grow on non-fermentable carbons sources, thus indicating the 
importance of GSH for mitochondrial function in yeast (Grant et al., 1996). A S. 
cerevisiae grande strain with a γgcs null mutation was generated, which 
possesses functional mitochondria but displays a nine times increased tendency 
to form petite daughter cells and demonstrates again the importance of GSH for 
the maintenance of functional mitochondria (Lee et al., 2001). 
Other cellular changes due to the lack of GSH were reported to occur in S. 
cerevisiae and mammals before any damage in mitochondria is detected. 
Removal of GSH from the culture medium of a GSH auxotroph ∆gsh1 strain of S. 
cerevisiae allows these cells to continue growing for approximately 10 cell cycles 
before GSH levels become limiting and growth arrest is observed (Sipos et al., 
2002). After depleting GSH for 8 cell divisions, the mitochondria of these cells 
are still intact and Fe-S cluster maturation within them is normal and several 
mitochondrial enzymes display unchanged activity. However, maturation of 
cytosolic Fe-S proteins is already severely impaired under these conditions, even 
when cells are cultured under anaerobic conditions (Sipos et al., 2002). The high 
efficiency of GSH import into the mitochondria, which has been reported in 
other organisms, may also protect these organelles in S. cerevisiae longer from 
the effects of GSH depletion (Green et al., 2006; Zechmann et al., 2008). In 
mammalian cells, depletion of GSH leads to increased formation of aberrant 
proteins in the endoplasmatic reticulum (ER) (Chakravarthi and Bulleid, 2004; 
Molteni et al., 2004). Unlike in the cytososl, the GSH:GSSG ratio in the ER is 
between 1:1 and 3:1 and thus allows efficient formation of disulphide bonds 
(Chakravarthi et al., 2006). GSH acts as the main antagonist of the human Ero1 
protein, an oxidase for human protein disulphide isomerase. While Ero1 
increases the formation of disulphide bonds in the ER lumen, GSH decreases 
their formation and can either directly reduce non-native bonds or maintain 
protein disulphide isomerases in a reduced state so they can in turn reduce and 
isomerize non-native disulphide bonds in other proteins (Chakravarthi and 
Bulleid, 2004; Chakravarthi et al., 2006; Molteni et al., 2004). Loss of GSH 
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decreases the cell’s ability to isomerize disulphide bonds and leads to 
accumulation of aberrant non-native forms of proteins.  
GSH is also vital for the function of glutaredoxins. S. cerevisiae contains five 
glutaredoxins (grx1 to 5) and while single null mutants for each glutaredoxin are 
viable, double mutants for grx2 and grx5 or triple mutants of grx3, grx4 and grx5 
are non viable (Rodriguez-Manzaneque et al., 1999). GSH is the hydrogen donor 
for the reduction of glutaredoxins, which in turn supply reducing equivalents for 
other enzymes. One important protein that is maintained in a reduced state by 
glutaredoxins is ribonucleotide reductase, an enzyme involved in 
deoxyribonucleotide formation for DNA biosynthesis (Holmgren, 1976; Luthman 
et al., 1979; Prinz et al., 1997). 
It may not be one but several cellular processes that depend on the presence of 
GSH for their function in P. falciparum and thus multiple effects may cause 
lethality if GSH is not present.  
6.3.4 Over-expression studies 
The generation of three parasite lines expressing recombinant PfγGCS-HA and 
one line expressing PfGS-HA was in the first instance aimed at elucidating 
whether (a) episomal expression of both enzymes was possible and (b) whether 
recombination of the expression plasmids with the endogenous genes is possible 
and if the respective gene loci can be tagged with the HA-tag sequence. 
The genotype of the lines was analysed by Southern blotting and it has also been 
established by western blotting that both enzymes can be expressed from 
episomal copies. However, for co-transfection studies the genotypes of any lines 
have to be established before transfections with knockout constructs, because of 
the possibility of recombination of the expression constructs with the 
endogenous gene locus. The recombination between pCHD-derived plasmids and 
endogenous genes offers the possibility to use this plasmid in the future not only 
for episomal expression of recombinant proteins, but also to C-terminally tag 
endogenous genes. The tagging of endogenous genes can also be achieved using 
sequences homologous to only the 3’-end of the target gene rather than the full 
ORF, thus ensuring that only one functional copy of the target gene is present in 
the recombined locus. The generation of parasite lines encoding for endogenous 
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HA-tagged pfγgcs and pfgs under control of their endogenous promoter without 
the presence of an additional copy of the genes will be of interest for future 
studies to analyse the expression pattern of these proteins. 
Preliminary data indicate that PfγGCS-HA over-expression decreases sensitivity 
to L-BSO, while PfGS-HA appears to cause a slight increase in sensitivity to the 
drug. While no statistical analysis of the significance of these data is possible 
yet, the decreased sensitivity of the PfγGCS over-expressing line strongly 
suggests that the parasite enzyme is targeted by the drug and that the anti-
malarial effect of L-BSO is not primarily caused by the premature death of the 
host cell. If the latter was the case, one would expect that changing expression 
levels in the parasites does not influence the susceptibility to the drug. It also 
indicates correct folding of the recombinant PfγGCS protein, as the substrate 
analogue L-BSO binds to the active site in order to inhibit the enzyme and thus 
would not likely be sequestered by misfolded enzyme. 
The observation that PfGS over-expression may increase L-BSO sensitivity in the 
parasite is rather peculiar and may be caused by an adverse effect of the 
enzyme in the absence of the substrate γGC. However, this experiment has only 
been performed once and thus needs to be confirmed in the future. Because of 
the unexpected banding pattern detected in the genotype analysis of this line, a 
negative effect of a random recombination event of the plasmid in these 
parasites is also possible. To further analyse this, a second transfected parasite 
line should be generated to confirm the results. 
Future steps will involve analyses of the GSH levels in these lines, as an over-
expression of the biosynthesis enzymes may not generate high GSH levels if the 
availability of substrates is limited. These lines can provide a tool to determine 
if γGCS is rate limiting in P. falciparum. In yeast, over-expression of the rate 
limiting γGCS leads to an increase in GSH levels, while the over-expression of GS 
cannot change GSH levels due to an unchanged supply of γGC (Grant et al., 
1997). They can also offer further insight in the role of GSH on redox metabolism 
and on the redox state of mitochondria and ER. With regard to the hypothesis 
that elevated GSH levels are related to CQ resistance, the analysis of the 
susceptibility of these lines to CQ will be highly interesting.  
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6.4 Glutathione and chloroquine resistance 
6.4.1 Glutathione transport by mutant PfCRT 
Resistance to CQ is primarily conferred by mutated forms of PfCRT, a DV 
transmembrane protein that functions either as a channel or a transporter to 
reduce CQ accumulation in the DV. Other factors also contribute to CQ 
resistance; parasite strains possessing the same PfCRT allele can widely differ in 
their susceptibility to CQ. One factor previously suggested to be involved in CQ 
resistance was GSH. 
While in P. berghei CQ resistance was found to be correlated with increased GSH 
levels and increased activity of GST, no such correlation was found in P. 
chabaudi, another murine species (Dubois et al., 1995; Ferreira et al., 2004). In 
P. falciparum CQ resistance appears not to be linked to the activity of GST 
either, since no CQ conjugates or metabolites can be observed in resistant 
parasites (Berger et al., 1995). There was no up-regulation of GST expression 
detected in the CQ resistant parasites in this study. 
It has been shown in vitro that the tripeptide destroys heme, the target of CQ. 
Thus it was proposed that GSH modulates CQ sensitivity through removal of the 
target rather than by direct interaction with CQ (Atamna and Ginsburg, 1995). 
The heme degradation by GSH can be competitively inhibited by CQ and 
amodiaquine, suggesting that elevated GSH levels may result in increased CQ 
resistance (Ginsburg et al., 1998; Ginsburg and Golenser, 2003). Indeed, 
artificial increase or decrease of GSH levels leads to increased or decreased 
sensitivity to CQ in vitro and in vivo (Deharo et al., 2003; Dubois et al., 1995; 
Ginsburg et al., 1998; Ginsburg and Golenser, 2003; Platel et al., 1999). Higher 
GSH levels have been reported for the CQ resistant parasite strain Dd2 in 
comparison to the sensitive strain 3D7 (Meierjohann et al., 2002b). 
However, while earlier studies hypothesized that up to 70 % of heme released 
during hemoglobin degradation reach the cytosol (Ginsburg et al., 1998), later 
studies showed that the heme released is largely contained within this organelle 
and less than 5 % reach the cytosol (Egan et al., 2002). The hypothesis that 
elevated GSH levels contribute to CQ resistance is not consistent with the 
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intracellular organization of the parasite if GSH is synthesized in the cytosol, as 
shown in the present study and heme is released and contained within the DV 
(Egan et al., 2002). Moreover, in CQ resistant parasites CQ is expelled from the 
food vacuole by mutant PfCRT and it remains unclear how both CQ and GSH 
should compete for binding to heme retained in the DV (Sanchez et al., 2007b; 
Valderramos and Fidock, 2006).  
To address these problems, we investigated the GSH metabolism and its 
influence on CQ resistance in four isogenic parasite lines, genetically only 
differing in their pfcrt alleles. The lines analysed were the CQ sensitive lines 
GC03 and C2GC03 and the resistant lines C3Dd2 and C67G8. In previous studies on P. 
falciparum, strains widely differing in their genetic background were used and 
thus it is difficult to conclude if differences in GSH metabolism are a cause or a 
consequence of CQ resistance. We proposed that with the lines used in this 
study, we would be able to manipulate GSH levels and be able to directly 
analyse the effects of GSH metabolism on CQ susceptibility in CQ sensitive and 
resistant parasites. In collaboration with colleagues at the Liverpool School of 
Tropical Medicine we found an unsuspected role for PfCRT in changing the 
distribution of GSH within the parasite cell. 
I confirmed the susceptibility to CQ of the four lines and found that all lines 
show the expected CQ sensitive or resistant phenotype (Sidhu et al., 2002). 
Extracellular GSH has only a marginal effect on the CQ IC50 in these lines. 
Despite uptake of GSH into infected RBC, the increase of GSH in the RBC cytosol 
has little effect on the CQ IC50. Several lines of evidence suggest that GSH in the 
host cell cytosol is delivered to the DV within endocytotic vesicles and thus an 
increase of RBC GSH can potentially benefit parasites under CQ pressure. This 
was in particular suggested as a mechanism of decreased susceptibility for CQ 
resistant P. berghei parasites infecting reticulocytes (Platel et al., 1999; Vega-
Rodriguez et al., 2009). However, GSH uptake into the DV by this mechanism 
may be too little and the rate of endocytosis too slow to allow additional GSH in 
the medium to compete against CQ, which can enter the DV much faster by 
diffusion. It is possible that higher concentrations of extracellular GSH than the  
1 mM concentration tested in this study have a more pronounced effect. 
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Surprisingly, the allelic exchange of pfcrt led to significantly reduced GSH levels 
in the two CQ resistant lines analysed. In some previous studies GSH levels of P. 
falciparum were reported to be between 0.07 and 0.14 µmol/ 1010 cells in 
sensitive and resistant parasites (Lüersen et al., 2000; Meierjohann et al., 
2002b), while other authors reported higher GSH levels of 0.79 µmol / 1010 cells 
(Atamna and Ginsburg, 1997). The GSH levels I determined in the present study 
were between 0.75 and 1.5 µmol/ 1010 cells and thus similar to those reported 
by Atamna and Ginsburg. Both Lüersen and Meierjohann determined GSH levels 
after parasitized RBC had been purified from non-infected RBC with Percoll and 
gelafundin gradients. During this study, I found that purification with MACS 
columns greatly decreases the GSH levels in the parasites and it is likely that 
other purification methods have similar effects on the GSH levels, which can 
explain the differences between the various studies. The GSH levels I 
determined without initial enriching of infected RBC were also in the range of 
GSH levels previously reported for P. berghei parasites, where infected RBC 
equally had not been purified prior to lysis and determination of GSH content 
(Dubois et al., 1995; Platel et al., 1999). The P. berghei GSH levels ranged from 
0.2 µmol/ 1010 cells for CQ sensitive strains to 2.7 µmol/ 1010 cells for CQ 
resistant stains. Interestingly, the differences I detected between CQ sensitive 
C2GC03 parasites and CQ resistant C67G8 parasites remained, regardless of the 
isolation method employed, with the resistant line displaying lower GSH levels. 
The lower GSH levels in C3Dd2 and C67G8 are not consistent with the previous 
hypothesis that CQ resistant parasites display elevated GSH levels (reviewed 
in(Ginsburg and Golenser, 2003)). 
Despite the different GSH levels, the susceptibility to oxidative stress remained 
largely unchanged in the parasites. Both juglone and phenazine methyl sulphate 
are considered as inducers of intracellular oxidative stress due to their ability to 
cross cell membranes. While juglone is a redox-active naphthoquinone, 
phenazine methyl sulphate generates superoxide anions (Kampkotter et al., 
2003; Nishikimi et al., 1972). This suggests that even though reduced in CQ 
resistant lines, GSH levels are still sufficient for the maintenance of an efficient 
antioxidant system. Using a less specific way to deplete GSH with CDNB, a GST 
substrate, I found no significant differences between the isogenic parasite lines, 
although the resistant lines appeared slightly more susceptible to the drug. A 
technical problem with CDNB and both juglone and phenazine methyl sulphate is 
Discussion  177 
 
their low solubility in aqueous solutions such as RPMI medium. This results in a 
high variability between the data in independent assays and therefore it has to 
be considered that small differences between the parasite lines may not have 
been detected. 
The lower GSH levels in CQ resistant parasites were however accompanied by 
significantly increased sensitivity to the inhibition of GSH biosynthesis by L-BSO. 
This is not due to a difference in mRNA expression of the two genes involved in 
GSH biosynthesis and presumably also not the amount of the proteins in the 
cells. GSH uptake into infected RBC was investigated in one sensitive and one 
resistant line and no significant difference was detected. This suggests that the 
lower GSH levels may be caused by an increased loss of GSH from the resistant 
parasites. A decrease in GR can potentially cause an increased efflux of GSSG 
from the cells in order to maintain a high GSH:GSSG ratio and thus lead to an 
enhanced loss of GSH (Lüersen et al., 2000). This efflux should be investigated in 
future studies. However, we did not find a difference in GR expression between 
the lines analysed, suggesting that this might not be the reason for increased 
loss of GSH or GSSG. Equal levels of GST also suggest that there is no difference 
in GSH-conjugation between the PfCRT allelic-exchanged lines. We did not 
investigate the activity of these enzymes in the parasites and it is possible that 
lower GSH levels could negatively affect the activity of GST (Tripathi et al., 
2007). 
When PfCRT was expressed in oocytes of X. laevis our collaborators found 
conclusive evidence that the mutant, but not the wild-type form of PfCRT, is 
capable of transporting GSH across membranes. A role of PfCRT as transporter 
for small peptides has previously been suggested from bioinformatic studies 
(Martin and Kirk, 2004), but no natural substrate has yet been identified. 
Unfortunately our study does not change this, as we only observed uptake of 
GSH by mutant, but not wild-type PfCRT. 
6.4.2 Effects of glutathione re-distribution 
How can the transport of GSH by mutant PfCRT explain the lower GSH levels and 
greater sensitivity to L-BSO in resistant parasites? The transport of erythrocyte 
derived GSH from the DV into the cytosol should increase the GSH levels in these 
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parasites rather than decrease them. The data presented in this study suggest 
that GSH is likely to be transported into the opposite direction, from the cytosol 
into the DV. Inside this organelle the multitude of peptidases may eventually 
destroy GSH by proteolysis and thus decrease the overall GSH level in the 
parasite. Destruction of GSH by carboxypeptidases and dipeptidases has been 
suggested for plant vacuoles, which do not contain any detectable levels of GSH 
(Foyer et al., 2001; Wolf et al., 1996; Zechmann et al., 2008). Degradation of 
erythrocyte derived GSH may be an important source for the amino acids 
cysteine and glutamate, which are both limited in hemoglobin (Francis et al., 
1997). 
The efflux of GSH into the DV of resistant parasite lines only offers an 
explanation as to why NAC increases the CQ IC50 of resistant C3
Dd2 while only 
marginally affecting sensitive C2GC03 parasites. If GSH cannot enter the DV and 
thus has no access to heme, an increase in its biosynthesis can only have a slight 
effect on the parasites’ general fitness by protecting it from some of the CQ 
induced damage. However, if GSH biosynthesis is increased and the tripeptide is 
subsequently transported into the DV, increased heme degradation by GSH 
results in a reduced concentration of the heme target and increased CQ 
resistance. GSH was shown to destroy heme at neutral pH as well as at the acidic 
pH found inside the DV, albeit less efficiently (Atamna and Ginsburg, 1995).  
A reduced concentration of free heme due to degradation by GSH is consistent 
with the reduced accumulation ratio of CQ observed in this study and with 
reduced CQ binding in the CQ resistant progeny of a genetic cross reported 
previously (Sanchez et al., 1997). It is also consistent with the reported lower 
hemozoin concentration of the C3Dd2 line compared to C2GC03 (Gligorijevic et al., 
2006b). In addition to the destruction of free heme, GSH inside the DV is able to 
compete with CQ for the binding to the remaining heme (Ginsburg et al., 1998). 
It is currently a subject of debate whether PfCRT acts as a channel, permitting 
passive diffusion, or an active transporter for CQ (recently reviewed in (Sanchez 
et al., 2007b). Our results do not offer any further insight which model is 
appropriate, as the transport or flux of GSH across the DV membrane can be 
accommodated into both models. It is likely that the GSH concentration inside 
the DV is substantially lower than the millimolar concentration found in the 
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cytosol and the resulting gradient potentially drives the influx of GSH. 
Furthermore, in the near neutral pH of the parasite cytosol GSH is deprotonated 
and thus negatively charged. The positive charge in the DV may also drive the 
flux of GSH. In the wild-type form of PfCRT, the positive charge at the lysine at 
position 76 possibly retains negatively charged GSH and thus does not allow flux 
of the tripeptide into the food vacuole. If PfCRT is a carrier and not a channel, 
GSH translocation is potentially coupled to CQ transport and the inward 
movement could trans-accelerate the CQ efflux. These hypotheses will be 
investigated in detail in the future. 
We found an intriguing effect of CDNB on CQ accumulation in this study. While 
killing parasites at low µM concentrations and reversing CQ resistance (Ginsburg 
et al., 1998), it also caused an increase in CQ accumulation in resistant parasites 
similar to the effect of verapamil. The depletion of GSH by CDNB minimizes or 
stops the influx of GSH into the DV and thus CQ no longer has to compete with 
the tripeptide for the binding to heme and accumulation increases. Regarding 
the carrier model of PfCRT, the depletion the tripeptide potentially depletes a 
trans-acceleration of CQ efflux by GSH. It is further possible, that the GS-CDNB 
adduct is another substrate for mutated PfCRT, but unlike GSH alone, the 
lipophilic adduct could inhibit a channel or transporter in a similar way as 
postulated for verapamil (Bray et al., 2005; Cooper et al., 2002; Lakshmanan et 
al., 2005; Sidhu et al., 2002). 
If mutations of PfCRT are responsible for the translocation of GSH into the DV 
where it is subsequently degraded, it raises the question why the previously 
analysed CQ resistant line Dd2 has a higher GSH level than the sensitive line 3D7 
(Meierjohann et al., 2002b). These two lines are however not isogenic and the 
Dd2 line has been shown to contain a higher activity of PfγGCS than 3D7, which 
is likely to compensate for any loss of GSH into the DV. Such adaptations are 
likely to be important for the parasites as the reduced cytoplasmic GSH levels 
may well have a fitness cost for these lines. The four isogenic parasite lines 
analysed in this study did not display any differences in their expression levels 
for PfγGCS and PfGS, suggesting they may not have adapted in a similar way as 
the field isolates to the re-distribution of GSH. These laboratory generated lines 
will not have encountered the same selective pressures that can cause changes 
in field isolates. Since the GC03 parental line of our genetically modified 
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parasites is the progeny of a genetic cross between the strains HB3 and Dd2, it is 
also possible that the isogenic lines have inherited the adaptations in the Dd2 
GSH metabolism responsible for high levels of GSH biosynthesis. This suggests 
that potentially the two CQ sensitive lines GC03 and C2GC03 have a comparably 
high GSH level and the resistant lines C3Dd2 and C67G8 have a more normal level. 
This could be further investigated by determination of GSH levels in a variety of 
parasite strains of the Dd2 x HB3 progeny in order to determine an “average” 
GSH level for CQ sensitive P. falciparum. Comparisons to other studies are 
difficult, because as I have shown here the method of sample preparation can 
deplete cells of GSH. 
The re-emergence of CQ sensitive parasites after withdrawal of CQ use in areas 
where resistance has been widespread, indicates that changes to PfCRT have a 
negative effect on parasite fitness. One of these negative side effects caused by 
PfCRT mutations is the decrease in the cytosolic GSH concentration, where GSH 
has to be constantly re-synthesized to maintain a variety of cellular functions. 
Recently it has been demonstrated that the DV in CQ resistant parasites is larger 
than in sensitive parasites (Gligorijevic et al., 2006a). The GSH influx and thus 
increasing GSH concentration inside the DV is a potential reason for increased 
osmotic pressure and swelling of the DV. Furthermore, influx of GSH may further 
acidify the DV and thus offers one possible explanation for the lower DV pH of 
resistant parasites found in some studies (Bennett et al., 2004; Gligorijevic et 
al., 2006a). 
6.5 Conclusions and future perspectives 
The low molecular weight thiol GSH serves very important functions in the 
malaria parasite P. falciparum and several studies have indicated that the 
tripeptide is an essential metabolite for the parasites (Atamna and Ginsburg, 
1997; Lüersen et al., 2000). However, several organisms can scavenge GSH, 
provided they are supplied with high enough concentrations of the tripeptide 
and thus are not dependent on its de novo synthesis (Baek et al., 2004; Grant et 
al., 1996; Huynh et al., 2003; Kim et al., 2005; Lee et al., 2001). This appears to 
be the case in the rodent parasite, P. berghei (Vega-Rodriguez et al., 2009). 
However, the results of this study indicate a different situation in the human 
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parasite P. falciparum, where a knockout of the GSH biosynthesis pathway 
cannot be achieved. The reasons for this are likely to be that P. falciparum 
cannot scavenge GSH to the same extent as P. berghei, as well as a greater 
redundancy in the antioxidant system of the murine parasite than in that of the 
human pathogen. Future studies will need to investigate the possibility of GSH 
uptake by the parasites in more detail. 
Overall these results show a great importance for an effective antioxidant 
system in malaria parasites. That GSH levels in the host cell and in the blood 
plasma may determine the importance of the GSH biosynthesis has some 
implications on the potential of γGCS and GS as drug targets for malaria 
parasites in general, especially for those species that invade reticulocytes such 
as P. vivax. The importance of GSH for malaria parasites remains unquestioned, 
but the importance of its de novo biosynthesis appears to vary between the 
different species of Plasmodium. Redundancy between single components of the 
antioxidant system means that more than one component will have to be 
targeted at any one time to inhibit or kill the parasites. However, drugs lowering 
GSH levels in parasites may be interesting for combination therapies. 
The results of this study also show some of the problems when working with a 
model organism. Despite the obvious advantages of working with an in vivo 
rather than an in vitro system and being able to study all the life cycle stages of 
Plasmodium in the rodent parasite, P. berghei does not always resemble the 
situation in P. falciparum. 
We found an unsuspected additional role for mutant PfCRT in CQ resistance 
through the redistribution of GSH. This redistribution can amplify CQ resistance 
and provides further insight into how the variety of resistant phenotypes of P. 
falciparum is established, which cannot be explained by the efflux of CQ alone. 
It also offers an answer to the question how cytosolic GSH can gain access to and 
destroy FPIX in the parasites DV. This can be further analysed in the future with 
parasite lines over-expressing PfγGCS and PfGS in CQ sensitive and CQ resistant 
backgrounds. From the results obtained in this study, one would expect that the 
over-expression will significantly alter the CQ IC50 in those lines possessing 
mutant forms of PfCRT, but not in those with a wild-type form. CQ sensitive 
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lines over-expressing the enzymes have already been generated and the 
transfection of a CQ resistant strain is currently in progress. 
The transport of GSH by the mutant forms of PfCRT clearly demonstrates the 
ability of PfCRT to transport small peptides, a function previously suggested by 
bioinformatic analyses (Martin and Kirk, 2004). Unfortunately the natural 
substrate of wild-type PfCRT sill remains elusive. 
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